WO2023078287A1 - Systèmes et procédés pour des immunothérapies améliorées - Google Patents
Systèmes et procédés pour des immunothérapies améliorées Download PDFInfo
- Publication number
- WO2023078287A1 WO2023078287A1 PCT/CN2022/129201 CN2022129201W WO2023078287A1 WO 2023078287 A1 WO2023078287 A1 WO 2023078287A1 CN 2022129201 W CN2022129201 W CN 2022129201W WO 2023078287 A1 WO2023078287 A1 WO 2023078287A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- population
- fold
- engineered
- cell
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 238000009169 immunotherapy Methods 0.000 title abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 338
- 210000002865 immune cell Anatomy 0.000 claims abstract description 336
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- 238000000338 in vitro Methods 0.000 claims abstract description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 22
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 352
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 227
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 221
- 229920001184 polypeptide Polymers 0.000 claims description 219
- 230000014509 gene expression Effects 0.000 claims description 199
- 230000000694 effects Effects 0.000 claims description 130
- 108090000623 proteins and genes Proteins 0.000 claims description 128
- 230000002829 reductive effect Effects 0.000 claims description 120
- 239000000427 antigen Substances 0.000 claims description 107
- 108091007433 antigens Proteins 0.000 claims description 107
- 102000036639 antigens Human genes 0.000 claims description 107
- 102000005962 receptors Human genes 0.000 claims description 102
- 108020003175 receptors Proteins 0.000 claims description 102
- 230000011664 signaling Effects 0.000 claims description 96
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 86
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 85
- 230000027455 binding Effects 0.000 claims description 84
- 108090000172 Interleukin-15 Proteins 0.000 claims description 79
- 102000003812 Interleukin-15 Human genes 0.000 claims description 79
- -1 CCL-21 Proteins 0.000 claims description 70
- 102000015696 Interleukins Human genes 0.000 claims description 65
- 108010063738 Interleukins Proteins 0.000 claims description 65
- 229940124644 immune regulator Drugs 0.000 claims description 62
- 210000000130 stem cell Anatomy 0.000 claims description 46
- 230000002688 persistence Effects 0.000 claims description 42
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 38
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 38
- 108010002350 Interleukin-2 Proteins 0.000 claims description 26
- 102000000588 Interleukin-2 Human genes 0.000 claims description 26
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 24
- 230000003013 cytotoxicity Effects 0.000 claims description 22
- 231100000135 cytotoxicity Toxicity 0.000 claims description 22
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 21
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 21
- 230000001105 regulatory effect Effects 0.000 claims description 21
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 20
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 20
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims description 20
- 102000003814 Interleukin-10 Human genes 0.000 claims description 20
- 108090000174 Interleukin-10 Proteins 0.000 claims description 20
- 102100039373 Membrane cofactor protein Human genes 0.000 claims description 20
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 19
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 19
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 19
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 18
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 18
- 230000007783 downstream signaling Effects 0.000 claims description 17
- 108091006024 signal transducing proteins Proteins 0.000 claims description 17
- 102000034285 signal transducing proteins Human genes 0.000 claims description 17
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 16
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 15
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 15
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 15
- 230000003248 secreting effect Effects 0.000 claims description 15
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims description 14
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 14
- 108700002010 MHC class II transactivator Proteins 0.000 claims description 14
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 13
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 13
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 13
- 239000010445 mica Substances 0.000 claims description 13
- 229910052618 mica group Inorganic materials 0.000 claims description 13
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 12
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 12
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 12
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 12
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 12
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 12
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 12
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 11
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 11
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 claims description 11
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 11
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 11
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 claims description 11
- 230000026731 phosphorylation Effects 0.000 claims description 11
- 238000006366 phosphorylation reaction Methods 0.000 claims description 11
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 10
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 9
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 9
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 8
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 8
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 8
- 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 claims description 8
- 101000607306 Homo sapiens UL16-binding protein 1 Proteins 0.000 claims description 8
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 8
- 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 claims description 8
- 102100040012 UL16-binding protein 1 Human genes 0.000 claims description 8
- 230000034994 death Effects 0.000 claims description 8
- 231100000517 death Toxicity 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 102100025221 CD70 antigen Human genes 0.000 claims description 7
- 102000000311 Cytosine Deaminase Human genes 0.000 claims description 7
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 7
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 claims description 7
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 7
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 claims description 7
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 7
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims description 6
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 6
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 6
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 6
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 5
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 5
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 5
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 5
- 108020004440 Thymidine kinase Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims description 4
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 108090000397 Caspase 3 Proteins 0.000 claims description 4
- 108090000567 Caspase 7 Proteins 0.000 claims description 4
- 102100029855 Caspase-3 Human genes 0.000 claims description 4
- 102100038902 Caspase-7 Human genes 0.000 claims description 4
- 102100026550 Caspase-9 Human genes 0.000 claims description 4
- 108090000566 Caspase-9 Proteins 0.000 claims description 4
- 102100021044 DNA-binding protein RFXANK Human genes 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 101001075464 Homo sapiens DNA-binding protein RFXANK Proteins 0.000 claims description 4
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 4
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 4
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 4
- 101000979565 Homo sapiens Protein NLRC5 Proteins 0.000 claims description 4
- 101001075466 Homo sapiens Regulatory factor X-associated protein Proteins 0.000 claims description 4
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 4
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 4
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 4
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 4
- 102100023432 Protein NLRC5 Human genes 0.000 claims description 4
- 102100021043 Regulatory factor X-associated protein Human genes 0.000 claims description 4
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 4
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 claims description 4
- 102100028082 Tapasin Human genes 0.000 claims description 4
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 4
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 claims description 3
- 102000011727 Caspases Human genes 0.000 claims description 2
- 108010076667 Caspases Proteins 0.000 claims description 2
- 101100101727 Homo sapiens RAET1L gene Proteins 0.000 claims description 2
- 101001132524 Homo sapiens Retinoic acid early transcript 1E Proteins 0.000 claims description 2
- 101000607316 Homo sapiens UL-16 binding protein 5 Proteins 0.000 claims description 2
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 claims description 2
- 101000607318 Homo sapiens UL16-binding protein 3 Proteins 0.000 claims description 2
- 102100033964 Retinoic acid early transcript 1E Human genes 0.000 claims description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 2
- 102100040010 UL-16 binding protein 5 Human genes 0.000 claims description 2
- 102100039989 UL16-binding protein 2 Human genes 0.000 claims description 2
- 102100040011 UL16-binding protein 3 Human genes 0.000 claims description 2
- 102100040013 UL16-binding protein 6 Human genes 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 10
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 4
- 108700009171 B-Cell Lymphoma 3 Proteins 0.000 claims 3
- 102100021570 B-cell lymphoma 3 protein Human genes 0.000 claims 3
- 101150072667 Bcl3 gene Proteins 0.000 claims 3
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 3
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 3
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 claims 3
- 101000653369 Homo sapiens Methylcytosine dioxygenase TET3 Proteins 0.000 claims 3
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims 3
- 102100033461 Interleukin-17A Human genes 0.000 claims 3
- 102100033454 Interleukin-17F Human genes 0.000 claims 3
- 102100030812 Methylcytosine dioxygenase TET3 Human genes 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000649068 Homo sapiens Tapasin Proteins 0.000 claims 1
- 102100029740 Poliovirus receptor Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical class FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 108010048507 poliovirus receptor Proteins 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 7
- 201000000050 myeloid neoplasm Diseases 0.000 abstract description 6
- 102000004127 Cytokines Human genes 0.000 description 106
- 108090000695 Cytokines Proteins 0.000 description 106
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 76
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 50
- 102000040430 polynucleotide Human genes 0.000 description 35
- 108091033319 polynucleotide Proteins 0.000 description 35
- 239000002157 polynucleotide Substances 0.000 description 35
- 210000001744 T-lymphocyte Anatomy 0.000 description 32
- 239000012634 fragment Substances 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 102000013691 Interleukin-17 Human genes 0.000 description 24
- 108050003558 Interleukin-17 Proteins 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 23
- 238000010362 genome editing Methods 0.000 description 22
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 21
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 21
- 108091008874 T cell receptors Proteins 0.000 description 21
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 20
- 102000053602 DNA Human genes 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 14
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 14
- 210000002304 esc Anatomy 0.000 description 14
- 150000007523 nucleic acids Chemical group 0.000 description 14
- 102100030704 Interleukin-21 Human genes 0.000 description 13
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 13
- 102000040945 Transcription factor Human genes 0.000 description 13
- 108091023040 Transcription factor Proteins 0.000 description 13
- 108010074108 interleukin-21 Proteins 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 12
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 12
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 12
- 239000002771 cell marker Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 230000002062 proliferating effect Effects 0.000 description 12
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 11
- 101000688606 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Proteins 0.000 description 11
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 11
- 108010043610 KIR Receptors Proteins 0.000 description 11
- 102000002698 KIR Receptors Human genes 0.000 description 11
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 11
- 102100024242 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Human genes 0.000 description 11
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 11
- 108091005735 TGF-beta receptors Proteins 0.000 description 11
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 11
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 11
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 11
- 108010049777 Ankyrins Proteins 0.000 description 10
- 102000008102 Ankyrins Human genes 0.000 description 10
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 10
- 108091033409 CRISPR Proteins 0.000 description 10
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 10
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 10
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 102000004389 Ribonucleoproteins Human genes 0.000 description 10
- 108010081734 Ribonucleoproteins Proteins 0.000 description 10
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 10
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 229920002477 rna polymer Polymers 0.000 description 10
- 229950010342 uridine triphosphate Drugs 0.000 description 10
- 102100032937 CD40 ligand Human genes 0.000 description 9
- 238000010354 CRISPR gene editing Methods 0.000 description 9
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 9
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 9
- 108010065805 Interleukin-12 Proteins 0.000 description 9
- 102000013462 Interleukin-12 Human genes 0.000 description 9
- 102100021592 Interleukin-7 Human genes 0.000 description 9
- 108010002586 Interleukin-7 Proteins 0.000 description 9
- 101150069255 KLRC1 gene Proteins 0.000 description 9
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 9
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 9
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 description 9
- 101710137422 Suppressor of cytokine signaling 2 Proteins 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 238000007480 sanger sequencing Methods 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 108010029697 CD40 Ligand Proteins 0.000 description 8
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 8
- 102000001301 EGF receptor Human genes 0.000 description 8
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 8
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 8
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 7
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 7
- 102100031789 Myeloid-derived growth factor Human genes 0.000 description 7
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 7
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 6
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 6
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 6
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 6
- 102100034980 ICOS ligand Human genes 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102000017578 LAG3 Human genes 0.000 description 6
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 6
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 6
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 6
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 6
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 238000003209 gene knockout Methods 0.000 description 6
- 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 description 6
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 6
- 230000004068 intracellular signaling Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102000008682 Argonaute Proteins Human genes 0.000 description 5
- 108010088141 Argonaute Proteins Proteins 0.000 description 5
- 108700012439 CA9 Proteins 0.000 description 5
- 102100027207 CD27 antigen Human genes 0.000 description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 5
- 206010010144 Completed suicide Diseases 0.000 description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 5
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 5
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 5
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 5
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 5
- 108010065637 Interleukin-23 Proteins 0.000 description 5
- 102000013264 Interleukin-23 Human genes 0.000 description 5
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 108010002335 Interleukin-9 Proteins 0.000 description 5
- 102000000585 Interleukin-9 Human genes 0.000 description 5
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102000003735 Mesothelin Human genes 0.000 description 5
- 108090000015 Mesothelin Proteins 0.000 description 5
- 102100034256 Mucin-1 Human genes 0.000 description 5
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000003198 gene knock in Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000001226 triphosphate Substances 0.000 description 5
- 235000011178 triphosphate Nutrition 0.000 description 5
- RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 description 4
- BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 4
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 4
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 4
- 101150083678 IL2 gene Proteins 0.000 description 4
- 102100025390 Integrin beta-2 Human genes 0.000 description 4
- 102100030694 Interleukin-11 Human genes 0.000 description 4
- 108090000177 Interleukin-11 Proteins 0.000 description 4
- 102000003816 Interleukin-13 Human genes 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 102000003810 Interleukin-18 Human genes 0.000 description 4
- 108090000171 Interleukin-18 Proteins 0.000 description 4
- 102100030703 Interleukin-22 Human genes 0.000 description 4
- 108010066979 Interleukin-27 Proteins 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- 102000000646 Interleukin-3 Human genes 0.000 description 4
- 102100021596 Interleukin-31 Human genes 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 210000003981 ectoderm Anatomy 0.000 description 4
- 210000001900 endoderm Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 108010074109 interleukin-22 Proteins 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003716 mesoderm Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108010025415 Cyclin-Dependent Kinase 8 Proteins 0.000 description 3
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 3
- 102100020986 DNA-binding protein RFX5 Human genes 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 101001075432 Homo sapiens DNA-binding protein RFX5 Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 3
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 3
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 3
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 3
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 description 3
- 101000945340 Homo sapiens Killer cell immunoglobulin-like receptor 2DS1 Proteins 0.000 description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 3
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 3
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 3
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 description 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 3
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 3
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 3
- 101800003050 Interleukin-16 Proteins 0.000 description 3
- 102000049772 Interleukin-16 Human genes 0.000 description 3
- 102100039879 Interleukin-19 Human genes 0.000 description 3
- 108050009288 Interleukin-19 Proteins 0.000 description 3
- 102100036679 Interleukin-26 Human genes 0.000 description 3
- 101710181613 Interleukin-31 Proteins 0.000 description 3
- 108010067003 Interleukin-33 Proteins 0.000 description 3
- 101710181549 Interleukin-34 Proteins 0.000 description 3
- 108091007973 Interleukin-36 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 description 3
- 102100033631 Killer cell immunoglobulin-like receptor 2DS1 Human genes 0.000 description 3
- 101150030213 Lag3 gene Proteins 0.000 description 3
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100023123 Mucin-16 Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100035487 Nectin-3 Human genes 0.000 description 3
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 3
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 3
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 3
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 3
- 108010020764 Transposases Proteins 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 102100022748 Wilms tumor protein Human genes 0.000 description 3
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 3
- 102000034337 acetylcholine receptors Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 229960002204 daratumumab Drugs 0.000 description 3
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 229950009760 epratuzumab Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 102000027596 immune receptors Human genes 0.000 description 3
- 108091008915 immune receptors Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 108090000681 interleukin 20 Proteins 0.000 description 3
- 102000004114 interleukin 20 Human genes 0.000 description 3
- 102000003898 interleukin-24 Human genes 0.000 description 3
- 108090000237 interleukin-24 Proteins 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 229950003734 milatuzumab Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 108010059434 tapasin Proteins 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 229960003989 tocilizumab Drugs 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 229950000815 veltuzumab Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 102100032412 Basigin Human genes 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 102100024210 CD166 antigen Human genes 0.000 description 2
- 102100038077 CD226 antigen Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 2
- 241000218631 Coniferophyta Species 0.000 description 2
- 101710132484 Cytokine-inducible SH2-containing protein Proteins 0.000 description 2
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 241000214054 Equine rhinitis A virus Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 2
- 108050001931 Folate receptor alpha Proteins 0.000 description 2
- 102000010451 Folate receptor alpha Human genes 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 102100040578 G antigen 7 Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 2
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 2
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 2
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 2
- 101710186083 Interleukin-17 receptor A Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 102100027159 Membrane primary amine oxidase Human genes 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 2
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 2
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 2
- 102000002755 Natural Cytotoxicity Triggering Receptor 1 Human genes 0.000 description 2
- 108010004220 Natural Cytotoxicity Triggering Receptor 2 Proteins 0.000 description 2
- 102000002751 Natural Cytotoxicity Triggering Receptor 2 Human genes 0.000 description 2
- 102000002752 Natural Cytotoxicity Triggering Receptor 3 Human genes 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 108060006580 PRAME Proteins 0.000 description 2
- 102000036673 PRAME Human genes 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 241001672814 Porcine teschovirus 1 Species 0.000 description 2
- 102100040120 Prominin-1 Human genes 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 2
- 102100029216 SLAM family member 5 Human genes 0.000 description 2
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 2
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 2
- 101150063267 STAT5B gene Proteins 0.000 description 2
- 102100034201 Sclerostin Human genes 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 2
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 101710137414 Suppressor of cytokine signaling 4 Proteins 0.000 description 2
- 101710137416 Suppressor of cytokine signaling 6 Proteins 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 2
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 2
- 241001648840 Thosea asigna virus Species 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101710127857 Wilms tumor protein Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 229960000106 biosimilars Drugs 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 108091092259 cell-free RNA Proteins 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229940126610 derlotuximab biotin Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960004497 dinutuximab Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
- 229960004413 flucytosine Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 229950002140 futuximab Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 238000003197 gene knockdown Methods 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 102000056003 human IL15 Human genes 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000008004 immune attack Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229950001237 lilotomab Drugs 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 229950005674 modotuximab Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229960003347 obinutuzumab Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- BNJNAEJASPUJTO-DUOHOMBCSA-N vadastuximab talirine Chemical compound COc1ccc(cc1)C2=CN3[C@@H](C2)C=Nc4cc(OCCCOc5cc6N=C[C@@H]7CC(=CN7C(=O)c6cc5OC)c8ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN9C(=O)C[C@@H](SC[C@H](N)C(=O)O)C9=O)C(C)C)cc8)c(OC)cc4C3=O BNJNAEJASPUJTO-DUOHOMBCSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229950007157 zolbetuximab Drugs 0.000 description 2
- MFZSNESUTRVBQX-XEURHVNRSA-N (2S)-2-amino-6-[4-[[3-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-3-oxopropyl]disulfanyl]pentanoylamino]hexanoic acid Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSSC(C)CCC(=O)NCCCC[C@H](N)C(O)=O)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 MFZSNESUTRVBQX-XEURHVNRSA-N 0.000 description 1
- FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical compound N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 description 1
- ZMEWRPBAQVSBBB-GOTSBHOMSA-N (2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[[2-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetyl]amino]hexanoic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 ZMEWRPBAQVSBBB-GOTSBHOMSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- LAXVMANLDGWYJP-UHFFFAOYSA-N 2-amino-5-(2-aminoethyl)naphthalene-1-sulfonic acid Chemical compound NC1=CC=C2C(CCN)=CC=CC2=C1S(O)(=O)=O LAXVMANLDGWYJP-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- 108010005465 AC133 Antigen Proteins 0.000 description 1
- 102000005908 AC133 Antigen Human genes 0.000 description 1
- 229940127148 AGS67E Drugs 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102100021305 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 235000016626 Agrimonia eupatoria Nutrition 0.000 description 1
- 101100385358 Alicyclobacillus acidoterrestris (strain ATCC 49025 / DSM 3922 / CIP 106132 / NCIMB 13137 / GD3B) cas12b gene Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 description 1
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102100025665 Angiopoietin-related protein 1 Human genes 0.000 description 1
- 102000004149 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000218495 Bactrocera correcta Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 108010064528 Basigin Proteins 0.000 description 1
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001536303 Botryococcus braunii Species 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108060001253 CD99 Proteins 0.000 description 1
- 102000024905 CD99 Human genes 0.000 description 1
- 101150108242 CDC27 gene Proteins 0.000 description 1
- 229940038671 CDX-1401 vaccine Drugs 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102100039532 Calcium-activated chloride channel regulator 2 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000013602 Cardiac Myosins Human genes 0.000 description 1
- 108010051609 Cardiac Myosins Proteins 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101710181340 Chaperone protein DnaK2 Proteins 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 244000249214 Chlorella pyrenoidosa Species 0.000 description 1
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 1
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 101710198480 Clumping factor A Proteins 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 101150074775 Csf1 gene Proteins 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100024462 Cyclin-dependent kinase 4 inhibitor B Human genes 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102100033553 Delta-like protein 4 Human genes 0.000 description 1
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 1
- 101710127030 Dermatan-sulfate epimerase Proteins 0.000 description 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 101100219190 Drosophila melanogaster byn gene Proteins 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100035078 ETS-related transcription factor Elf-2 Human genes 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- 229940126626 Ektomab Drugs 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 108010055191 EphA3 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 description 1
- 101100129584 Escherichia coli (strain K12) trg gene Proteins 0.000 description 1
- 229940126611 FBTA05 Drugs 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 102100039699 G antigen 4 Human genes 0.000 description 1
- 102100039698 G antigen 5 Human genes 0.000 description 1
- 101710092267 G antigen 5 Proteins 0.000 description 1
- 102100039713 G antigen 6 Human genes 0.000 description 1
- 101710092269 G antigen 6 Proteins 0.000 description 1
- 101150106478 GPS1 gene Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 1
- 101150063370 Gzmb gene Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100040407 Heat shock 70 kDa protein 1B Human genes 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102100028721 Hermansky-Pudlak syndrome 5 protein Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 1
- 101001042227 Homo sapiens Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Proteins 0.000 description 1
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000888580 Homo sapiens Calcium-activated chloride channel regulator 2 Proteins 0.000 description 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101000980919 Homo sapiens Cyclin-dependent kinase 4 inhibitor B Proteins 0.000 description 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 description 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000877377 Homo sapiens ETS-related transcription factor Elf-2 Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 description 1
- 101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000886678 Homo sapiens G antigen 2D Proteins 0.000 description 1
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 description 1
- 101001055308 Homo sapiens Immunoglobulin heavy constant epsilon Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 1
- 101001010591 Homo sapiens Interleukin-20 Proteins 0.000 description 1
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 description 1
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 1
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 1
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 description 1
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 description 1
- 101000945337 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5A Proteins 0.000 description 1
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 1
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 description 1
- 101000945343 Homo sapiens Killer cell immunoglobulin-like receptor 2DS3 Proteins 0.000 description 1
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 description 1
- 101000945346 Homo sapiens Killer cell immunoglobulin-like receptor 2DS5 Proteins 0.000 description 1
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 1
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 description 1
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 description 1
- 101000945492 Homo sapiens Killer cell immunoglobulin-like receptor 3DS1 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 101000694615 Homo sapiens Membrane primary amine oxidase Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 101000721712 Homo sapiens NTF2-related export protein 1 Proteins 0.000 description 1
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 1
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 description 1
- 101000610208 Homo sapiens Poly(A) polymerase gamma Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 101000842302 Homo sapiens Protein-cysteine N-palmitoyltransferase HHAT Proteins 0.000 description 1
- 101001109419 Homo sapiens RNA-binding protein NOB1 Proteins 0.000 description 1
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 description 1
- 101000727472 Homo sapiens Reticulon-4 Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101000713322 Homo sapiens SAP30-binding protein Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 description 1
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 description 1
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101100370133 Homo sapiens TPH1 gene Proteins 0.000 description 1
- 101000626112 Homo sapiens Telomerase protein component 1 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 1
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 1
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102100026212 Immunoglobulin heavy constant epsilon Human genes 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108050002021 Integrator complex subunit 2 Proteins 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100032816 Integrin alpha-6 Human genes 0.000 description 1
- 102100032832 Integrin alpha-7 Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102100035014 Interleukin-17 receptor B Human genes 0.000 description 1
- 101710186071 Interleukin-17 receptor B Proteins 0.000 description 1
- 102100035012 Interleukin-17 receptor C Human genes 0.000 description 1
- 101710186068 Interleukin-17 receptor C Proteins 0.000 description 1
- 102100035015 Interleukin-17 receptor D Human genes 0.000 description 1
- 101710186062 Interleukin-17 receptor D Proteins 0.000 description 1
- 102100035016 Interleukin-17 receptor E Human genes 0.000 description 1
- 101710186076 Interleukin-17 receptor E Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100030692 Interleukin-20 Human genes 0.000 description 1
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 description 1
- 101710131691 Interleukin-31 receptor subunit alpha Proteins 0.000 description 1
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N Iodine I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 1
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 1
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 1
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 description 1
- 102100033629 Killer cell immunoglobulin-like receptor 2DL5A Human genes 0.000 description 1
- 102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 description 1
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 description 1
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 description 1
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 description 1
- 102100033626 Killer cell immunoglobulin-like receptor 2DS5 Human genes 0.000 description 1
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 1
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 description 1
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 description 1
- 102100034833 Killer cell immunoglobulin-like receptor 3DS1 Human genes 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 101001089108 Lotus tetragonolobus Anti-H(O) lectin Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102000034655 MIF Human genes 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 102000005727 Mammaglobin A Human genes 0.000 description 1
- 108010031030 Mammaglobin A Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241000196323 Marchantiophyta Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 1
- 101001062862 Mus musculus Fatty acid-binding protein, adipocyte Proteins 0.000 description 1
- 101100176487 Mus musculus Gzmc gene Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 1
- 102100021831 Myelin-associated glycoprotein Human genes 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- 241001250129 Nannochloropsis gaditana Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 description 1
- 101000621505 Peanut clump virus (isolate 87/TGTA2) Suppressor of RNA silencing Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102000017794 Perilipin-2 Human genes 0.000 description 1
- 108010067163 Perilipin-2 Proteins 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 102100040153 Poly(A) polymerase gamma Human genes 0.000 description 1
- 241000985694 Polypodiopsida Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 description 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030616 Protein-cysteine N-palmitoyltransferase HHAT Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 101100443768 Rattus norvegicus Dock9 gene Proteins 0.000 description 1
- 101001023831 Rattus norvegicus Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 1
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100036909 SAP30-binding protein Human genes 0.000 description 1
- 102100031778 SH2 domain-containing protein 1B Human genes 0.000 description 1
- 101710097986 SH2 domain-containing protein 1B Proteins 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 101150058731 STAT5A gene Proteins 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000593524 Sargassum patens Species 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 102100038689 Scm-like with four MBT domains protein 1 Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 1
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 102000008036 Suppressor of Cytokine Signaling Proteins Human genes 0.000 description 1
- 108010075383 Suppressor of Cytokine Signaling Proteins Proteins 0.000 description 1
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 description 1
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 1
- 102100030524 Suppressor of cytokine signaling 4 Human genes 0.000 description 1
- 102100030523 Suppressor of cytokine signaling 5 Human genes 0.000 description 1
- 101710137415 Suppressor of cytokine signaling 5 Proteins 0.000 description 1
- 102100030530 Suppressor of cytokine signaling 6 Human genes 0.000 description 1
- 102100030529 Suppressor of cytokine signaling 7 Human genes 0.000 description 1
- 101710137344 Suppressor of cytokine signaling 7 Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 241001196954 Theilovirus Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 1
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- JCZSFCLRSONYLH-UHFFFAOYSA-N Wyosine Natural products N=1C(C)=CN(C(C=2N=C3)=O)C=1N(C)C=2N3C1OC(CO)C(O)C1O JCZSFCLRSONYLH-UHFFFAOYSA-N 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 description 1
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 description 1
- NOXMCJDDSWCSIE-DAGMQNCNSA-N [[(2R,3S,4R,5R)-5-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O NOXMCJDDSWCSIE-DAGMQNCNSA-N 0.000 description 1
- AZJLCKAEZFNJDI-DJLDLDEBSA-N [[(2r,3s,5r)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 AZJLCKAEZFNJDI-DJLDLDEBSA-N 0.000 description 1
- AZRNEVJSOSKAOC-VPHBQDTQSA-N [[(2r,3s,5r)-5-[5-[(e)-3-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]prop-1-enyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(\C=C\CNC(=O)CCCCCNC(=O)CCCC[C@H]2[C@H]3NC(=O)N[C@H]3CS2)=C1 AZRNEVJSOSKAOC-VPHBQDTQSA-N 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N [[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- ZXZIQGYRHQJWSY-NKWVEPMBSA-N [hydroxy-[[(2s,5r)-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)O)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 ZXZIQGYRHQJWSY-NKWVEPMBSA-N 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229950005008 abituzumab Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229950004283 actoxumab Drugs 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229950008995 aducanumab Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960003227 afelimomab Drugs 0.000 description 1
- 229950008459 alacizumab pegol Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
- 229950009106 altumomab Drugs 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006061 anatumomab mafenatox Drugs 0.000 description 1
- 229950006588 anetumab ravtansine Drugs 0.000 description 1
- 108010069801 angiopoietin 4 Proteins 0.000 description 1
- 229950010117 anifrolumab Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229950005794 anrukinzumab Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 101150059062 apln gene Proteins 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229950005725 arcitumomab Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229950000847 ascrinvacumab Drugs 0.000 description 1
- 229950002882 aselizumab Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950005122 atinumab Drugs 0.000 description 1
- 229950000103 atorolimumab Drugs 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- 229950003269 bectumomab Drugs 0.000 description 1
- 229960004965 begelomab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 229950010015 bertilimumab Drugs 0.000 description 1
- 229950010559 besilesomab Drugs 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- CXQCLLQQYTUUKJ-ALWAHNIESA-N beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1<->1')-Cer(d18:1/18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 CXQCLLQQYTUUKJ-ALWAHNIESA-N 0.000 description 1
- 229950008086 bezlotoxumab Drugs 0.000 description 1
- 229950001303 biciromab Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229950006326 bimagrumab Drugs 0.000 description 1
- 229950002853 bimekizumab Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229950005042 blosozumab Drugs 0.000 description 1
- 229950011350 bococizumab Drugs 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 229950000025 brolucizumab Drugs 0.000 description 1
- 229950001478 brontictuzumab Drugs 0.000 description 1
- 229940126608 cBR96-doxorubicin immunoconjugate Drugs 0.000 description 1
- 229950009667 camidanlumab tesirine Drugs 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- 229950011547 cantuzumab ravtansine Drugs 0.000 description 1
- 229950002176 caplacizumab Drugs 0.000 description 1
- 108010023376 caplacizumab Proteins 0.000 description 1
- 229940034605 capromab pendetide Drugs 0.000 description 1
- 229950000771 carlumab Drugs 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 229950006754 cedelizumab Drugs 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229950010905 citatuzumab bogatox Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 229950001565 clazakizumab Drugs 0.000 description 1
- 229950002334 clenoliximab Drugs 0.000 description 1
- 229950002595 clivatuzumab tetraxetan Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229950007906 codrituzumab Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229950005458 coltuximab ravtansine Drugs 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 229950009735 concizumab Drugs 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 229950001954 crenezumab Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108010012154 cytokine inducible SH2-containing protein Proteins 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 229950005026 dapirolizumab pegol Drugs 0.000 description 1
- 108010048522 dapirolizumab pegol Proteins 0.000 description 1
- 229950008135 dectrekumab Drugs 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229950007998 demcizumab Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229950004079 denintuzumab mafodotin Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 229950002756 depatuxizumab Drugs 0.000 description 1
- 229950008925 depatuxizumab mafodotin Drugs 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000027832 depurination Effects 0.000 description 1
- 229950008962 detumomab Drugs 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 229950011037 diridavumab Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229950005168 dorlimomab aritox Drugs 0.000 description 1
- 229950009964 drozitumab Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229950011453 dusigitumab Drugs 0.000 description 1
- 229950000006 ecromeximab Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229950011109 edobacomab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229950002209 efungumab Drugs 0.000 description 1
- 229950010217 eldelumab Drugs 0.000 description 1
- 229950002519 elgemtumab Drugs 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229950002507 elsilimomab Drugs 0.000 description 1
- 229950004647 emactuzumab Drugs 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 229950004255 emibetuzumab Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 229950003048 enavatuzumab Drugs 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229950004930 enfortumab vedotin Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950000565 enlimomab pegol Drugs 0.000 description 1
- 229950004270 enoblituzumab Drugs 0.000 description 1
- 229950007313 enokizumab Drugs 0.000 description 1
- 229950001752 enoticumab Drugs 0.000 description 1
- 229950010640 ensituximab Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229950006414 epitumomab cituxetan Drugs 0.000 description 1
- 229950004292 erlizumab Drugs 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229950004912 etrolizumab Drugs 0.000 description 1
- 229950004341 evinacumab Drugs 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 229950005562 exbivirumab Drugs 0.000 description 1
- 229940093443 fanolesomab Drugs 0.000 description 1
- 229950001488 faralimomab Drugs 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- 229950000335 fasinumab Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229950001563 felvizumab Drugs 0.000 description 1
- 229950010512 fezakinumab Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229950002846 ficlatuzumab Drugs 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 229950004409 firivumab Drugs 0.000 description 1
- 229950010320 flanvotumab Drugs 0.000 description 1
- 229950010043 fletikumab Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 229950004923 fontolizumab Drugs 0.000 description 1
- 229950004356 foralumab Drugs 0.000 description 1
- 229950011078 foravirumab Drugs 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 229950009370 fulranumab Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 229950002508 gantenerumab Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229950004792 gavilimomab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 229950003717 gevokizumab Drugs 0.000 description 1
- 229950002026 girentuximab Drugs 0.000 description 1
- 229950009672 glembatumumab vedotin Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 229940126613 gomiliximab Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229950010864 guselkumab Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000007446 host cell death Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229950010245 ibalizumab Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229950006359 icrucumab Drugs 0.000 description 1
- 229960002308 idarucizumab Drugs 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 229950002200 igovomab Drugs 0.000 description 1
- 229950003680 imalumab Drugs 0.000 description 1
- 229950007354 imciromab Drugs 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 229950009230 inclacumab Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229950011428 indatuximab ravtansine Drugs 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 229950000932 indusatumab vedotin Drugs 0.000 description 1
- 229950005015 inebilizumab Drugs 0.000 description 1
- 229940050282 inebilizumab-cdon Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229950007937 inolimomab Drugs 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 108010043603 integrin alpha4beta7 Proteins 0.000 description 1
- 108010024084 integrin alpha7 Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 230000006831 intrinsic signaling Effects 0.000 description 1
- 229940005977 iodine i-131 Drugs 0.000 description 1
- 229950003629 ipafricept Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 229950009645 istiratumab Drugs 0.000 description 1
- 229950003818 itolizumab Drugs 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 229950010828 keliximab Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 229950004881 labetuzumab govitecan Drugs 0.000 description 1
- CBNAAKBWBABMBY-LQCKLLCCSA-N labetuzumab-sn38 Chemical compound N([C@@H](CCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O CBNAAKBWBABMBY-LQCKLLCCSA-N 0.000 description 1
- 229950000482 lampalizumab Drugs 0.000 description 1
- 108010032674 lampalizumab Proteins 0.000 description 1
- 229950002183 lebrikizumab Drugs 0.000 description 1
- 229950001275 lemalesomab Drugs 0.000 description 1
- 229950007439 lenzilumab Drugs 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 229950005173 libivirumab Drugs 0.000 description 1
- 229950004529 lifastuzumab vedotin Drugs 0.000 description 1
- 229950009923 ligelizumab Drugs 0.000 description 1
- 229940126616 lilotomab satetraxetan Drugs 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229950006208 lodelcizumab Drugs 0.000 description 1
- 229950000359 lokivetmab Drugs 0.000 description 1
- 229950009758 loncastuximab tesirine Drugs 0.000 description 1
- 229950003526 lorvotuzumab mertansine Drugs 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 229950008140 lulizumab pegol Drugs 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- 229950010079 lumretuzumab Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 229950003135 margetuximab Drugs 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 229950008083 maslimomab Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 229950007254 mavrilimumab Drugs 0.000 description 1
- 101150094281 mcl1 gene Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000000135 megakaryocyte-erythroid progenitor cell Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229950005555 metelimumab Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 229950002142 minretumomab Drugs 0.000 description 1
- 229950000035 mirvetuximab soravtansine Drugs 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229950008897 morolimumab Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 229950003027 nacolomab tafenatox Drugs 0.000 description 1
- 229950007708 namilumab Drugs 0.000 description 1
- 229950009793 naptumomab estafenatox Drugs 0.000 description 1
- 229950008353 narnatumab Drugs 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229960002915 nebacumab Drugs 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229950010012 nemolizumab Drugs 0.000 description 1
- 229950009675 nerelimomab Drugs 0.000 description 1
- 229950002697 nesvacumab Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229960003419 obiltoxaximab Drugs 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229950010465 odulimomab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229950010006 olokizumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 229950002104 ontuxizumab Drugs 0.000 description 1
- 229950010704 opicinumab Drugs 0.000 description 1
- 229950009057 oportuzumab monatox Drugs 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229950009007 orticumab Drugs 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 229950000121 otlertuzumab Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229950003709 oxelumab Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229950009723 ozanezumab Drugs 0.000 description 1
- 229950004327 ozoralizumab Drugs 0.000 description 1
- 229950010626 pagibaximab Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940126618 pankomab Drugs 0.000 description 1
- 229950003570 panobacumab Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229950004260 parsatuzumab Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 229950000037 pasotuxizumab Drugs 0.000 description 1
- 229950003522 pateclizumab Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950010966 patritumab Drugs 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 229950011098 pendetide Drugs 0.000 description 1
- 229940067082 pentetate Drugs 0.000 description 1
- 229950005079 perakizumab Drugs 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229950010074 pinatuzumab vedotin Drugs 0.000 description 1
- 229940126620 pintumomab Drugs 0.000 description 1
- 229950008092 placulumab Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229950009416 polatuzumab vedotin Drugs 0.000 description 1
- 229950003486 ponezumab Drugs 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229950003700 priliximab Drugs 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229950011407 pritoxaximab Drugs 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 239000013635 pyrimidine dimer Substances 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- QQXQGKSPIMGUIZ-AEZJAUAXSA-N queuosine Chemical compound C1=2C(=O)NC(N)=NC=2N([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=C1CN[C@H]1C=C[C@H](O)[C@@H]1O QQXQGKSPIMGUIZ-AEZJAUAXSA-N 0.000 description 1
- 229950003033 quilizumab Drugs 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 229950011613 racotumomab Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229950011639 radretumab Drugs 0.000 description 1
- 229950002786 rafivirumab Drugs 0.000 description 1
- 229950009885 ralpancizumab Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229960004910 raxibacumab Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229950000987 refanezumab Drugs 0.000 description 1
- 229950005854 regavirumab Drugs 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229950005978 rinucumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- 229950010699 roledumab Drugs 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 229950010316 rontalizumab Drugs 0.000 description 1
- 229950009092 rovelizumab Drugs 0.000 description 1
- 229950005374 ruplizumab Drugs 0.000 description 1
- 229950000143 sacituzumab govitecan Drugs 0.000 description 1
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229950000106 samalizumab Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229950007308 satumomab Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229950008834 seribantumab Drugs 0.000 description 1
- 229950003850 setoxaximab Drugs 0.000 description 1
- 229950004951 sevirumab Drugs 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 229950010077 sifalimumab Drugs 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 229950006094 sirukumab Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229950003763 sofituzumab vedotin Drugs 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 229950011267 solitomab Drugs 0.000 description 1
- 229950006551 sontuzumab Drugs 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 229950002549 stamulumab Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229950010708 sulesomab Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229950001915 suvizumab Drugs 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229950010265 tabalumab Drugs 0.000 description 1
- 229950001072 tadocizumab Drugs 0.000 description 1
- 229950004218 talizumab Drugs 0.000 description 1
- 229950008160 tanezumab Drugs 0.000 description 1
- 229950001603 taplitumomab paptox Drugs 0.000 description 1
- 229950007435 tarextumab Drugs 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229950000864 technetium (99mtc) nofetumomab merpentan Drugs 0.000 description 1
- 229950001788 tefibazumab Drugs 0.000 description 1
- 229950008300 telimomab aritox Drugs 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- 229950001289 tenatumomab Drugs 0.000 description 1
- 229950000301 teneliximab Drugs 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- 229950010259 teprotumumab Drugs 0.000 description 1
- 229950009054 tesidolumab Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- IBVCSSOEYUMRLC-GABYNLOESA-N texas red-5-dutp Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(C#CCNS(=O)(=O)C=2C=C(C(C=3C4=CC=5CCCN6CCCC(C=56)=C4OC4=C5C6=[N+](CCC5)CCCC6=CC4=3)=CC=2)S([O-])(=O)=O)=C1 IBVCSSOEYUMRLC-GABYNLOESA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- 229950005515 tildrakizumab Drugs 0.000 description 1
- 229950004269 tisotumab vedotin Drugs 0.000 description 1
- 101150061299 tme gene Proteins 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- 229950008836 tosatoxumab Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229950005808 tovetumab Drugs 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000037918 transfusion-transmitted disease Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 229950010086 tregalizumab Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 229950006444 trevogrumab Drugs 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 229950005082 tuvirumab Drugs 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- 229950010095 ulocuplumab Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229950004362 urtoxazumab Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229950003520 utomilumab Drugs 0.000 description 1
- 229950001694 vadastuximab talirine Drugs 0.000 description 1
- 229950001876 vandortuzumab vedotin Drugs 0.000 description 1
- 229950008718 vantictumab Drugs 0.000 description 1
- 229950000449 vanucizumab Drugs 0.000 description 1
- 229950000386 vapaliximab Drugs 0.000 description 1
- 229950001067 varlilumab Drugs 0.000 description 1
- 229950002148 vatelizumab Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229950005208 vepalimomab Drugs 0.000 description 1
- 229950010789 vesencumab Drugs 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229950003511 votumumab Drugs 0.000 description 1
- JCZSFCLRSONYLH-QYVSTXNMSA-N wyosin Chemical compound N=1C(C)=CN(C(C=2N=C3)=O)C=1N(C)C=2N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JCZSFCLRSONYLH-QYVSTXNMSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 108010015889 zeta receptor Proteins 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009083 ziralimumab Drugs 0.000 description 1
- 229950001346 zolimomab aritox Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- Cancer e.g., neoplasm, tumor
- cancer is a leading cause of death worldwide, accounting for about 10 million deaths annually. Cancer continues to bring increasing health, economic, and emotional burden on individuals, families, communities, and countries. Increase understanding of cancer biology (e.g., specifically cancer immune biology) and genetic engineering has encouraged development of adoptive cell therapies (e.g., cellular immunotherapy) , with a goal to treat or control a number of different cancers.
- adoptive cell therapies e.g., cellular immunotherapy
- the present disclosure provides methods and systems for treating cancer.
- Some aspects of the present disclosure provides engineered immune cells (e.g., engineered natural killer (NK) cells) and methods of use thereof for treatment of cancer, such as, e.g., as hematologic malignancies or solid tumors.
- engineered immune cells e.g., engineered natural killer (NK) cells
- NK natural killer
- the present disclosure provides a population of engineered NK cells, wherein: an engineered NK cell of the population of engineered NK cells comprises a heterologous polypeptide, wherein the heterologous polypeptide comprises a heterologous IL-15; and a persistence level of the population of engineered NK cells in an environment that is substantially free of an exogenous interleukin-2 (IL-2) is at least about 5%greater than a control persistence level of a comparable population of NK cells in a control environment comprising the exogenous IL-2.
- IL-2 exogenous interleukin-2
- the present disclosure provides a population of engineered NK cells, wherein: an engineered NK cell of the population comprises a heterologous secretory IL-15; and the population of engineered NK cells exhibits a signaling level of an endogenous downstream signaling protein of IL-15 that is at least about 0.1-fold greater than a control signaling level of the endogenous downstream signaling protein of a control population of NK cells lacking the heterologous secretory IL-15.
- an engineered NK cell of the population of engineered NK cells comprises at least one heterologous hypo-immunity regulator polypeptide comprising one or more members selected from the group consisting of PD-L2, TGF-beta, CD46, CD55, and CD59; and the population of engineered NK cells exhibits enhanced resistance against immune rejection, as compared to that of a control population of NK cells lacking the at least one heterologous hypo-immunity regulator polypeptide.
- the present disclosure provides a population of engineered NK cells, wherein: an engineered NK cell of the population of engineered NK cells comprises a plurality of heterologous hypo-immunity regulator polypeptides; and the population of engineered NK cells exhibits enhanced resistance against immune rejection by at least about 5%, as compared to that of a control population of NK cells lacking one or more of the plurality of heterologous hypo-immunity regulator polypeptides.
- the present disclosure provides a population of engineered NK cells, wherein: an engineered NK cell of the population of engineered NK cells comprises reduced expression of at least one endogenous immune regulating polypeptide that is not PTPN2; and a persistence level or an anti-target cell cytotoxicity of the population of engineered NK cells that is greater than a control persistence level of a control population of NK cells lacking the reduced expression of the at least one endogenous immune regulating polypeptide that is not PTPN2.
- the present disclosure provides a composition comprising the population of engineered NK cells as disclosed herein.
- the present disclosure provides a method of generating the population of engineered NK cells as disclosed herein.
- the population pf engineered NK cells are generated from induced pluripotent stem cells (iPSCs) .
- the present disclosure provides a method of treating a subject in need thereof, the method comprising administering to the subject the population of engineered NK cells as disclosed herein.
- FIGs. 1A-1G illustrate engineered NK cells comprising a CD16 variant for enhanced CD16 signaling
- FIGs. 2A-2G illustrate engineered NK cells comprising a chimeric antigen receptor against CD19
- FIGs. 3A and 3B illustrate engineered T cells comprising heterologous human IL-15.
- FIGs. 4A-4E illustrate expression of CD56 + , NKG2A + , NKp30 + , NKp44 + , and NKp46 + among WT iNK and iNK differentiated from different hnCD16-iPSC clones.
- FIG. 4A the percentage of CD56 + cells in the total differentiated cells.
- FIG. 4B the percentage of NKG2A + in the CD56 + population.
- FIG. 4C the percentage of NKp30 + in the CD56 + population.
- FIG. 4D the percentage of NKp44 + in the CD56 + population.
- FIG. 4E the percentage of NKp46 + cells in the CD56 + population.
- FIG. 5 illustrates an overexpression of CD16 in hnCD16 (a variant with enhanced CD16 signaling) NK-92 cells detected by FACS (fluorescence-activated cell sorting) with PE (phycoerythrin) conjugated anti-CD16 antibody.
- FIG. 6 illustrates the surface expression of IL-15 in iNK cells differentiated from hIL15-IL15Ra fused-1 iPSC clones detected by FACS with APC (allophycocyanin) conjugated anti-IL-15 antibody.
- PW15, PW18, and PW23 are clones expressing membrane-bound IL-15.
- FIG. 7 illustrates an in-vitro growth curve of eNK cells differentiated from mbIL-15-expressing iPSC clones (KB-15) cultured with or without IL-2.
- FIGs. 8A-8E illustrate expression of CD56 + , NKG2A + , NKp30 + , NKp44 + , and NKp46 + among WT iNK and iNK differentiated from different mbIL-15-iPSC clones.
- FIG. 8A the percentage of CD56 + cells in the total differentiated cells.
- FIG. 8B the percentage of NKG2A + in the CD56 + population.
- FIG. 8C the percentage of NKp30 + in the CD56 + population.
- FIG. 8D the percentage of NKp44 + in the CD56 + population.
- FIG. 8E the percentage of NKp46 + cells in the CD56 + population.
- FIGs. 9A-9B illustrate NK cell concentrations in the peripheral blood of NCG mice having a Nalm-6 xenograft model at 8, 15 and 22 days post-infusion with engineered mbIL-15 eNK cells.
- FIG. 9A NK cells detected by FACS with CD56-APC antibody.
- FIG. 9B quantification of FIG. 9A.
- QN-019 denotes eNK expressing aCD19 CAR + hnCD16 + membrane-bound IL-15.
- QN-001 denotes WT eNK.
- FIGs. 10A-10C illustrate properties of NK cells differentiated from iPSC clones expressing secreted IL-15.
- FIG. 10A the percentage of CD56 + cells in the total differentiated cells among WT iNK cells and iNK differentiated from different sIL15-iPSC clones.
- FIG. 10B the concentration of IL-15 in culture medium from WT iNK cells and iNK cells differentiated from iPSC clones expressing secreted IL-15 (KA08) .
- FIG. 10C an in-vitro growth curve of WT eNK cells and eNK cells differentiated from secretory IL-15-expressing iPSC clones (OQ-20) , in absence of an exogenous cytokine.
- FIG. 11 illustrates a testing scheme for hypoimmunity via editing and differentiating iPSC.
- FIGs. 12A-12Q illustrate confirmed establishment of edit-1 clones to edit-9 clones.
- FIG. 12A illustrates FACS analysis of edit-1 clones (hiPSC electroporated with pre-mixed ribonucleoprotein [RNP] targeting B2M) .
- FIG. 12B illustrates sanger sequencing of edit-1 clones.
- FIG. 12C illustrates sanger sequencing of edit-2 clones (hiPSC electroporated with RNP targeting CIITA) .
- FIG. 12D illustrates FACS analysis of edit-3 clones (hiPSC electroporated with two RNPs targeting B2M and CIITA) .
- FIG. 12E illustrates sanger sequencing of edit-3 clones.
- FIG. 12A illustrates FACS analysis of edit-1 clones (hiPSC electroporated with pre-mixed ribonucleoprotein [RNP] targeting B2M) .
- FIG. 12B illustrates sanger sequencing of edit-1 clones
- FIG. 12F illustrates FACS analysis of edit-4 clones (hiPSC electroporated with a construct overexpressing PD-L1, PD-L2, TGF- ⁇ , HLA-E, HLA-G, CD47, IL-10, CCL-21, CD46, CD55, CD59 and two RNPs, targeting B2M and CIITA) .
- FIG. 12G illustrates sanger sequencing of edit-4 clones.
- FIG. 12H illustrates FACS analysis of edit-5 clones (hiPSC electroporated with a construct overexpressing of PD-L1, HLA-E, CD47, IL-10, CCL-21 and two RNPs, targeting B2M and CIITA) .
- FIG. 12I illustrates sanger sequencing of edit-5 clones.
- FIG. 12F illustrates FACS analysis of edit-4 clones (hiPSC electroporated with a construct overexpressing PD-L1, PD-L2, TGF- ⁇ , HLA-E, HLA-G,
- FIG. 12J illustrates FACS analysis of edit-6 clones (hiPSC electroporated with a construtct overexpressing PD-L1, HLA-E, CD47, CD46, CD55, CD59 and two RNPs, targeting B2M and CIITA) .
- FIG. 12K illustrates sanger sequencing of edit-6 clones.
- FIG. 12L illustrates FACS analysis of edit-7 clones (hiPSC electroporated with a construct overexpressing PD-L1, HLA-E, CD47, CCL-21, CD55 and two RNPs, targeting B2M and CIITA) .
- FIG. 12M illustrates sanger sequencing of edit-7 clones.
- FIG. 12J illustrates FACS analysis of edit-6 clones (hiPSC electroporated with a construtct overexpressing PD-L1, HLA-E, CD47, CD46, CD55, CD59 and two RNPs, targeting B2M and CIITA) .
- FIG. 12N illustrates FACS analysis of edit-8 clones (hiPSC electroporated with a construct overexpressing of CD47 and two RNPs, targeting B2M and CIITA) .
- FIG. 12O illustrates sanger sequencing of edit-8 clones.
- FIG. 12P illustrates FACS analysis of edit-9 clones (hiPSC electroporated with a construct overexpressing PD-L1, PD-L2, TGF- ⁇ , HLA-E, HLA-G, CD47, IL-10, CCL-21, CD46, CD55, CD59, two RNPs, targeting B2M and CIITA) .
- FIG. 12Q illustrates sanger sequencing of edit-9 clones. The gene edits from edit-1 through edit-9 are summarized in FIG. 18.
- FIGs. 13A-13S illustrate functional properties of edit-1 clones to edit-9 clones.
- FIG. 13A cell lysis when different edited iPSC clones co-incubating with human complement.
- FIG. 13B cell lysis when different edited iPSC clones co-incubating with cord blood-derived natural killer (CBNK) .
- FIG. 13C cell counts of CD56 + cells among different iNK differentiated from corresponding edited iPSC. The iPSC clone number was shown in the parenthesis.
- FIG. 13D CD56 + percentage among different iNK differentiated from corresponding edited iPSC. The iPSC clone number was shown in the parenthesis.
- FIG. 13A cell lysis when different edited iPSC clones co-incubating with human complement.
- FIG. 13B cell lysis when different edited iPSC clones co-incubating with cord blood-derived natural killer (CBNK) .
- FIG. 13C cell counts
- FIG. 13E NKG2A + percentage among different iNK differentiated from corresponding edited iPSC. The iPSC clone number was shown in the parenthesis.
- FIG. 13F NK cell-mediated lysis of K562 cells when co-cultured with corresponding eNKs at a single time point.
- FIG. 13G NK cell-mediated lysis of K562 cells when co-cultured with corresponding eNKs over 6 days.
- FIG. 13H the percentage of proliferating CD8 + T cells when iNK with different edits are co-cultured with peripheral blood mononuclear cell (PBMC) from donor 1.
- PBMC peripheral blood mononuclear cell
- FIG. 13I the percentage of proliferating CD8 + T cells when iNK with different edits are co-cultured with PBMC from donor 2.
- FIG. 13J the percentage of proliferating CD8 + T cells when iNK with different edits are co-cultured with PBMC from donor 3.
- FIG. 13K the percentage of proliferating CD8 + T cells when iNK with different edits are co-cultured with PBMC from donor 4.
- FIG. 13L the percentage of proliferating CD8 + T cells when iNK with different edits are co-cultured with PBMC from donor 5.
- FIG. 13M the percentage of proliferating CD8 + T cells when iNK with different edits are co-cultured with PBMC from donor 6.
- FIG. 13N the percentage of proliferating CD4 + T cells when iNK with different edits are co-cultured with PBMC from donor 1.
- FIG. 13O the percentage of proliferating CD4 + T cells when iNK with different edits are co-cultured with PBMC from donor 2.
- FIG. 13P the percentage of proliferating CD4 + T cells when iNK with different edits are co-cultured with PBMC from donor 3.
- FIG. 13Q the percentage of proliferating CD4 + T cells when iNK with different edits are co-cultured with PBMC from donor 4.
- FIG. 13R the percentage of proliferating CD4 + T cells when iNK with different edits are co-cultured with PBMC from donor 5.
- FIG. 13S the percentage of proliferating CD4 + T cells when iNK with different edits are co-cultured with PBMC from donor 6.
- FIGs. 14A-14C illustrate a screen of engineered NK cells for persistency.
- FIG. 14A method design for in-vitro screening of the NK persistency related genes comparing culturing with low or high cytokine.
- FIG. 14B the percentage of indel in FCER1G deficient editing when cultured with low or high cytokine.
- FIG. 14C the percentage of indel in PTPN2 deficient editing when cultured with low or high cytokine.
- FIGs. 15A-15G illustrate a screen of engineered NK cells for persistency.
- FIG. 15A the method design for in-vivo screening of the NK persistency related genes comparing in vitro culture and in-vivo growth.
- FIG. 15B the percentage of indel in STAT3 deficient editing in mouse liver versus being cultured with high cytokine.
- FIG. 15C the percentage of indel in STAT3 deficient editing in mouse spleen versus being cultured with high cytokine.
- FIG. 15D the percentage of indel in STAT3 deficient editing in mouse bone marrow (BM) versus being cultured with high cytokine.
- FIG. 15A the method design for in-vivo screening of the NK persistency related genes comparing in vitro culture and in-vivo growth.
- FIG. 15B the percentage of indel in STAT3 deficient editing in mouse liver versus being cultured with high cytokine.
- FIG. 15C the percentage of indel in STAT3
- FIG. 15E the percentage of indel in PTPN2 deficient editing in mouse liver versus being cultured with high cytokine.
- FIG. 15F the percentage of indel in PTPN2 deficient editing in mouse spleen versus being cultured with high cytokine.
- FIG. 15G the percentage of indel in PTPN2 deficient editing in mouse bone marrow (BM) versus being cultured with high cytokine.
- FIGs. 16A-16B illustrate properties of NK92 cells with CD33-CAR integration.
- FIG. 16A schematic of CD33 CAR structure design. TM stands for transmembrane domain; SCFV stands for single chain variable fragment.
- FIG. 16B targeted cytotoxicity of CD33-CAR NK92 cells on KG1 cells.
- FIGs. 17A-17D illustrate properties of NK92 cells with BCMA-CAR integration.
- FIG. 17A schematic of BCMA CAR structure design. TM stands for transmembrane domain; SCFV stands for single chain variable fragment.
- FIG. 17B targeted cytotoxicity of BCMA-CAR NK92 cells on RPMI8826 cells.
- FIG. 17C percentage of expression of CD107a in BCMA-CAR NK92 cells versus WT NK92 cells.
- FIG. 17D percentage of expression of IFN- ⁇ in BCMA-CAR NK92 cells versus WT NK92 cells.
- FIG. 18 is a summary of the gene edits from edit-1 through edit-9.
- FIG. 19A shows different chimeric receptor polypeptide constructs (e.g., different chimeric antigen receptor constructs) comprising an antigen binding moiety capable of specific binding to CD19.
- FIGs. 19B and 19C show targeted cytotoxicity of NK cells comprising one of the different chimeric receptor polypeptides shown in FIG. 19A, against CD19-presneting target cells.
- FIG. 20 illustrates an in-vitro growth curve of engineered NK cells expressing membrane-bound IL-15 cultured with or without an exogenous interleukin.
- FIG. 21 shows different combinations of heterologous gene knock-in (s) and endogenous gene knock-out (s) to generate engineered NK cells as disclosed herein.
- FIG. 22A demonstrates heterologous gene knock-in (s) and endogenous gene knock-out (s) of engineered NK cells, as described by Combo 1 of FIG. 21.
- FIG. 22B shows cytotoxicity of the engineered NK cells against target cells, in absence of heterologous immune cells.
- FIG. 22C shows cytotoxicity of the engineered NK cells against target cells, in presence of heterologous immune cells.
- FIG. 23A demonstrates heterologous gene knock-in (s) and endogenous gene knock-out (s) of engineered NK cells, as described by Combo 2 of FIG. 21.
- FIG. 23B shows cytotoxicity of the engineered NK cells against target cells, in absence of heterologous immune cells.
- FIG. 23C shows cytotoxicity of the engineered NK cells against target cells, in presence of heterologous immune cells.
- FIG. 24A demonstrates heterologous gene knock-in (s) and endogenous gene knock-out (s) of engineered NK cells, as described by Combo 3 of FIG. 21.
- FIG. 24B shows cytotoxicity of the engineered NK cells against target cells, in absence of heterologous immune cells.
- FIG. 24C shows cytotoxicity of the engineered NK cells against target cells, in presence of heterologous immune cells.
- FIG. 25A demonstrates heterologous gene knock-in (s) and endogenous gene knock-out (s) of engineered NK cells, as described by Combo 4 of FIG. 21.
- FIG. 25B shows cytotoxicity of the engineered NK cells against target cells, in absence of heterologous immune cells.
- FIG. 25C shows cytotoxicity of the engineered NK cells against target cells, in presence of heterologous immune cells.
- FIG. 26A shows different examples of SOCS2 knock out clones.
- FIGs. 26B and 267C show FACS quantification of CD45+/CD46+ NK cells differentiated from iPSCs engineered with SOCS2 knockout.
- FIGs. 26D and 26E show number of CD45+/CD46+ NK cells cultured in presence of peripheral blood cells with IL-2 or IL-15 supplementation, respectively, to compare persistency level of NK cells with SOCS2 knockout, that of unmodified NK cells, and that of NK cells with CISH knockout.
- FIGs. 27A and 27B show cytokine downstream signaling levels of various NK cells under low cytokine conditions.
- FIG. 28A shows various iPSC clones having SOCS2 knockout.
- FIGs. 28B and 28C show cytokine downstream signaling levels of various NK cells differentiated from the SOCS2 knockout iPSC clones.
- FIGs. 28D and 28E show persistency levels of various NK cells differentiated from iPSCs that are not engineered as controls (ANB) , engineered with SOCS2 knockout (TD clones) , and engineered with heterologous fusion polypeptide comprising IL-15 and IL-15 receptor (PW) .
- ANB engineered as controls
- TD clones engineered with SOCS2 knockout
- PW heterologous fusion polypeptide comprising IL-15 and IL-15 receptor
- FIG. 29A shows cellular expansion of CBLB knockout NK cells and control unmodified NK cells.
- FIG. 29B shows cytotoxicity against target Raji cells by the CBLB knockout NK cells and the control unmodified NK cells.
- FIG. 29C shows CD107a degranulation assay of the CBLB knockout NK cells and the control unmodified NK cells, after various expansions after the gene knockout.
- FIG. 29D shows the presence of IFN- ⁇ positive NK cells in the CBLB knockout NK cells and the control unmodified NK cells.
- FIG. 30A shows cellular expansion of CDK8 knockout NK cells and control unmodified NK cells.
- FIG. 30B shows cytotoxicity against target K562 cells by the CDK8 knockout NK cells and the control unmodified NK cells.
- FIG. 30C shows the presence of IFN- ⁇ positive NK cells in the CDK8 knockout NK cells and the control unmodified NK cells.
- a chimeric transmembrane receptor includes a plurality of chimeric transmembrane receptors.
- the term “about” or “approximately” generally mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1%of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated, the term “about” meaning within an acceptable error range for the particular value should be assumed.
- a cell generally refers to a biological cell.
- a cell can be the basic structural, functional and/or biological unit of a living organism.
- a cell can originate from any organism having one or more cells. Some non-limiting examples include: a prokaryotic cell, eukaryotic cell, a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a protozoa cell, a cell from a plant (e.g.
- algal cell e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens C. Agardh, and the like
- seaweeds e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens C. Agardh, and the like
- seaweeds e.g.
- a fungal cell e.g., a yeast cell, a cell from a mushroom
- an animal cell e.g. fruit fly, cnidarian, echinoderm, nematode, etc.
- a cell from a vertebrate animal e.g., fish, amphibian, reptile, bird, mammal
- a cell from a mammal e.g., a pig, a cow, a goat, a sheep, a rodent, a rat, a mouse, a non-human primate, a human, etc.
- a cell is not originating from a natural organism (e.g. a cell can be a synthetically made, sometimes termed an artificial cell) .
- reprogramming generally refers to a method of increasing the potency of a cell or dedifferentiating the cell to a less differentiated state.
- a cell that has an increased cell potency has more developmental plasticity (i.e., can differentiate into more cell types) compared to the same cell in the non-reprogrammed state.
- a reprogrammed cell is one that is in a less differentiated state than the same cell in a non-reprogrammed state.
- differentiated generally refers to a process by which an unspecialized ( “uncommitted” ) or less specialized cell acquires the features of a specialized cell such as, e.g., an immune cell.
- a differentiated or differentiation-induced cell is one that has taken on a more specialized ( “committed” ) position within the lineage of a cell.
- the term “committed” generally refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type.
- pluripotent generally refers to the ability of a cell to form all lineages of the body or soma (i.e., the embryo proper) .
- embryonic stem cells are a type of pluripotent stem cells that are able to form cells from each of the three germs layers, the ectoderm, the mesoderm, and the endoderm.
- Pluripotency can be a continuum of developmental potencies ranging from the incompletely or partially pluripotent cell (e.g., an epiblast stem cell) , which is unable to give rise to a complete organism to the more primitive, more pluripotent cell, which is able to give rise to a complete organism (e.g., an embryonic stem cell) .
- iPSCs induced pluripotent stem cells
- differentiated cells e.g., differentiated adult, neonatal, or fetal cells
- iPSCs reprogrammed stem cells
- the iPSCs produced do not refer to cells as they are found in nature.
- iPSCs can be engineered to differentiation directly into committed cells (e.g., natural killer (NK) cells.
- NK natural killer
- iPSCs can be engineered to differentiate first into tissue-specific stem cells (e.g., hematopoietic stem cells (HSCs) ) , which can be further induced to differentiate into committed cells (e.g., NK cells) .
- tissue-specific stem cells e.g., hematopoietic stem cells (HSCs)
- HSCs hematopoietic stem cells
- ESCs generally refers to naturally occurring pluripotent stem cells of the inner cell mass of the embryonic blastocyst. Embryonic stem cells are pluripotent and give rise during development to all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm.
- ESCs can be engineered to differentiation directly into committed cells (e.g., NK cells) .
- ESCs can be engineered to differentiate first into tissue-specific stem cells (e.g., HSCs) , which can be further induced to differentiate into committed cells (e.g., NK cells) .
- isolated stem cells generally refers to any type of stem cells disclosed herein (e.g., ESCs, HSCs, mesenchymal stem cells (MSCs) , etc. ) that are isolated from a multicellular organism.
- HSCs can be isolated from a mammal’s body, such as a human body.
- an embryonic stem cells can be isolated from an embryo.
- isolated generally refers to a cell or a population of cells, which has been separated from its original environment.
- a new environment of the isolated cells is substantially free of at least one component as found in the environment in which the “un-isolated” reference cells exist.
- An isolated cell can be a cell that is removed from some or all components as it is found in its natural environment, for example, isolated from a tissue or biopsy sample.
- the term also includes a cell that is removed from at least one, some or all components as the cell is found in non-naturally occurring environments, for example, isolated form a cell culture or cell suspension. Therefore, an isolated cell is partly or completely separated from at least one component, including other substances, cells or cell populations, as it is found in nature or as it is grown, stored or subsisted in non-naturally occurring environments.
- hematopoietic stem and progenitor cells generally refers to cells which are committed to a hematopoietic lineage but are capable of further hematopoietic differentiation (e.g., into NK cells) and include, multipotent hematopoietic stem cells (hematoblasts) , myeloid progenitors, megakaryocyte progenitors, erythrocyte progenitors, and lymphoid progenitors.
- hematoblasts multipotent hematopoietic stem cells
- HSCs Hematopoietic stem and progenitor cells
- myeloid monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells
- lymphoid lineages T cells, B cells, NK cells
- HSCs can be CD34+ hematopoietic cells capable of giving rise to both mature myeloid and lymphoid cell types including T cells, NK cells and B cells.
- immune cell generally refers to a differentiated hematopoietic cell.
- Non-limiting examples of an immune cell can include an NK cell, a T cell, a monocyte, an innate lymphocyte, a tumor-infiltrating lymphocyte, a macrophage, a granulocyte, etc.
- NK cell or “Natural Killer cell” generally refers to a subset of peripheral blood lymphocytes defined by the expression of CD56 or CD16 and the absence of the T cell receptor (CD3) .
- NK cells that are phenotypically CD3-and CD56+, expressing at least one of NKG2C and CD57 (e.g., NKG2C, CD57, or both in same or different degrees) , and optionally, CD16, but lack expression of one or more of the following: PLZF, SYK, FceR ⁇ , and EAT-2.
- isolated subpopulations of CD56+ NK cells can exhibit expression of CD16, NKG2C, CD57, NKG2D, NCR ligands, NKp30, NKp40, NKp46, activating and inhibitory KIRs, NKG2A and/or DNAM-1.
- nucleotide generally refers to a base-sugar-phosphate combination.
- a nucleotide can comprise a synthetic nucleotide.
- a nucleotide can comprise a synthetic nucleotide analog.
- Nucleotides can be monomeric units of a nucleic acid sequence (e.g. deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) ) .
- nucleotide can include ribonucleoside triphosphates adenosine triphosphate (ATP) , uridine triphosphate (UTP) , cytosine triphosphate (CTP) , guanosine triphosphate (GTP) and deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof.
- Such derivatives can include, for example, [ ⁇ S] dATP, 7-deaza-dGTP and 7-deaza-dATP, and nucleotide derivatives that confer nuclease resistance on the nucleic acid molecule containing them.
- nucleotide as used herein can refer to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives.
- ddNTPs dideoxyribonucleoside triphosphates
- Illustrative examples of dideoxyribonucleoside triphosphates can include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP.
- a nucleotide may be unlabeled or detectably labeled by well-known techniques. Labeling can also be carried out with quantum dots.
- Detectable labels can include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels.
- Fluorescent labels of nucleotides may include but are not limited fluorescein, 5-carboxyfluorescein (FAM) , 2′7′-dimethoxy-4′5-dichloro-6-carboxyfluorescein (JOE) , rhodamine, 6-carboxyrhodamine (R6G) , N, N, N′, N′-tetramethyl-6-carboxyrhodamine (TAMRA) , 6-carboxy-X-rhodamine (ROX) , 4- (4′dimethylaminophenylazo) benzoic acid (DABCYL) , Cascade Blue, Oregon Green, Texas Red, Cyanine and 5- (2′-aminoethyl) aminonaphthalene-1-sulfonic acid (EDANS) .
- FAM 5-carboxyfluorescein
- JE 2′7′-dimethoxy-4′5-dichloro-6-carboxyfluorescein
- fluorescently labeled nucleotides can include [R6G] dUTP, [TAMRA] dUTP, [R110] dCTP, [R6G] dCTP, [TAMRA] dCTP, [JOE] ddATP, [R6G] ddATP, [FAM] ddCTP, [R110] ddCTP, [TAMRA] ddGTP, [ROX] ddTTP, [dR6G] ddATP, [dR110] ddCTP, [dTAMRA] ddGTP, and [dROX] ddTTP available from Perkin Elmer, Foster City, Calif.
- Chromosome Labeled Nucleotides BODIPY-FL-14-UTP, BODIPY-FL-4-UTP, BODIPY-TMR-14-UTP, BODIPY-TMR-14-dUTP, BODIPY-TR-14-UTP, BODIPY-TR-14-dUTP, Cascade Blue-7-UTP, Cascade Blue-7-dUTP, fluorescein-12-UTP, fluorescein-12-dUTP, Oregon Green 488-5-dUTP, Rhodamine Green-5-UTP, Rhodamine Green-5-dUTP, tetramethylrhodamine-6-UTP, tetramethylrhodamine-6-dUTP, Texas Red-5-UTP, Texas Red-5-dUTP, and Texas Red-12-dUTP available from Molecular Probes, Eugene, Oreg.
- Nucleotides can also be labeled or marked by chemical modification.
- a chemically-modified single nucleotide can be biotin-dNTP.
- biotinylated dNTPs can include, biotin-dATP (e.g., bio-N6-ddATP, biotin-14-dATP) , biotin-dCTP (e.g., biotin-11-dCTP, biotin-14-dCTP) , and biotin-dUTP (e.g. biotin-11-dUTP, biotin-16-dUTP, biotin-20-dUTP) .
- polynucleotide oligonucleotide, ” or “nucleic acid, ” as used interchangeably herein, generally refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof, either in single-, double-, or multi-stranded form.
- a polynucleotide can be exogenous or endogenous to a cell.
- a polynucleotide can exist in a cell-free environment.
- a polynucleotide can be a gene or fragment thereof.
- a polynucleotide can be DNA.
- a polynucleotide can be RNA.
- a polynucleotide can have any three dimensional structure, and can perform any function, known or unknown.
- a polynucleotide can comprise one or more analogs (e.g. altered backbone, sugar, or nucleobase) . If present, modifications to the nucleotide structure can be imparted before or after assembly of the polymer. Some non-limiting examples of analogs include: 5-bromouracil, peptide nucleic acid, xeno nucleic acid, morpholinos, locked nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, florophores (e.g.
- rhodamine or flurescein linked to the sugar thiol containing nucleotides, biotin linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudourdine, dihydrouridine, queuosine, and wyosine.
- Non-limiting examples of polynucleotides include coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA) , transfer RNA (tRNA) , ribosomal RNA (rRNA) , short interfering RNA (siRNA) , short-hairpin RNA (shRNA) , micro-RNA (miRNA) , ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, cell-free polynucleotides including cell-free DNA (cfDNA) and cell-free RNA (cfRNA) , nucleic acid probes, and primers.
- the sequence of nucleotides can be interrupted by non-nucleotide components.
- the term “gene” generally refers to a nucleic acid (e.g., DNA such as genomic DNA and cDNA) and its corresponding nucleotide sequence that is involved in encoding an RNA transcript.
- genomic DNA includes intervening, non-coding regions as well as regulatory regions and can include 5′and 3′ends.
- the term encompasses the transcribed sequences, including 5′and 3′untranslated regions (5′-UTR and 3′-UTR) , exons and introns.
- the transcribed region will contain “open reading frames” that encode polypeptides.
- a “gene” comprises only the coding sequences (e.g., an “open reading frame” or “coding region” ) necessary for encoding a polypeptide.
- genes do not encode a polypeptide, for example, ribosomal RNA genes (rRNA) and transfer RNA (tRNA) genes.
- rRNA ribosomal RNA genes
- tRNA transfer RNA
- the term “gene” includes not only the transcribed sequences, but in addition, also includes non-transcribed regions including upstream and downstream regulatory regions, enhancers and promoters.
- a gene can refer to an “endogenous gene” or a native gene in its natural location in the genome of an organism.
- a gene can refer to an “exogenous gene” or a non-native gene.
- a non-native gene can refer to a gene not normally found in the host organism but which is introduced into the host organism by gene transfer.
- a non-native gene can also refer to a gene not in its natural location in the genome of an organism.
- a non-native gene can also refer to a naturally occurring nucleic acid or polypeptide sequence that comprises mutations, insertions and/or deletions (e.g., non-native sequence) .
- expression generally refers to one or more processes by which a polynucleotide is transcribed from a DNA template (such as into an mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins.
- Transcripts and encoded polypeptides can be collectively referred to as “gene product. ” If the polynucleotide is derived from genomic DNA, expression can include splicing of the mRNA in a eukaryotic cell.
- Up-regulated, with reference to expression, generally refers to an increased expression level of a polynucleotide (e.g., RNA such as mRNA) and/or polypeptide sequence relative to its expression level in a wild-type state while “down-regulated” generally refers to a decreased expression level of a polynucleotide (e.g., RNA such as mRNA) and/or polypeptide sequence relative to its expression in a wild-type state.
- Expression of a transfected gene can occur transiently or stably in a cell. During “transient expression” the transfected gene is not transferred to the daughter cell during cell division. Since its expression is restricted to the transfected cell, expression of the gene is lost over time.
- stable expression of a transfected gene can occur when the gene is co-transfected with another gene that confers a selection advantage to the transfected cell.
- a selection advantage may be a resistance towards a certain toxin that is presented to the cell.
- amino acid chains of any length, including full length proteins, and proteins with or without secondary and/or tertiary structure (e.g., domains) .
- the terms also encompass an amino acid polymer that has been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, oxidation, and any other manipulation such as conjugation with a labeling component.
- amino acid and amino acids, ” as used herein, generally refer to natural and non-natural amino acids, including, but not limited to, modified amino acids and amino acid analogues.
- Modified amino acids can include natural amino acids and non-natural amino acids, which have been chemically modified to include a group or a chemical moiety not naturally present on the amino acid.
- Amino acid analogues can refer to amino acid derivatives.
- amino acid includes both D-amino acids and L-amino acids.
- derivative, ” “variant, ” or “fragment, ” as used herein with reference to a polypeptide generally refers to a polypeptide related to a wild type polypeptide, for example either by amino acid sequence, structure (e.g., secondary and/or tertiary) , activity (e.g., enzymatic activity) and/or function.
- Derivatives, variants and fragments of a polypeptide can comprise one or more amino acid variations (e.g., mutations, insertions, and deletions) , truncations, modifications, or combinations thereof compared to a wild type polypeptide.
- engineered, ” “chimeric, ” or “recombinant, ” as used herein with respect to a polypeptide molecule generally refers to a polypeptide molecule having a heterologous amino acid sequence or an altered amino acid sequence as a result of the application of genetic engineering techniques to nucleic acids which encode the polypeptide molecule, as well as cells or organisms which express the polypeptide molecule.
- Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion.
- an engineered or recombinant polynucleotide e.g.,
- gene editing moiety generally refers to a moiety which can edit a nucleic acid sequence, whether exogenous or endogenous to a cell comprising the nucleic acid sequence.
- a gene editing moiety regulates expression of a gene by editing a nucleic acid sequence.
- a gene editing moiety can regulate expression of a gene by editing genomic DNA sequence.
- a gene editing moiety can regulate expression of a gene by editing an mRNA template. Editing a nucleic acid sequence can, in some cases, alter the underlying template for gene expression.
- a gene editing moiety can be capable of regulating expression or activity of a gene by specifically binding to a target sequence operatively coupled to the gene (or a target sequence within the gene) , and regulating the production of mRNA from DNA, such as chromosomal DNA or cDNA.
- a gene editing moiety can recruit or comprise at least one transcription factor that binds to a specific DNA sequence, thereby controlling the rate of transcription of genetic information from DNA to mRNA.
- a gene editing moiety can itself bind to DNA and regulate transcription by physical obstruction, for example preventing proteins such as RNA polymerase and other associated proteins from assembling on a DNA template.
- a gene editing moiety can regulate expression of a gene at the translation level, for example, by regulating the production of protein from mRNA template.
- a gene editing moiety can regulate gene expression by affecting the stability of an mRNA transcript.
- antibody generally refers to a proteinaceous binding molecule with immunoglobulin-like functions.
- the term antibody includes antibodies (e.g., monoclonal and polyclonal antibodies) , as well as derivatives, variants, and fragments thereof.
- Antibodies include, but are not limited to, immunoglobulins (Ig's ) of different classes (i.e. IgA, IgG, IgM, IgD and IgE) and subclasses (such as IgG1, IgG2, etc. ) .
- a derivative, variant or fragment thereof can refer to a functional derivative or fragment which retains the binding specificity (e.g., complete and/or partial) of the corresponding antibody.
- Antigen-binding fragments include Fab, Fab′, F (ab′) 2, variable fragment (Fv) , single chain variable fragment (scFv) , minibodies, diabodies, and single-domain antibodies ( “sdAb” or “nanobodies” or “camelids” ) .
- the term antibody includes antibodies and antigen-binding fragments of antibodies that have been optimized, engineered or chemically conjugated. Examples of antibodies that have been optimized include affinity-matured antibodies. Examples of antibodies that have been engineered include Fc optimized antibodies (e.g., antibodies optimized in the fragment crystallizable region) and multispecific antibodies (e.g., bispecific antibodies) .
- chimeric polypeptide receptor generally refers to a non-natural polypeptide receptor comprising one or more antigen binding moieties, each antigen binding moiety capable of binding to a specific antigen.
- a chimeric polypeptide receptor can be monospecific (i.e., capable of binding to one type of specific antigen) .
- a chimeric polypeptide receptor can be multi-specific (i.e., capable of binding to two or more different types of specific antigens) .
- a chimeric polypeptide receptor can be monovalent (i.e., comprising a single antigen binding moiety) .
- a chimeric polypeptide receptor can be multivalent (i.e., comprising a plurality of antigen binding moieties) .
- a chimeric polypeptide receptor can comprise a T-cell receptor (TCR) fusion protein (TFP) or a chimeric antigen receptor (CAR) .
- TCR T-cell receptor
- TFP T-cell receptor
- an antigen binding domain generally refers to a construct exhibiting preferential binding to a specific target antigen.
- An antigen binding domain can be a polypeptide construct, such as an antibody, a functional variant thereof (e.g., a designed ankyrin repeat protein (DARPin) ) , modification thereof, fragment thereof, or a combination thereof.
- the antigen binding domain can be any antibody as disclosed herein, or a functional variant thereof.
- Non-limiting examples of an antigen binding domain can include a murine antibody, a human antibody, a humanized antibody, a camel Ig, a shark heavy-chain-only antibody (VNAR) , Ig NAR, a chimeric antibody, a recombinant antibody, or antibody fragment thereof.
- Non-limiting examples of antibody fragment include Fab, Fab′, F (ab) ′2, F (ab) ′3, Fv, single chain antigen binding fragment (scFv) , (scFv) 2, disulfide stabilized Fv (dsFv) , minibody, diabody, triabody, tetrabody, single-domain antigen binding fragments (sdAb, Nanobody) , recombinant heavy-chain-only antibody (VHH) , and other antibody fragments that maintain the binding specificity of the whole antibody.
- designed ankyrin repeat protein generally refers to a synthetic polypeptide comprising one or more ankyrin repeat domains, wherein the one or more ankyrin repeat domains are capable of binding to one or more antigens.
- the ankyrin repeat domains described herein generally comprise at least one ankyrin repeat motif.
- the ankyrin repeat motif comprises of two anti-parallel ⁇ -helices followed by a beta-bulge and beta-hairpin containing loop connecting it to the next repeat, each of which has about 33 residues.
- Recombinant proteins, or binding domains thereof, comprising designed ankyrin repeat motifs may be referred to as DARPin proteins or DARPin polypeptides.
- the ankyrin repeat domains described herein may comprise (i) a core scaffold that provides structure and (ii) target binding residues that bind to a target (e.g., a target antigen) .
- the structural core may comprise conserved amino acid residues, and the target binding surface may comprise amino acid residues that differ depending on the target.
- an ankyrin repeat motif can comprise the following sequence: DxxGxTPLHLAxxxGxxxVVxLLLxxGADVNAx (SEQ ID NO: 1) , wherein “x” denotes any amino acid.
- an ankyrin repeat motif can comprise the following sequence: DxxGxTPLHLAxxxGxxx
- multiple ankyrin repeat domains can be linked (either through a covalent bond or non-covalent association) to form bispecific or multi-specific molecules (e.g., bispecific or multi-specific chimeric polypeptide receptors) .
- safety switch generally refers to an engineered polypeptide construct designed to prevent potential toxicity or otherwise adverse effects of a cell therapy. When expressed in a cell, the safety switch can induce death of the host cell, thereby inactivating activity of the cell in a host (e.g., in a subject’s body) .
- the safety switch can be a suicide moiety.
- the cell can be programmed to express the suicide moiety at certain stage of its life-cycle (e.g., time-programmed) . In some cases, expression of the suicide moiety in a cell can be conditional or inducible.
- conditional regulation (e.g., expression) of a suicide moiety can include control through a small molecule-mediated post-translational activation and tissue-specific and/or temporal transcriptional regulation.
- the safety switch can be an inducible suicide moiety.
- a safety switch can mediate induction of apoptosis, inhibition of protein synthesis, DNA replication, growth arrest, transcriptional and post-transcriptional genetic regulation, and/or antibody-mediated depletion.
- a safety switch can be activated by an exogenous molecule (e.g., a drug or a prodrug) that, when activated, triggers apoptosis and/or cell death of a cell (e.g., engineered NK cell as disclosed herein) .
- an exogenous molecule e.g., a drug or a prodrug
- apoptosis and/or cell death of a cell e.g., engineered NK cell as disclosed herein
- immune regulator polypeptide generally refers to a polypeptide construct (e.g., protein, antibody, membrane-bound polypeptide, secretory polypeptide, cleavable polypeptide, non-cleavable polypeptide, etc. ) capable of regulating or controlling one or more attributes of an immune cell, such as a NK cell.
- One or more attributes of an immune cell can comprise differentiation of the immune cell, immune cell morphology, expression of a polynucleotide or polypeptide construct within the immune cell, or activity of the immune cell (e.g., cytotoxic activity of an engineered NK cell against a diseased cell, such as a cancer cell) .
- An immune regulator polypeptide can be endogenous to a host cell.
- an immune regulator polypeptide can be heterologous to a hots cell.
- controlling the one or more attributes of the immune cell can be mediated by downregulating expression of the immune regulator polypeptide (e.g., suppression, knock-down or knock-out) .
- controlling the one or more attributes of the immune cell can be mediated by upregulating expression of the immune regulator polypeptide (e.g., upregulation of an endogenous gene or knock-in of a heterologous gene encoding the immune regulator polypeptide) .
- controlling the one or more attributes of the immune cell can be mediated by maintaining expression of the immune regulator polypeptide for time period that is longer than a natural or normal expression profile of the immune regulator polypeptide in a host cell.
- an immune regulator polypeptide can comprise a hypo-immunity regulator.
- an immune regulator polypeptide can comprise an immune checkpoint inhibitor.
- hypo-immunity regulator generally refers to a polypeptide construct in a cell, wherein either enhanced expression (e.g., via knock-in of a heterologous gene) or reduced expression (e.g., via knock-out or knock-down of an endogenous gene) of the hypo-immunity regulator in the cell can help the cell to reduce or avoid immune response (e.g., immune attack, such as adaptive immune rejection) from a host’s body upon administration to the host’s body.
- immune response e.g., immune attack, such as adaptive immune rejection
- cells e.g., engineered NK cells as disclosed herein
- the hypo-immunity regulator can be modified to exhibit either enhanced expression or reduced expression of the hypo-immunity regulator, such that the cells can evade the host immune attack upon second or further infusion of the cells into the host (i.e., recipient) .
- the cells would not be rejected by the host’s immune system (e.g., antibody-mediated complement cytotoxicity, or antibody-dependent cellular cytotoxicity (ADCC) ) and/or (ii) would be rejected at a slower rate by the host’s immune system as compared with a control cell without the enhanced expression or reduced expression of the hypo-immunity regulator.
- the host’s immune system e.g., antibody-mediated complement cytotoxicity, or antibody-dependent cellular cytotoxicity (ADCC)
- ADCC antibody-dependent cellular cytotoxicity
- a cell exhibiting the enhanced expression or reduced expression of the hypo-immunity regulator can be referred to as exhibiting “hypo-immunity” or being “immune- privileged. ”
- enhanced hypo-immunity e.g., enhanced resistance against ADCC
- a population of engineered immune cells e.g., a population of engineered NK cells
- an antibody e.g., SSEA-4 antibody
- in vivo e.g., upon administration to a subject’s bloodstream
- engineering of an immune cell can enhance the immune cell’s resistance against immune rejection (e.g., ADCC) by at least or up to about 5%, at least or up to about 10%, at least or up to about 15%, at least or up to about 20%, at least or up to about 25%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, at least or up to about 80%, at least or up to about 85%, at least or up to about 90%, at least or up to about 95%, at least or up to about 100%, at least or up to about 150%, at least or up to about 200%, at least or up to about 300%, at least or up to about 400%, or at least or up to about 500% (e.g., as compared to that of a NK cell or a control population of NK cells lacking one or more heterologous hypo-immunity regulator polypeptid
- the enhanced resistance against immune rejection (e.g., ADCC) can be ascertained in vitro in a medium comprising at least or up to about 5%, at least or up to about 10%, at least or up to about 15%, at least or up to about 20%, at least or up to about 25%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, or at least or up to about 80%, human complement.
- a medium comprising at least or up to about 5%, at least or up to about 10%, at least or up to about 15%, at least or up to about 20%, at least or up to about 25%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, or at least or up to about 80%, human complement.
- immune checkpoint inhibitor generally refers to a group of molecules presented on a cell surface of an immune cell (e.g., T cells, myeloid cells, NK cells, B cells, etc. ) that can modulate immune response of the cell by down-regulating or inhibiting the immune response of the immune cell against a target cell, such as a cancer cell (i.e., anti-cancer or anti-tumor immune response) .
- a target cell such as a cancer cell (i.e., anti-cancer or anti-tumor immune response) .
- the target cell can express a receptor or a ligand of the immune checkpoint inhibitor presented on the surface of the immune cell, to engage with the immune checkpoint inhibitor and down-regulate or inhibit the immune response of the immune cells against the target cell.
- down-regulating or inhibiting expression of the immune checkpoint inhibitor in the immune cell can, in some cases, enhance or prolong the immune response of the immune cell against a target cell.
- immune response generally refers to T cell mediated and/or B cell mediated immune responses from a host’s immune system to an object (e.g., a foreign object) .
- An example of an immune response include T cell responses, e.g., cytokine production and cellular cytotoxicity.
- an immune response can be indirectly effected by T cell activation, e.g., antibody production (humoral responses) and activation of cytokine responsive cells, such as macrophages.
- the term “enhanced expression, ” “increased expression, ” or “upregulated expression” generally refers to production of a moiety of interest (e.g., a polynucleotide or a polypeptide) to a level that is above a normal level of expression of the moiety of interest in a host strain (e.g., a host cell) .
- the normal level of expression can be substantially zero (or null) or higher than zero.
- the moiety of interest can comprise an endogenous gene or polypeptide construct of the host strain.
- the moiety of interest can comprise a heterologous gene or polypeptide construct that is introduced to or into the host strain.
- a heterologous gene encoding a polypeptide of interest can be knocked-in (KI) to a genome of the host strain for enhanced expression of the polypeptide of interest in the host strain.
- the term “enhanced activity, ” “increased activity, ” or “upregulated activity” generally refers to activity of a moiety of interest (e.g., a polynucleotide or a polypeptide) that is modified to a level that is above a normal level of activity of the moiety of interest in a host strain (e.g., a host cell) .
- the normal level of activity can be substantially zero (or null) or higher than zero.
- the moiety of interest can comprise a polypeptide construct of the host strain.
- the moiety of interest can comprise a heterologous polypeptide construct that is introduced to or into the host strain.
- a heterologous gene encoding a polypeptide of interest can be knocked-in (KI) to a genome of the host strain for enhanced activity of the polypeptide of interest in the host strain.
- reduced expression, ” “decreased expression, ” or “downregulated expression” generally refers to a production of a moiety of interest (e.g., a polynucleotide or a polypeptide) to a level that is below a normal level of expression of the moiety of interest in a host strain (e.g., a host cell) .
- the normal level of expression is higher than zero.
- the moiety of interest can comprise an endogenous gene or polypeptide construct of the host strain.
- the moiety of interest can be knocked-out or knocked-down in the host strain.
- reduced expression of the moiety of interest can include a complete inhibition of such expression in the host strain.
- reduced activity, ” “decreased activity, ” or “downregulated activity” generally refers to activity of a moiety of interest (e.g., a polynucleotide or a polypeptide) that is modified to a level that is below a normal level of activity of the moiety of interest in a host strain (e.g., a host cell) .
- the normal level of activity is higher than zero.
- the moiety of interest can comprise an endogenous gene or polypeptide construct of the host strain.
- the moiety of interest can be knocked-out or knocked-down in the host strain.
- reduced activity of the moiety of interest can include a complete inhibition of such activity in the host strain.
- subject generally refers to a vertebrate, preferably a mammal such as a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro are also encompassed.
- treatment generally refers to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit.
- a treatment can comprise administering a system or cell population disclosed herein.
- therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment.
- a composition can be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested.
- an effective amount or “therapeutically effective amount” generally refers to the quantity of a composition, for example a composition comprising immune cells such as lymphocytes (e.g., T lymphocytes and/or NK cells) comprising a system of the present disclosure, that is sufficient to result in a desired activity upon administration to a subject in need thereof.
- lymphocytes e.g., T lymphocytes and/or NK cells
- therapeutically effective generally refers to that quantity of a composition that is sufficient to delay the manifestation, arrest the progression, relieve or alleviate at least one symptom of a disorder treated by the methods of the present disclosure.
- T cells are part of the adaptive immune system and can be primed to recognize a specific threat by recognizing immune proteins (i.e., antigens) on a foreign cell surface.
- immune proteins i.e., antigens
- NK cells are part of the innate immune response and can respond to a broad range of objects that consider to be “non-self. ”
- NK cells can attack their target cells without sensitization (i.e., antigen-specific priming) to eliminate foreign substances.
- Unmodified NK cells derived from a subject can be cultured and expanded ex vivo, then administered to the subject as a treatment to attack their target cells, e.g., cancer cells.
- target cells e.g., cancer cells.
- NK cell-based therapies can be limited due to short half-life and/or poor proliferation of NK cells ex vivo or in vivo.
- unmodified NK cells can be ineffective in targeting harder-to-treat cancers, such as myeloma or solid tumors.
- ex vivo production of NK cells based on blood-derived stem cells e.g., HSCs
- NK cells sourced and engineered to exhibit, for example, enhanced proliferation, half-life, and cytotoxic activity against target cells.
- Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell) .
- Immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell.
- Immune cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target.
- the engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo.
- the engineered Immune cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors) .
- the engineered Immune cells can be autologous to the subject. Alternatively, the engineered immune cells can be allogeneic to the subject.
- engineered immune cells e.g., engineered NK cells
- engineered immune cells disclosed herein can be derived from an isolated stem cell (e.g., isolated ESCs) .
- engineered immune cells disclosed herein can be derived from induced stem cells (e.g., iPSCs) .
- the stem cell disclosed herein can be an autologous cell or derived from the autologous cell.
- the autologous cell can be obtained from a subject having a condition or is suspected of having the condition. Alternatively, the autologous cell can be obtained from the subject before the subject is found to have the condition.
- the autologous cell can be an allogeneic cell, e.g., a universal stem cell with reduced immunogenicity and with reduced amount or no need for immunosuppressive drugs.
- the autologous cell can be obtained from a healthy donor.
- the engineered immune cell (e.g., engineered NK cell) can be an autologous cell.
- the engineered immune cell can be obtained from a subject having a condition or is suspected of having the condition. Alternatively, the engineered immune cell can be obtained from the subject before the subject is found to have the condition.
- the engineered immune cell can be an allogeneic cell, e.g., for a universal allogenic immunotherapy with reduced immunogenicity and with reduced amount or no need for immunosuppressive drugs.
- the engineered immune cell can be obtained from a healthy donor.
- T cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered T cell) .
- T cells can be engineered to exhibit enhanced proliferation as compared to a control cell.
- T cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target.
- the engineered T cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo.
- the engineered T cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors) .
- the engineered T cells can be autologous to the subject. Alternatively, the engineered T cells can be allogeneic to the subject.
- NK cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered NK cell) .
- NK cells can be engineered to exhibit enhanced proliferation as compared to a control cell.
- NK cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target.
- the engineered NK cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo.
- the engineered NK cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors) .
- the engineered NK cells can be autologous to the subject. Alternatively, the engineered NK cells can be allogeneic to the subject.
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise a cytokine (e.g., a secretory cytokine) that is heterologous to the immune cell.
- the heterologous cytokine can comprise a heterologous interleukin (IL) (e.g., a heterologous secretory IL-15) .
- the engineered immune cell can further comprise one or both of: (i) a CD16 variant for enhanced CD16 signaling as compared to a control cell and (ii) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen.
- the antigen is not CD19.
- the antigen binding moiety may not and need not exhibit any specific binding to CD19, but rather a specific binding to an antigen (e.g., one or more antigens) that is not CD19.
- the engineered immune cell (e.g., an engineered NK cell) as disclosed herein can comprise a heterologous receptor that is a respective receptor of the heterologous cytokine as disclosed herein (e.g., heterologous IL-15 receptor (IL-15R, such as IL-15 ⁇ or IL-15 ⁇ ) for heterologous IL-15) .
- the engineered immune cell may not and need not comprise any heterologous receptor that is a respective receptor of the heterologous cytokine.
- the engineered immune cell comprising a heterologous IL e.g., IL-15
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise a cytokine (e.g., a secretory cytokine) that is heterologous to the immune cell.
- the heterologous cytokine can further comprise a heterologous interleukin (IL) (e.g., a heterologous secretory IL-15) .
- IL interleukin
- the engineered immune cell may and need not comprise a heterologous receptor that is a respective receptor of the heterologous cytokine (e.g., a heterologous IL-15R) .
- the heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be of the same species as that of the engineered immune cell (e.g., the engineered NK cell) .
- both the heterologous cytokine and the engineered immune cell can be of human origin.
- the heterologous cytokine can be of a different species than that of the engineered immune cell.
- a heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be introduced to the engineered immune cell (e.g., engineered NK cell) by contacting a heterologous polynucleotide encoding the heterologous cytokine to the engineered immune cell.
- the heterologous polynucleotide can be integrated into the engineered immune cell’s chromosome (e.g., nuclear chromosome) .
- the heterologous polynucleotide may not and need not be integrated into the chromosome of the engineered immune cell.
- a mRNA encoding a heterologous cytokine can be introduced (or inserted into) the engineered immune cell.
- the heterologous cytokine as disclosed herein can be a heterologous IL.
- a heterologous IL as disclosed herein can comprise at least 1, 2, 3, 4, 5, or more different types of heterologous ILs.
- a heterologous IL as disclosed herein can comprise at most 5, 4, 3, or 2 different type of heterologous ILs.
- the heterologous IL can be a single type of heterologous IL.
- Non-limiting examples of the heterologous IL can include, but are not limited to, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and IL-36.
- the heterologous IL can comprise one or more members selected from the group consisting of IL2, IL4, IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, IL21, and functional modifications thereof.
- the engineered immune cell e.g., an engineered NK cell
- the engineered immune cell can comprise at least a portion of heterologous human IL-15 (or a gene encoding thereof) .
- the heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be a secretory cytokine.
- the heterologous cytokine may not and need not be secreted by the engineered immune cell.
- the heterologous cytokine can be bound to a cell surface of the engineered immune cell.
- the heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be a secretory cytokine.
- An expression cassette encoding the heterologous cytokine can be introduced to the engineered immune cell.
- the expression cassette can further encode an additional heterologous polypeptide, e.g., a heterologous receptor.
- a first polynucleotide sequence encoding the heterologous cytokine and a second polynucleotide sequence encoding the additional heterologous polypeptide (e.g., the heterologous receptor) can be coupled to each other via a polynucleotide linker encoding a cleavage linker.
- the heterologous receptor can be a respective receptor of the heterologous cytokine (e.g., heterologous IL-15 ⁇ or IL-15 ⁇ for heterologous IL-15) .
- the expression cassette may not and need not encode any additional heterologous polypeptide other than the heterologous cytokine.
- a cleavable linker as disclosed herein can comprise a self-cleaving peptide, such as a self-cleaving 2A peptide.
- Self-cleaving peptides can be found in members of the Picornaviridae virus family, including aphthoviruses such as foot-and-mouth disease virus (FMDV) , equine rhinitis A virus (ERAV) , Thosea asigna virus (TaV) and porcine tescho virus-1 (PTV-I) , and cardioviruses such as Theilovirus (e.g., Theiler's murine encephalomyelitis) and encephalomyocarditis viruses.
- Non-limiting examples of the self-cleaving 2A peptide can include “F2A” , “E2A” , “P2A” , “T2A” , and functional variants thereof.
- the heterologous cytokine (e.g., the heterologous IL) as disclosed herein can be bound to a cell surface the engineered immune cell (e.g., the engineered NK cell) .
- the engineered immune cell can be genetically modified such that a heterologous polynucleotide sequence encoding the heterologous cytokine is coupled to a gene encoding an endogenous transmembrane protein of the engineered immune cell.
- the endogenous transmembrane protein can be a respective receptor of the heterologous cytokine (e.g., heterologous IL-15 ⁇ or IL-15 ⁇ for heterologous IL-15) .
- an expression cassette encoding a heterologous fusion polypeptide comprising (i) the heterologous cytokine that is coupled to (ii) a heterologous receptor can be introduced to the engineered immune cell.
- the heterologous cytokine may not and need not be cleavable from the heterologous receptor.
- Non-limiting examples of the heterologous receptor can include a respective receptor of the heterologous cytokine (e.g., heterologous IL-15 ⁇ or IL-15 ⁇ for heterologous IL-15) , or a different receptor such as a common gamma chain ( ⁇ C ) receptor or a modification thereof.
- An expression cassette as disclosed herein can be integrated into the genome of the engineered cell (e.g., the engineered NK cell) via action of a gene editing moiety as disclosed herein.
- the expression cassette may not and need not be integrated into the genome of the engineered cell.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit enhanced signaling of an endogenous signaling pathway that involves the heterologous cytokine (e.g., the heterologous IL, such as the heterologous IL-15) and/or the heterologous receptor (e.g., the heterologous IL receptor, such as the heterologous IL-15R) as disclosed herein.
- the enhanced signaling of the endogenous signaling pathway as disclosed herein can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation of a downstream signaling protein (e.g., JAK3, STAT3, STAT5, etc.
- a downstream gene e.g., Mcl1, Cdk4/6, Mki67, Tnf, Gzmb, Gzmc, Ifng, etc. for IL-15/IL-15R
- PCR polymerase chain reaction
- enhanced signaling of the endogenous signaling pathway that is induced by the heterologous cytokine and/or the heterologous receptor can be characterized by an increase in phosphorylation of a downstream signaling protein by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about
- enhanced signaling of the endogenous signaling pathway that is induced by the heterologous cytokine and/or the heterologous receptor can be characterized by an increased expression of a downstream gene by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or
- CD16 signaling e.g., constitutively activated signaling of CD16
- engineered immune cell e.g., engineered NK cell
- Enhanced CD16 signaling (e.g., constitutively activated signaling of CD16) of the engineered immune cell (e.g., engineered NK cell) as disclosed herein can be achieved by having non-cleavable CD16 variant in the subject cell.
- CD16 e.g., CD16a
- immune cells e.g., NK cells
- ADCC antibody-dependent cell-mediated cytotoxicity
- the binding between CD16 and the monomeric IgG can induce cleavage of the CD16 protein at a cleavage site near the transmembrane domain, to regulates the cell surface density of CD16 upon immune cell activation.
- the endogenous CD16 of the engineered immune cell can be modified to enhance its signaling.
- an enhanced signaling variant of CD16 can be artificially introduced to the engineered immune cell.
- the engineered immune cell’s endogenous gene encoding CD16 can be genetically modified in its ectodomain (e.g., F176V) via action of a gene editing moiety as disclosed herein, such that the modified CD16 exhibits higher binding affinity to its target (e.g., monomeric IgG) as compared to a natural CD16.
- a heterologous gene encoding such modified CD16 can be introduced to the cell.
- the engineered immune cell’s endogenous gene encoding CD16 can be genetically modified via action of a gene editing moiety as disclosed herein, such that the modified CD16 is non-cleavable and can induce enhanced CD16 signaling.
- the cleavage site e.g., position 195-198 in the membrane-proximal region (position 189-212) of CD16 can be modified or eliminated (e.g., CD16 S197P variant as a non-cleavable CD16 variant) .
- a heterologous gene encoding such modified CD16 can be introduced to the cell.
- a heterologous gene encoding a heterologous CD16 variant that (i) exhibits higher binding affinity to its target (e.g., monomeric IgG) and (ii) is non-cleavable can be introduced to the cell (i.e., hnCD16) .
- the heterologous CD16 variant can be a modified CD16 comprising, for example, F176V and S197P, as disclosed herein.
- the heterologous CD variant can be a fusion receptor protein comprising (i) at least a portion of CD16 with an inactivated cleavage site and (ii) an ectodomain of a different cell surface protein, such as a glycoprotein (e.g., CD64) , that exhibits enhanced binding to the target (e.g., monomeric IgG) as compared to an unmodified CD16.
- a fusion receptor protein comprising (i) at least a portion of CD16 with an inactivated cleavage site and (ii) an ectodomain of a different cell surface protein, such as a glycoprotein (e.g., CD64) , that exhibits enhanced binding to the target (e.g., monomeric IgG) as compared to an unmodified CD16.
- a heterologous gene as disclosed herein can be integrated into the genome of the engineered cell (e.g., the engineered NK cell) via action of a gene editing moiety as disclosed herein.
- the heterologous gene may not and need not be integrated into the genome of the engineered cell.
- the enhanced CD16 signaling of the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation of a downstream signaling protein (e.g., SHP-1) via Western blotting or (ii) expression of a downstream gene (e.g., CD25, IFN-gamma, TNF, etc. ) via Western blotting or PCR techniques.
- a downstream signaling protein e.g., SHP-1
- a downstream gene e.g., CD25, IFN-gamma, TNF, etc.
- the CD16 signaling of the engineered immune cell (e.g., the engineered NK cell comprising hnCD16) of the present disclosure can be greater than CD16 signaling of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold,
- enhanced CD16 signaling of the engineered immune cell e.g., the engineered NK cell comprising hnCD16
- the engineered immune cell can be characterized by an increase in phosphorylation of a downstream signaling protein by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up or
- enhanced CD16 signaling of the engineered immune cell e.g., the engineered NK cell comprising hnCD16
- the engineered immune cell can be characterized by an increased expression of a downstream gene by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold,
- the CD16 signaling of the engineered immune cell e.g., the engineered NK cell comprising hnCD16
- the CD16 signaling of the engineered immune cell can be more prolonged (e.g., a longer duration of time of activated CD16 signaling) than CD16 signaling of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise a heterologous cytokine as disclosed herein, wherein the heterologous cytokine is bound to a membrane (e.g., plasma membrane) of the engineered immune cell.
- the heterologous cytokine can comprise a heterologous IL as disclosed herein (e.g., a heterologous IL-15) .
- the engineered immune cell can further comprise one, two, or all of: (a) a different heterologous cytokine (e.g., a heterologous cytokine as disclosed herein, other than the one that is bound to the membrane of the subject cell) , (b) reduced expression or activity of an endogenous immune regulator polypeptide, and (c) a safety switch.
- a different heterologous cytokine e.g., a heterologous cytokine as disclosed herein, other than the one that is bound to the membrane of the subject cell
- the endogenous immune regulator polypeptide is not B2M.
- the endogenous immune regulator can be, for example, a polypeptide other than B2M.
- the engineered immune cell (e.g., an engineered NK cell) can comprise the different heterologous cytokine and one or both of (b) the reduced expression or activity of an endogenous immune regulator polypeptide (e.g., a non-B2M polypeptide) and (c) the safety switch.
- the engineered immune cell comprise the reduced expression or activity of an endogenous immune regulator polypeptide (e.g., a non-B2M polypeptide) and one or both of (a) the different heterologous cytokine and (c) the safety switch.
- the engineered immune cell comprise the safety switch and one or both of (a) the different heterologous cytokine and (b) the reduced expression or activity of an endogenous immune regulator polypeptide (e.g., a non-B2M polypeptide) .
- the engineered immune cell comprise all of (a) , (b) , and (c) .
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit enhanced signaling of an endogenous signaling pathway that involves the heterologous cytokine as compared to a control cell, as disclosed herein.
- the expression or activity of the endogenous immune regulator polypeptide can be reduced in the engineered immune cell (e.g., the engineered NK cell) , for example, via action of a gene editing moiety as disclosed herein.
- the reduced expression or activity of the endogenous immune regulator polypeptide in the engineered immune cell can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation or dephosphorylation of a downstream signaling protein (e.g., SHP2, Ig ⁇ / ⁇ , Syk, etc. for PD1/PDL1 signaling) or (ii) expression of the endogenous immune regulator polypeptide (e.g., PD1) via Western blotting or PCR techniques.
- a downstream signaling protein e.g., SHP2, Ig ⁇ / ⁇ , Syk, etc. for PD1/PDL1 signaling
- a downstream signaling protein e.g., SHP2, Ig ⁇ / ⁇ , Syk, etc. for PD1/PDL1 signaling
- expression of the endogenous immune regulator polypeptide e.g., PD1
- reduced expression of the endogenous immune regulator polypeptide in the engineered immune cell can be characterized by a decrease in the expression of the endogenous immune regulator polypeptide (e.g., PD1) by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about
- reduced activity of the endogenous immune regulator polypeptide in the engineered immune cell can be characterized by a decrease in phosphorylation of a downstream signaling protein (e.g., SHP2 for PD1/PDL1 signaling) by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or
- a downstream signaling protein e.g., SHP2 for PD
- reduced activity of the endogenous immune regulator polypeptide in the engineered immune cell can be characterized by an increase in phosphorylation of a downstream target signaling protein (e.g., Ig ⁇ / ⁇ or Syk for PD1/PDL1 signaling) by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-
- a downstream target signaling protein e.g., Ig ⁇ / ⁇
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise a CD16 variant as disclosed herein for enhanced CD16 signaling in the engineered NK cell.
- the CD16 variant e.g., a heterologous CD16 variant
- the engineered immune cell can further comprise reduced expression or activity of an endogenous immune regulator polypeptide as compared to a control cell, as disclosed herein.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit enhanced CD16 signaling as compared to a control cell, as disclosed herein.
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise reduced activity of endogenous cytokine signaling (e.g., endogenous IL signaling, such as endogenous IL-17 signaling) .
- the engineered immune cell can be derived from an isolated stem cell (e.g., an isolated ESC) .
- the engineered immune cell can be derived from an induced stem cell (e.g., an iPSC) .
- the engineered NK cell can be treated with inhibitors (e.g., small molecule inhibitors) of the endogenous cytokine signaling.
- the engineered NK cell can comprise reduced expression of endogenous IL-17 or endogenous receptor thereof (e.g., via indel or transgene mutation, via transient or permanent suppression, etc. ) .
- the engineered NK cell can comprise reduced expression of endogenous IL-17.
- the engineered NK cell can comprise reduced expression of endogenous IL-17R.
- the engineered NK cell can comprise reduced expression of endogenous IL-17 and endogenous IL-17R.
- the endogenous cytokine as disclosed herein can be an endogenous IL.
- An endogenous IL as disclosed herein can comprise at least 1, 2, 3, 4, 5, or more different types of endogenous ILs.
- An endogenous IL as disclosed herein can comprise at most 5, 4, 3, or 2 different type of endogenous ILs.
- the endogenous IL can be a single type of endogenous IL.
- Non-limiting examples of the endogenous IL can include, but are not limited to, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and IL-36.
- the endogenous IL can be IL-17.
- Non-limiting examples of endogenous Il-17 can include IL-17A, IL-17F, and natural mutations thereof.
- the engineered immune cell e.g., an engineered NK cell
- the engineered immune cell as disclosed herein can exhibit reduced expression or activity of IL-17A or IL-17F.
- an endogenous gene encoding the endogenous cytokine e.g., an endogenous IL, such as IL-17
- an endogenous cytokine e.g., an endogenous IL, such as IL-17
- a gene editing moiety as disclosed herein.
- the endogenous receptor can be a respective receptor of any cytokine as disclosed herein (e.g., a respective receptor of any IL as disclosed herein) .
- the endogenous receptor can be a respective receptor of IL (e.g., IL-17R for IL-7 signaling) .
- IL-17R can include IL-17RA, IL-17RB, IL-17RC, IL-17RD, IL-17RE, and variants thereof.
- the endogenous IL-17R comprises IL-17RA.
- the reduced expression or activity of the endogenous cytokine e.g., an endogenous IL, such as IL-17
- endogenous receptor thereof as disclosed herein can be ascertained by a number of methods, including, but are not limited to, (i) phosphorylation of a downstream signaling protein (e.g., PI3K, Act1, MAP3K, MEK1/2, MKK3/6, MKK4/7, MKK3/6, ERK, p38, JNK, etc. for IL-17) or (ii) expression of a downstream gene via Western blotting or PCT techniques.
- a downstream signaling protein e.g., PI3K, Act1, MAP3K, MEK1/2, MKK3/6, MKK4/7, MKK3/6, ERK, p38, JNK, etc.
- a downstream gene of IL cytokine can include a chemokine (e.g., CXCL1, CXCL2, CXCL8, CXCL9, CXCL10, CCL2, CCL20, etc. ) , a cytokine (e.g., IL-6, TNFa, G-CSF, GM-CSF, etc. ) , an acute phase response molecule (e.g., SAA, CRP, lipocalin 2/24p3, etc. ) , and/or an enzyme (e.g., a metalloproteinase, such as MMP1, MMP3, MMP9, MMP13) .
- a chemokine e.g., CXCL1, CXCL2, CXCL8, CXCL9, CXCL10, CCL2, CCL20, etc.
- a cytokine e.g., IL-6, TNFa, G-CSF, GM-CSF, etc.
- reduced expression or activity of the endogenous cytokine e.g., the endogenous IL, such as IL-17
- engineered immune cell e.g., engineered NK cell
- reduced expression or activity of the endogenous cytokine can be characterized by a decrease in phosphorylation of a downstream signaling protein of the endogenous cytokine by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-
- reduced expression or activity of the endogenous cytokine e.g., the endogenous IL, such as IL-17
- engineered immune cell e.g., engineered NK cell
- reduced expression or activity of the endogenous cytokine can be characterized by a decrease in the expression of a downstream gene of the endogenous cytokine by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit enhanced expression profile of a specific cell marker for a committed immune cell (e.g., a NK cell marker) as compared to a control cell that does not exhibit the reduced activity of the endogenous cytokine signaling (e.g., endogenous IL signaling, such as endogenous IL-17 signaling) as disclosed herein.
- a specific cell marker for committed NK cells can include CD57 or killer immunoglobulin-like receptors (KIR) .
- KIR can comprise KIR2D and/or KIR3D.
- KIR2D can comprise KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, and/or KIR2DS5.
- KIR3D can comprise KIR3DL1, KIR3DL2, KIR3DL3, and/or KIR3DS1.
- the enhanced expression profile of the specific cell marker for the committed immune cell (e.g., CD57 or KIR for NK cells) as disclosed herein can be ascertained by a number of methods, including, but are not limited to, Western blotting or PCR techniques.
- the expression of the specific cell marker for a committed immune cell (e.g., CD57 or KIR or NK cells) in the engineered immune cell of the present disclosure can be greater than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise one or both of: (i) a heterologous transcription factor (e.g., a heterologous STAT) , (ii) reduced activity of endogenous cytokine signaling (e.g., endogenous IL signaling as disclosed herein) , and (iii) reduced expression or activity of endogenous enzyme (e.g., a ligase, such as CBL-B) .
- the engineered immune cell can be derived from an isolated stem cell (e.g., an isolated ESC) .
- the engineered immune cell can be derived from an induced stem cell (e.g., an iPSC) .
- the heterologous transcription factor can comprise at least 1, 2, 3, 4, 5, or more different types of heterologous transcription factor.
- the heterologous transcription factor can comprise at most 5, 4, 3, or 2 different types of transcription factor.
- the heterologous transcription factor can have a single type of transcription factor.
- the transcription factor can be involved in the engineered immune cell’s immune activity, proliferation, apoptosis, and/or differentiation.
- the heterologous transcription factor for the engineered immune cell e.g., the engineered NK cell
- STAT can include STAT1, STAT2, STAT3, STAT4, STAT3, STAT4, STAT5A, STAT5B, STAT6, and modifications thereof.
- STAT can comprise STAT3.
- STAT can comprise STAT5B.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can exhibit enhanced survival in the presence of tumor cells as compared to a control cell without (i) the heterologous transcription factor (e.g., the heterologous STAT) or (ii) the reduced activity of endogenous cytokine signaling (e.g., endogenous IL-17 signaling) .
- the heterologous transcription factor e.g., the heterologous STAT
- endogenous cytokine signaling e.g., endogenous IL-17 signaling
- the engineered immune cell can, in the presence of tumor cells, survive longer than the control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can exhibit reduced expression or activity of a specific endogenous cell marker for a committed immune cell as disclosed herein (e.g., a NK cell marker, such as KIR) as compared to a control cell.
- a specific endogenous cell marker is KIR.
- the engineered immune cell can further comprise one or more of: (a) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, as disclosed herein, (b) a heterologous cytokine (e.g., a heterologous IL, such as IL-15) , as disclosed herein, (c) a CD16 variant for enhanced CD16 signaling as compared to a control cell, wherein the CD16 variant is heterologous to the engineered NK cell, as disclosed herein, (d) an immune regulator polypeptide as disclosed herein, wherein the immune regulator polypeptide is heterologous to the engineered immune cell, and (e) reduced expression or activity of an endogenous immune regulator polypeptide, as disclosed herein.
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, as disclosed herein
- a heterologous cytokine e.g., a heterologous IL, such as IL-15
- the engineered immune cell can comprise the chimeric polypeptide receptor and one or more of (e.g., 1, 2, 3, or 4 of) : (b) the heterologous cytokine, (c) the CD16 variant for enhanced CD16 signaling, (d) the heterologous immune regulator, and (e) the reduced expression or activity of an endogenous immune regulator polypeptide.
- the engineered immune cell can comprise the heterologous cytokine and one or more of (e.g., 1, 2, 3, or 4 of) : (a) the chimeric polypeptide receptor, (c) the CD16 variant for enhanced CD16 signaling, (d) the heterologous immune regulator, and (e) the reduced expression or activity of an endogenous immune regulator polypeptide.
- the engineered immune cell can comprise the CD16 variant for enhanced CD16 signaling and one or more of (e.g., 1, 2, 3, or 4 of) : (a) the chimeric polypeptide receptor, (b) the heterologous cytokine, (d) the heterologous immune regulator, and (e) the reduced expression or activity of an endogenous immune regulator polypeptide.
- the CD16 variant for enhanced CD16 signaling and one or more of (e.g., 1, 2, 3, or 4 of) : (a) the chimeric polypeptide receptor, (b) the heterologous cytokine, (d) the heterologous immune regulator, and (e) the reduced expression or activity of an endogenous immune regulator polypeptide.
- the engineered immune cell can comprise the heterologous immune regulator and one or more of (e.g., 1, 2, 3, or 4 of) : (a) the chimeric polypeptide receptor, (b) the heterologous cytokine, (c) the CD16 variant for enhanced CD16 signaling, and (e) the reduced expression or activity of an endogenous immune regulator polypeptide.
- the heterologous immune regulator e.g., 1, 2, 3, or 4 of
- the engineered immune cell can comprise the reduced expression or activity of an endogenous immune regulator polypeptide and one or more of (e.g., 1, 2, 3, or 4 of) : (a) the chimeric polypeptide receptor, (b) the heterologous cytokine, (c) the CD16 variant for enhanced CD16 signaling, and (d) the heterologous immune regulator.
- an endogenous immune regulator polypeptide e.g., 1, 2, 3, or 4 of
- the reduced expression or activity of the specific endogenous cell marker for the committed immune cell e.g., KIR for NK cells
- KIR for NK cells
- the reduced expression or activity of the specific endogenous cell marker for the committed immune cell can be ascertained by a number of methods, including, but are not limited to, Western blotting or PCR techniques.
- the expression of the specific endogenous cell marker for a committed immune cell (e.g., KIR or NK cells) in the engineered immune cell of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can exhibit reduced expression or activity of one or more (e.g., 1, 2, 3, 4, 5, or more) endogenous immune checkpoint inhibitors (e.g., CD94, CD96, TGF beta receptor, SHIP2, etc. ) .
- the engineered immune cell can exhibit reduced expression or activity of one or more (e.g., 1, 2, 3, 4, 5, or more) of: (i) endogenous CD94, (ii) endogenous CD96, (iii) endogenous TGF beta receptor, and (iv) endogenous SHIP (e.g., SHIP2) .
- the engineered immune cell can exhibit reduced expression or activity of endogenous CD94 and also reduced expression or activity of one or more of (e.g., 1, 2, or all of) : (ii) endogenous CD96, (iii) endogenous TGF beta receptor, and (iv) endogenous SHIP (e.g., SHIP2) .
- the engineered immune cell can exhibit reduced expression or activity of endogenous CD96 and also reduced expression or activity of one or more of (e.g., 1, 2, or all of) : (i) endogenous CD94, (iii) endogenous TGF beta receptor, and (iv) endogenous SHIP (e.g., SHIP2) .
- the engineered immune cell can exhibit reduced expression or activity of endogenous TGF beta receptor and also reduced expression or activity of one or more of (e.g., 1, 2, or all of) : (i) endogenous CD94, (ii) endogenous CD96, and (iv) endogenous SHIP (e.g., SHIP2) .
- the engineered immune cell can exhibit reduced expression or activity of endogenous SHIP (e.g., SHIP2) and also reduced expression or activity of one or more of (e.g., 1, 2, or all of) : (i) endogenous CD94, (ii) endogenous CD96, and (iii) endogenous TGF beta receptor.
- endogenous SHIP e.g., SHIP2
- endogenous CD94 e.g., 1, 2, or all of
- the reduced expression or activity of the immune checkpoint inhibitor (e.g., CD94, CD96, TGF beta receptor, SHIP2, etc. ) in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about
- the reduced expression or activity of the endogenous CD94 in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold,
- the reduced expression or activity of the endogenous CD96 in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold,
- the reduced expression or activity of the endogenous TGF beta receptor in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-
- the reduced expression or activity of the endogenous SHIP (e.g., SHIP2) in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can exhibit reduced expression or activity of an endogenous immune regulator polypeptide, as disclosed herein.
- the endogenous immune regulator polypeptide comprise one or more (e.g., 1, 2, 3, 4, 5, or more) hypo-immunity regulators.
- the engineered immune cell exhibits reduced expression or activity of one or more (e.g., 1, 2, 3, 4, 5, or more) hypo-immunity regulators from: (i) endogenous CD80, (ii) endogenous CD86, (iii) endogenous ICOSL, (iv) endogenous CD40L, (v) endogenous MICA or MICB, or (vi) endogenous NKG2DL.
- the engineered immune cell can be derived from an isolated stem cell (e.g., an isolated ESC) .
- the engineered immune cell can be derived from an induced stem cell (e.g., an iPSC) .
- the reduced expression or activity of the endogenous hypo-immunity regulator (e.g., CD80, CD86, ICOSL, CD40L, MICA, MICB, NKG2DL, etc. ) in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-
- the reduced expression or activity of the endogenous CD80 in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold,
- the reduced expression or activity of the endogenous CD86 in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold,
- the reduced expression or activity of the endogenous ICOSL in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold
- the reduced expression or activity of the endogenous hypo-immunity regulator CD40L in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to
- the reduced expression or activity of the endogenous MICA or MICB in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about
- the reduced expression or activity of the endogenous NKG2DL in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can exhibit reduced expression or activity of an endogenous immune regulator polypeptide, as disclosed herein.
- the endogenous immune regulator polypeptide comprise a hypo-immunity regulator (e.g., ICAM1) .
- the engineered immune cell further comprises one or more of: (a) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, as disclosed herein, (b) a heterologous cytokine (e.g., a heterologous IL, such as IL-15) , as disclosed herein, and (c) a CD16 variant for enhanced CD16 signaling as compared to a control cell.
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, as disclosed herein
- a heterologous cytokine e.g., a heterologous IL, such as IL-15
- CD16 variant for enhanced CD16 signaling as compared to a control cell.
- the engineered immune cell (e.g., the engineered NK cell) comprises a chimeric polypeptide receptor as disclosed herein and one or both of: (b) the heterologous cytokine (e.g., a heterologous IL, such as IL-15) , as disclosed herein and (c) the CD16 variant for enhanced CD16 signaling.
- the heterologous cytokine e.g., a heterologous IL, such as IL-15
- the engineered immune cell e.g., the engineered NK cell
- the heterologous cytokine e.g., a heterologous IL, such as IL-15
- the engineered immune cell comprise the heterologous cytokine (e.g., a heterologous IL, such as IL-15) , as disclosed herein and one or both of: (a) the chimeric polypeptide receptor as disclosed herein and (c) the CD16 variant for enhanced CD16 signaling.
- the engineered immune cell (e.g., the engineered NK cell) comprises the CD16 variant for enhanced CD16 signaling and one or both of: (a) the chimeric polypeptide receptor as disclosed herein and (b) the heterologous cytokine (e.g., a heterologous IL, such as IL-15) , as disclosed herein.
- the heterologous cytokine e.g., a heterologous IL, such as IL-15
- the reduced expression or activity of the endogenous ICAM1 in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 4-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can exhibit reduced expression or activity of an endogenous immune regulator polypeptide, as disclosed herein.
- the endogenous immune regulator polypeptide comprise a hypo-immunity regulator (e.g., ICAM1) .
- the engineered immune cell can be derived from an induced stem cell (e.g., an iPSC) .
- the reduced expression or activity of the endogenous ICAM1 in the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be less than expression of the same by a control cell, as disclosed herein.
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise an immune regulator polypeptide as disclosed herein, wherein the immune regulator polypeptide is heterologous to the engineered immune cell.
- the immune regulator polypeptide comprises a hypo-immunity regulator.
- the hypo-immunity regulator can be PDL2.
- the hypo-immunity regulator can be TGF-beta.
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise an immune regulator polypeptide as disclosed herein, wherein the immune regulator polypeptide is heterologous to the engineered immune cell.
- the immune regulator polypeptide comprises a hypo-immunity regulator.
- the hypo-immunity regulator can comprise one or more (e.g., 1, 2, 3, 4, or more) members from: (i) a heterologous CCL21, (ii) a heterologous IL-10, (iii) a heterologous CD46, (iv) a heterologous CD55, and (v) a heterologous CD59.
- the engineered immune cell can be derived from an isolated stem cell (e.g., an isolated ESC) .
- the engineered immune cell can be derived from an induced stem cell (e.g., an iPSC) .
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the heterologous CCL21 and one or more of (e.g., 1, 2, 3, or all of) : (ii) a heterologous IL-10, (iii) a heterologous CD46, (iv) a heterologous CD55, and (v) a heterologous CD59.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the heterologous IL-10 and one or more of (e.g., 1, 2, 3, or all of) : (i) a heterologous CCL21, (iii) a heterologous CD46, (iv) a heterologous CD55, and (v) a heterologous CD59.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the heterologous CD46 and one or more of (e.g., 1, 2, 3, or all of) : (i) a heterologous CCL21, (ii) a heterologous IL-10, (iv) a heterologous CD55, and (v) a heterologous CD59.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the heterologous CD55 and one or more of (e.g., 1, 2, 3, or all of) : (i) a heterologous CCL21, (ii) a heterologous IL-10, (iii) a heterologous CD46, and (v) a heterologous CD59.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the heterologous CD59 and one or more of (e.g., 1, 2, 3, or all of) : (i) a heterologous CCL21, (ii) a heterologous IL-10, (iii) a heterologous CD46, and (iv) a heterologous CD55.
- the present disclosure provides an engineered immune cell (e.g., an engineered NK cell) .
- the engineered immune cell can comprise a heterologous cytokine (e.g., a heterologous IL) , as disclosed herein that is not IL-15.
- the heterologous cytokine comprises IL-21 or variants thereof.
- the engineered immune cell can be derived from an induced stem cell (e.g., iPSC) .
- a control cell can be a cell can be an immune cell, such as a NK cell, used for comparison purposes.
- a control cell can be a cell that does not comprise a heterologous cytokine (e.g., IL-15) .
- a control cell can be a cell that does not comprise a CD16 variant for enhanced CD16 signaling.
- a control cell can be a cell that a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen.
- a control cell can be a cell that comprises a heterologous IL-15R.
- a control cell can be a cell that does not comprise a membrane bound heterologous cytokine (e.g., IL-15) .
- a control cell can be a cell that does not exhibit reduced expression or activity of an endogenous immune regulator polypeptide.
- a control cell can be a cell that does not exhibit reduced expression or activity of an endogenous cytokine (e.g., IL-17) or a receptor thereof (e.g., IL-17R) .
- a control cell can be a cell that does not comprise a heterologous transcription factor (e.g., STAT) .
- a heterologous transcription factor e.g., STAT
- a control cell can be a cell that does not exhibit reduced expression or activity of a specific endogenous cell marker for a committed immune cell (e.g., a NK cell marker, such as KIR) .
- a control cell can be a cell that does not comprise a heterologous immune regulator polypeptide.
- a control cell can be a cell that does not exhibit reduced expression or activity of one or more (e.g., 1, 2, 3, or 4) of: endogenous CD94, endogenous CD96, endogenous TGF beta receptor, or endogenous SHIP2.
- a control cell can be a cell that does not exhibit reduced expression or activity of one or more (e.g., 1, 2, 3, 4, or 5) of: endogenous CD80, endogenous CD86, endogenous ICOSL, endogenous CD40L, endogenous MICA or MICB, or endogenous NKG2DL.
- a control cell can be a cell that does not exhibit reduced expression or activity of ICAM1.
- a control cell can be a cell that does not comprise a heterologous PDL2 or heterologous TGF beta.
- a control cell can be a cell that does not comprise one or more (e.g., 1, 2, 3, 4, or 5) of: heterologous CCL21, heterologous IL-10, heterologous CD46, heterologous CD55, or heterologous CD59.
- a control cell can be a cell that does not comprise heterologous IL-21.
- a control cell can be a cell that is not derived from a cell line.
- a control cell can be a cell that is not derived from an isolated ESC.
- a control cell can be a cell that is not derived from an iPSC.
- the present disclosure provides a population of engineered immune cells comprising any one of the engineered immune cells as disclosed herein (e.g., a population of engineered NK cells comprising any one of the engineered NK cells as disclosed herein) .
- An engineered immune cell (e.g., an engineered NK cell) of the population of immune cells (e.g., the population of NK cells) can comprise a heterologous polypeptide, wherein the heterologous polypeptide comprises a heterologous IL-15 (e.g., heterologous secretory IL-15, and/or membrane-bound Il-15, such as IL15-IL15 receptor fusion) .
- a heterologous IL-15 e.g., heterologous secretory IL-15, and/or membrane-bound Il-15, such as IL15-IL15 receptor fusion
- An activity level (e.g., persistence level) of the population of engineered immune cells in an environment that is substantially free of an exogenous interleukin can be at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, at least about or more greater than a control persistence level of a comparable population of immune cells (e.g., engineered to comprise a comparable heterologous IL-15 as disclosed herein) in a control environment comprising the exogenous interleukin.
- an exogenous interleukin e.g., IL-2, IL-15, etc.
- Such persistence level may ascertained after the population of immune cells are in the environment for at least or up to about 1 day, at least or up to about 2 days, at least or up to about 3 days, at least or up to about 4 days, at least or up to about 5 days, at least or up to about 6 days, at least or up to about 7 days, at least or up to about 8 days, at least or up to about 9 days, at least or up to about 10 days, at least or up to about 11 days, at least or up to about 12 days, at least or up to about 13 days, at least or up to about 14 days, at least or up to about 15 days, at least or up to about 16 days, at least or up to about 17 days, at least or up to about 18 days, at least or up to about 19 days, at least or up to about 20 days, at least or up to about 21 days, at least or up to about 22 days, at least or up to about 23 days, at least or up to about 24 days, at least or up to about 25 days, at least or up to about 26 days, at least
- the amount of the exogenous interleukin (e.g., IL-2, IL-15, etc. ) in the environment can be at least or up to about 1 unit per milliliter (U/ml) , at least or up to about 5 U/mL, at least or up to about 10 U/mL, at least or up to about 15 U/mL, at least or up to about 20 U/mL, at least or up to about 30 U/mL, at least or up to about 40 U/mL, at least or up to about 50 U/mL, at least or up to about 60 U/mL, at least or up to about 80 U/mL, at least or up to about 100 U/mL, at least or up to about 150 U/mL, at least or up to about 200 U/mL, at least or up to about 300 U/mL, at least or up to about 400 U/mL, or at least or up to about 500 U/mL.
- the environment can be in vitro, ex vivo, or in viv
- the population of engineered NK cells as disclosed herein can exhibit at least or up to about 10%, at least or up to about 20%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, at least or up to about 80%, at least or up to about 90%, at least or up to about 95%, or more persistence (or survival rate) after being in the environment that is substantially free of the exogenous interleukin (e.g., IL-2) for at least or up to about 1 day, at least or up to about 2 days, at least or up to about 3 days, at least or up to about 4 days, at least or up to about 5 days, at least or up to about 6 days, at least or up to about 7 days, at least or up to about 8 days, at least or up to about 9 days, at least or up to about 10 days, at least or up to about 11 days, at least or up to about 12 days, at least or up to about 13 days, at least or up
- the population of engineered NK cells as disclosed herein can exhibit at least about 50%survival after at least about 5 days (50%, after 9 days, 25%after 15 days) in the environment that is substantially free of the exogenous interleukin (e.g., IL-2) .
- the population of engineered NK cells as disclosed herein can exhibit at least about 50%survival after at least about 9 days in the environment that is substantially free of the exogenous interleukin (e.g., IL-2) .
- the population of engineered NK cells as disclosed herein can exhibit at least about 25%survival after at least about 15 days in the environment that is substantially free of the exogenous interleukin (e.g., IL-2) .
- the population of engineered NK cells as disclosed herein can exhibit enhanced persistence by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold, at least or up to about
- NK cells for at least or up to about 1 day, at least or up to about 2 days, at least or up to about 3 days, at least or up to about 4 days, at least or up to about 5 days, at least or up to about 6 days, at least or up to about 7 days, at least or up to about 8 days, at least or up to about 9 days, at least or up to about 10 days, at least or up to about 11 days, at least or up to about 12 days, at least or up to about 13 days, at least or up to about 14 days, at least or up to about 2 weeks, at least or up to about 3 weeks, at least or up to about 4 weeks, at least or up to about 6 weeks, or at least or up to about 8 weeks, as compared to that of a comparable population of NK cells lacking the heterologous polypeptide comprising the heterologous IL-15 (e.g., lacking a heterologous membrane-bound IL-15) .
- the population of engineered NK cells as disclosed herein can exhibit enhanced persistence by at least about 7-fold after
- having such enhanced persistence level by having the heterologous polypeptide comprising the enhanced IL-15 signaling can reduce the amount of exogenous proteins (e.g., IL-2) required for the production of the engineered immune cells, enhance the efficiency of producing the engineered immune cells, and/or reduce overall cost of the immune cell therapy.
- Any enhanced level of persistence ascertained in vitro can be translated to an event in vivo (e.g., in the blood stream of a subject in need thereof) .
- an exogenous interleukin can comprise an interleukin that is not secreted by the cell or the population of cells (e.g., the engineered immune cell (s) , such as the engineered NK cells as disclosed herein) , and can be artificially added to the environment.
- an exogenous interleukin may comprise a recombinant interleukin protein that is added to a medium.
- an exogenous interleukin may comprise a recombinant interleukin protein that is administered to a subject in need thereof.
- the term “persistence” as used herein may generally refer to a presence of at least a portion of a population of cells (e.g., a population of engineered immune cells, such as a population of engineered NK cells as disclosed herein) remaining in an environment after introducing the population of cells to the environment (e.g., in an in vitro medium, in the serum after intravenous (IV) administration, etc. ) .
- a persistence may be ascertained by a duration of time that at least a portion of the population of cells remain in the environment at a detectable level.
- persistence of a population of cells may correlate to the half-life of the population of cells in the environment (e.g., medium, blood stream, etc. ) .
- a population of cells of interest e.g., a population of engineered immune cells, such as a population of engineered NK cells
- a population of cells having a greater persistence level (e.g., at least 5%greater) in an environment after a period of time (e.g., after at least about 5 days) than a control population of cells in a comparable environment after a comparable period of time may indicate that a greater proportion (e.g., at least 5%greater) of the size of the population of cells have survived as compared to the control population of cells.
- the greater persistence of the population of cells (e.g., engineered NK cells as disclosed herein) as compared to the control population of cells (e.g., control NK cells lacking the engineered component of the engineered NK cells) level may be at least or up to about 1%, at least or up to about 2%, at least or up to about 5%, at least or up to about 10%, at least or up to about 20%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, at least or up to about 80%, at least or up to about 90%, at least or up to about 100%, at least or up to about 110%, at least or up to about 120%, at least or up to about 130%, at least or up to about 140%, at least or up to about 150%, at least or up to about 160%, at least or up to about 170%, at least or up to about 180%, at least or up to about 190%, at least or up to about
- the greater proportion of the population of cells (e.g., engineered NK cells as disclosed herein) as compared to the control population of cells (e.g., control NK cells lacking the engineered component of the engineered NK cells) may be at least or up to about 1%, at least or up to about 2%, at least or up to about 5%, at least or up to about 10%, at least or up to about 20%, at least or up to about 30%, at least or up to about 40%, at least or up to about 50%, at least or up to about 60%, at least or up to about 70%, at least or up to about 80%, at least or up to about 90%, at least or up to about 100%, at least or up to about 110%, at least or up to about 120%, at least or up to about 130%, at least or up to about 140%, at least or up to about 150%, at least or up to about 160%, at least or up to about 170%, at least or up to about 180%, at least or up to about 190%, at least or up to about 20
- the engineered immune cell can comprise a heterologous cytokine (e.g., a heterologous IL, such as IL-15) as disclosed herein.
- the heterologous cytokine can be a heterologous secretory cytokine.
- the heterologous cytokine can be a membrane-bound cytokine.
- the engineered immune cell e.g., the engineered NK cell
- the heterologous cytokine and the respective heterologous receptor can be provided as a fusion protein (e.g., IL15-IL15R fusion) .
- the engineered immune cell e.g., the engineered NK cell
- the heterologous receptor e.g., induced by the heterologous cytokine and/or heterologous receptor, such as IL-15/IL-15R
- the engineered immune cell can exhibit reduced expression or activity of endogenous CD38 as compared to a control cell.
- Such engineered immune cell may be used to treat a subject who has or is suspected of having white blood cell cancer, such as multiple myeloma (MM) .
- MM multiple myeloma
- any one of the engineered immune cell e.g., the engineered NK cell
- expression or activity of endogenous CD38 of the engineered immune cell may not and need not be modified.
- Such engineered immune cell may be used to treat a subject who has or is suspected of having a disease (e.g., cancer, tumor) that is not multiple myeloma.
- the engineered immune cell can comprise a heterologous IL-15 or a fragment thereof, and the heterologous IL-15 or the fragment thereof can be secreted by the engineered immune cell.
- the engineered immune cell can comprise a heterologous IL-15 or a fragment thereof, and the heterologous IL-15 or the fragment thereof can be bound to a cell surface membrane of the engineered immune cell.
- the engineered immune cell can comprise at least one chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, as provided in the present disclosure.
- the engineered immune cell can comprise a plurality of different chimeric polypeptide receptors to specifically bind a plurality of different antigens.
- the engineered immune cell can comprise at least one chimeric polypeptide receptor that comprises a plurality of antigen binding moieties to specifically bind a plurality of different antigens.
- the engineered immune cell can comprise a safety switch capable of effecting death of the engineered immune cell.
- the engineered immune cell can comprise a gene encoding the safety switch (e.g., integrated into the genome of the immune cell) , via action of the gene editing moiety, as disclosed herein.
- a prodrug can be introduced to the engineered immune cell (e.g., administered to a subject comprising the engineered immune cell) in the event of an adverse event or when the adaptive immunotherapy is no longer necessary, and the prodrug can be activated by the safety switch molecule to kill the subject immune cell.
- the safety switch can comprise one or more members selected from the group consisting of caspase (e.g., caspase 3, 7, or 9) , thymidine kinase, cytosine deaminase, modified EGFR (e.g., truncated EGFR or “tEGFR” ) , B-cell CD20, and functional variants thereof.
- the safety switch can be activated via an activator (e.g., a small molecule or a protein, such as an antibody) for post-translational, temporal, and/or site-specific regulation of death (or depletion) of the subject engineered immune cell.
- an activator e.g., a small molecule or a protein, such as an antibody
- Non-limiting examples of a safety switch and its activator can include Caspase 9 (or caspase 3 or 7) and AP1903; thymidine kinase (TK) and ganciclovir (GCV) ; and cytosine deaminase (CD) and 5-fluorocytosine (5-FC) .
- Caspase 9 or caspase 3 or 7
- AP1903 thymidine kinase
- GCV ganciclovir
- CD cytosine deaminase
- 5-FC 5-fluorocytosine
- modified epidermal growth factor receptor (EGFR) containing epitope recognized by an antibody e.g., anti-EGFR Ab, such as cetuximab
- an antibody e.g., anti-EGFR Ab, such as cetuximab
- the engineered immune cells e.g., the engineered NK cells
- the engineered immune cells can comprise a safety switch protein selected from the group consisting of caspase 9 (caspase 3 or 7) , thymidine kinase, cytosine deaminase, modified EGFR, and B-cell CD20.
- the engineered immune cell can comprise heterologous immune receptor polypeptide.
- the immune regulator polypeptide can comprise one or more (e.g., 1, 2, 3, 4, or more) members selected from the group consisting of HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59.
- the engineered immune cell can exhibits reduced expression or activity of an endogenous immune regulator polypeptide, as disclosed herein.
- the endogenous immune regulator polypeptide comprises an immune checkpoint inhibitor or a hypo-immunity regulator (or both) .
- the immune checkpoint inhibitor as disclosed herein can comprise one or more (e.g., 1, 2, 3, 4, or more) members selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, TIGIT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4.
- the immune checkpoint inhibitor can comprise SHIP2.
- the hypo-immunity regulator as disclosed herein can comprise one or more (e.g., 1, 2, 3, 4, or more) members selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, interleukin (e.g., IL10) , CD46, CD55, and CD59.
- members selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, P
- non-limiting examples of interleukin include, but are not limited to, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and IL-36.
- non-limiting examples of TGF-beta include, but are not limited to, TGF beta 1, TGF beta 2, TGF beta 3, TGF beta 4, and TGF beta 5.
- any one of the endogenous immune regulator polypeptides can enhance one or more functions of the engineered immune cell (e.g., engineered NK cell) as disclosed herein, e.g., enhanced persistence or survival, enhanced resistance against immune rejection (e.g., ADCC cytotoxicity) , enhanced cytotoxicity against a target cell (e.g., cancer cell) , etc.
- the engineered immune cell can comprise a CD16 variant for enhanced CD16 signaling as compared to a control cell, wherein the CD16 variant is heterologous to the engineered immune cell.
- the engineered immune cell can exhibit enhanced cytotoxicity against a target cell as compared to a control cell.
- the engineered immune cell as disclosed herein can exhibit cytotoxicity (e.g., in vitro, ex vivo, or in vivo) against a target cell or a target population of cells that is greater than that of a control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or
- the engineered immune cell can induce reduced immune response from separate immune cells (e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host) as compared to a control cell.
- separate immune cells e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host
- the engineered immune cell as disclosed herein can reduce the immune response from the separate immune cells by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up to about 50-fold,
- the engineered immune cell can exhibit enhanced half-life upon exposure to separate immune cells (e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host) as compared to a control cell.
- separate immune cells e.g., separate T cells and/or B-cells in vitro, or a host’s immune cells upon administration of the engineered immune cell to the host
- the half-life of the engineered immune cells can be greater than that of the control cell by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about
- the engineered immune cell can effect enhanced function or pathological condition of a bodily tissue of a subject as compared to a control cell.
- treatment with the engineered immune cell can effect enhanced function or pathological condition of a bodily tissue of a subject by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold,
- the engineered immune cell can effect delayed degeneration of function or pathological condition of a bodily tissue of a subject as compared to a control cell.
- treatment with the engineered immune cell can effect delayed degeneration of function or pathological condition of a bodily tissue of a subject by at least or up to about 0.1-fold, at least or up to about 0.2-fold, at least or up to about 0.3-fold, at least or up to about 0.4-fold, at least or up to about 0.5-fold, at least or up to about 0.6-fold, at least or up to about 0.7-fold, at least or up to about 0.8-fold, at least or up to about 0.9-fold, at least or up to about 1-fold, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 20-fold, at least or up to about 30-fold, at least or up to about 40-fold, at least or up
- the bodily tissue can comprise one or more (e.g., 1, 2, 3, 4, or more) members selected from the group consisting of blood, plasma, serum, urine, perilymph fluid, feces, saliva, semen, amniotic fluid, cerebrospinal fluid, bile, sweat, tears, sputum, synovial fluid, vomit, bone, heart, thymus, artery, blood vessel, lung, muscle, stomach, intestine, liver, pancreas, spleen, kidney, gall bladder, thyroid gland, adrenal gland, mammary gland, ovary, prostate gland, testicle, skin, adipose, eye, brain, infected tissue, diseased tissue, malignant tissue, calcified tissue, and healthy tissue.
- members selected from the group consisting of blood, plasma, serum, urine, perilymph fluid, feces, saliva, semen, amniotic fluid, cerebrospinal fluid, bile, sweat, tears, sputum, synovial fluid, vomit, bone
- the engineered immune cell can induce immune response towards a target cell.
- the target can be, for example, a diseased cell, a cancer cell, a tumor cell, etc.
- a heterologous gene can be operatively coupled to (e.g., for knock-in) a constitutive, inducible, temporal, tissue-specific, and/or cell type-specific promoter.
- a promoter of interest can include CMV, EF1a, PGK, CAG, and UBC.
- SOCS cytokine
- non-limiting examples of SOCS include, but are not limited to, CIS, SOCS-1, SOCS-2, SOCS-3, SOCS-4, SOCS-5, SOCS-6, and SOCS-7.
- the SOCS protein can comprise SOCS2.
- any one of the engineered immune cell e.g., the engineered NK cell
- TME tumor microenvironment gene
- having reduced expression or activity of a TME can enhance the engineered immune cell’s immune activity against a target cell.
- a TME gene may be an immune checkpoint inhibitor.
- Non-limiting examples of the TME can include: NKG2A, NKG2D, PD1, CTLA4, LAG3, TIM3, TIGIT, KIR2D, CD94, CD96, TGF beta receptor, 2B4, and SHIP2.
- any one of the engineered immune cell e.g., the engineered NK cell
- heterologous genes e.g., knocked-in
- CD137, CD80, CD86, DAP10 e.g., with or without point mutation
- any one of the engineered immune cell e.g., the engineered NK cell
- endogenous genes e.g., hypo-immunity: B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, and a NKG2DL (e.g., ULBP1) .
- any one of the engineered immune cell e.g., the engineered NK cell
- heterologous genes e.g., knocked-in for, e.g., hypo-immunity: HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59.
- any one of the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can comprise a chimeric polypeptide receptor as disclosed herein (e.g., at least 1, 2, 3, 4, 5, or more different types of chimeric polypeptide receptors) .
- the engineered immune cell can be engineered to express a chimeric polypeptide receptor transiently or permanently.
- a recombinant chimeric polypeptide receptor can be delivered to the engineered immune cell via, e.g., a liposome, and be incorporated into the engineered immune cell via membrane fusion.
- a heterologous polynucleotide construct encoding the chimeric polypeptide receptor can be delivered to the engineered immune cell.
- the heterologous polynucleotide construct i.e., a gene
- encoding the heterologous polynucleotide construct can be incorporated into the chromosome of the engineered immune cell (i.e., chromosomal gene) or, alternatively, may not or need not be integrated into the chromosome of the engineered immune cell as disclosed herein.
- a chimeric polypeptide receptor can comprises a T cell receptor fusion protein (TFP) .
- T cell receptor fusion protein or “TFP” generally refers to a recombinant polypeptide construct comprising (i) one or more antigen binding moieties (e.g., monospecific or multispecific) , (ii) at least a portion of TCR extracellular domain, (iii) at least a portion of TCR transmembrane domain, and (iv) at least a portion of TCR intracellular domain.
- an endogenous T cell receptor (TCR) of the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be inactivated.
- a function of the endogenous TCR of the engineered immune cell can be inhibited by an inhibitor.
- a gene encoding a subunit of the endogenous TCR can be inactivated (e.g., edited via action of the gene editing moiety as disclosed herein) such that the endogenous TCR is inactivated.
- the gene encoding the subunit of endogenous TCR can be one or more of: TCR ⁇ , TCR ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , and CD3 ⁇ .
- a chimeric polypeptide receptor can comprises a chimeric antigen receptor (CAR) .
- CAR chimeric antigen receptor
- the term “chimeric antigen receptor” or “CAR” generally refers to a recombinant polypeptide construct comprising at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as “an intracellular or intrinsic signaling domain” ) comprising a functional signaling domain derived from a stimulatory molecule.
- the stimulatory molecule may be the zeta chain associated with the T cell receptor complex.
- the intracellular signaling domain further comprises one or more functional signaling domains derived from at least one costimulatory molecule.
- the costimulatory molecule may comprise 4-1BB (i.e., CD137) , CD27, and/or CD28.
- the CAR comprises an optional leader sequence at the amino-terminus (N-ter) of the CAR fusion protein.
- the CAR further comprises a leader sequence at the N-terminus of the extracellular antigen recognition domain, wherein the leader sequence is optionally cleaved from the antigen recognition domain (e.g., a scFv, DARPin, etc. ) during cellular processing and localization of the CAR to the cellular membrane.
- the antigen recognition domain e.g., a scFv, DARPin, etc.
- a CAR may be a first-, second-, third-, or fourth-generation CAR system, a functional variant thereof, or any combination thereof.
- First-generation CARs include an antigen binding domain with specificity for a particular antigen (e.g., an antibody or antigen-binding fragment thereof such as a DARPin, an scFv, a Fab fragment, a VHH domain, or a VH domain of a heavy-chain only antibody) , a transmembrane domain derived from an adaptive immune receptor (e.g., the transmembrane domain from the CD28 receptor) , and a signaling domain derived from an adaptive immune receptor (e.g., one or more (e.g., three) ITAM domains derived from the intracellular region of the CD3 ⁇ receptor or Fc ⁇ RI ⁇ ) .
- an adaptive immune receptor e.g., one or more (e.g., three) ITAM domains derived from the intracellular region of the CD3 ⁇ receptor or
- Second-generation CARs modify the first-generation CAR by addition of a co-stimulatory domain to the intracellular signaling domain portion of the CAR (e.g., derived from co-stimulatory receptors that act alongside T-cell receptors such as CD28, CD137/4-1BB, and CD134/OX40) , which abrogates the need for administration of a co-factor (e.g., IL-2) alongside a first-generation CAR.
- Third-generation CARs add multiple co-stimulatory domains to the intracellular signaling domain portion of the CAR (e.g., CD3 ⁇ -CD28-OX40, or CD3 ⁇ -CD28-41BB) .
- Fourth-generation CARs modify second-or third-generation CARs by the addition of an activating cytokine (e.g., IL-12, IL-23, or IL-27) to the intracellular signaling portion of the CAR (e.g., between one or more of the costimulatory domains and the CD3 ⁇ ITAM domain) or under the control of a CAR-induced promoter (e.g., the NFAT/IL-2 minimal promoter) .
- a CAR may be a new generation CAR system that is different than the first-, second-, third-, or fourth-generation CAR system as disclosed herein.
- a hinge domain (e.g., the linker between the extracellular antigen binding domain and the transmembrane domain) of a CAR in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can comprise a full length or at least a portion of the native or modified transmembrane region of CD3D, CD3E, CD3G, CD3c CD4, CD8, CD8a, CD8b, CD27, CD28, CD40, CD84, CD166, 4-1BB, OX40, ICOS, ICAM-1, CTLA-4, PD-1, LAG-3, 2B4, BTLA, CD16, IL7, IL12, IL15, KIR2DL4, KIR2DS1, NKp30, NKp44, NKp46, NKG2C, NKG2D, or T cell receptor polypeptide.
- a transmembrane domain of a CAR in the engineered immune cell can comprise a full length or at least a portion of the native or modified transmembrane region of CD3D, CD3E, CD3G, CD3c CD4, CD8, CD8a, CD8b, CD27, CD28, CD40, CD84, CD166, 4-1BB, OX40, ICOS, ICAM-1, CTLA-4, PD-1, LAG-3, 2B4, BTLA, CD16, IL7, IL12, IL15, KIR2DL4, KIR2DS1, NKp30, NKp44, NKp46, NKG2C, NKG2D, or T cell receptor polypeptide.
- the hinge domain and the transmembrane domain of a CAR as disclosed herein can be derived from the same protein (e.g., CD8) .
- the hinge domain and the transmembrane domain of the CAR as disclosed herein can be derived from different proteins.
- a signaling domain of a CAR can comprise at least or up to about 1 signaling domain, at least or up to about 2 signaling domains, at least or up to about 3 signaling domains, at least or up to about 4 signaling domains, at least or up to about 5 signaling domains, at least or up to about 6 signaling domains, at least or up to about 7 signaling domains, at least or up to about 8 signaling domains, at least or up to about 9 signaling domains, or at least or up to about 10 signaling domains.
- a signaling domain (e.g., a signaling peptide of the intracellular signaling domain) of a CAR in the engineered immune cell (e.g., engineered NK cell) as disclosed herein can comprise a full length or at least a portion of a polypeptide of CD3 ⁇ , 2B4, DAP10, DAP12, DNAM1, CD137 (41BB) , IL21, IL7, IL12, IL15, NKp30, NKp44, NKp46, NKG2C, NKG2D, or any combination thereof.
- the signaling domain CAR in the engineered immune cell can comprise a full length or at least a portion of a polypeptide of CD27, CD28, 4-1BB, OX40, ICOS, PD-1, LAG-3, 2B4, BTLA, DAP10, DAP12, CTLA-4, or NKG2D, or any combination thereof.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell comprises the chimeric polypeptide receptor (e.g., CAR) that comprises at least CD8 transmembrane domain and one or more of: (i) 2B4 signaling domain and (ii) DAP10 signaling domain.
- the engineered cell e.g., the engineered NK cell
- the chimeric polypeptide receptor e.g., TFP or CAR
- the 2B4 signaling domain can be flanked by the CD8 transmembrane domain and the DAP10 signaling domain.
- the DAP10 signaling domain can be flanked by the CD8 transmembrane domain and the 2B4 signaling domain.
- the chimeric polypeptide receptor as disclosed herein can further comprise yet an additional signaling domain derived from CD3 ⁇ .
- An antigen (i.e., a target antigen) of an antigen binding moiety of a chimeric polypeptide receptor can be a cell surface marker, a secreted marker, or an intracellular marker.
- Non-limiting examples of an antigen (i.e., a target antigen) of an antigen binding moiety of a chimeric polypeptide receptor (e.g., TFP or CAR) as disclosed herein can include ADGRE2, carbonic anhydrase IX (CA1X) , CCRI, CCR4, carcinoembryonic antigen (CEA) , CD3 ⁇ , CD5, CD8, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD44V6, CD49f, CD56, CD70, CD74, CD99, CD123, CD133, CD138, CD269 (BCMA) , CD S, CLEC12A, an antigen of a cytomegalovirus (CMV) infected cell (e.g., a cell surface antigen) , epithelial glycoprotein2 (EGP 2) , epithelial glycoprotein-40 (EGP-40) , epithelial cell adhesion molecule (E
- antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include 1-40- ⁇ -amyloid, 4-1BB, 5AC, 5T4, activin receptor-like kinase 1, ACVR2B, adenocarcinoma antigen, AGS-22M6, alpha-fetoprotein, angiopoietin 2, angiopoietin 3, anthrax toxin, AOC3 (VAP-1) , B7-H3, Bacillus anthracis anthrax, BAFF, beta-amyloid, B-lymphoma cell, C242 antigen, C5, CA-125, Canis lupus familiaris IL31, carbonic anhydrase 9 (CA-IX) , cardiac myosin, CCL11 (eotaxin-1) , CCR4, CCR5, CD11, CD18, CD125, CD140a, CD147 (basigin) , CD15, CD152, CD154 (CD40L)
- coli shiga toxin type-1 E. coli shiga toxin type-2, EGFL7, EGFR, endotoxin, EpCAM, episialin, ERBB3, Escherichia coli, F protein of respiratory syncytial virus, FAP, fibrin II beta chain, fibronectin extra domain-B, folate hydrolase, folate receptor 1, folate receptor alpha, Frizzled receptor, ganglioside GD2, GD2, GD3 ganglioside, glypican 3, GMCSF receptor ⁇ -chain, GPNMB, growth differentiation factor 8, GUCY2C, hemagglutinin, hepatitis B surface antigen, hepatitis B virus, HER1, HER2/neu, HER3, HGF, HHGFR, histone complex, HIV-1, HLA-DR, HNGF, Hsp90, human scatter factor receptor kinase, human TNF, human beta-amyloid, ICAM-1 (CD54) , IFN- ⁇
- antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include 707-AP, a biotinylated molecule, a-Actinin-4, abl-bcr alb-b3 (b2a2) , abl-bcr alb-b4 (b3a2) , adipophilin, AFP, AIM-2, Annexin II, ART-4, BAGE, b-Catenin, bcr-abl, bcr-abl p190 (e1a2) , bcr-abl p210 (b2a2) , bcr-abl p210 (b3a2) , BING-4, CAG-3, CAIX, CAMEL, Caspase-8, CD171, CD19, CD20, CD22, CD23, CD24, CD30, CD33, CD38, CD44v7/8, CDC27, CDK-4, CEA, CLCA2, Cyp-B, DAM-10, DAM-6,
- antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include an antibody, a fragment thereof, or a variant thereof.
- antibody can be a natural antibody (e.g., naturally secreted by a subject’s immune cell, such as B cells) , a synthetic antibody, or a modified antibody.
- he antigen of the antigen binding moiety of the chimeric polypeptide receptor as disclosed herein can include an Fc domain of an antibody from the group comprising 20- (74) - (74) (milatuzumab; veltuzumab) , 20-2b-2b, 3F8, 74- (20) - (20) (milatuzumab; veltuzumab) , 8H9, A33, AB-16B5, abagovomab, abciximab, abituzumab, zlintuzumab) , actoxumab, adalimumab, ADC-1013, ADCT-301, ADCT-402, adecatumumab, aducanumab, afelimomab, AFM13, afutuzumab, AGEN1884, AGS15E, AGS-16C3F, AGS67E, alacizumab pegol, ALD518, alemt
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain
- the antigen binding domain can be capable of binding specifically and preferentially to an antigen comprising one or more (e.g., 1, 2, 3, 4, or more) members selected from the group comprising BCMA, CD20, CD22, CD30, CD33, CD38, CD70, CD123, Kappa, Lewis Y, NKG2D ligand, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and gp100.
- Non-limiting examples of the NKG2D ligand comprises one or more (e.g., 1, 2, 3, 4, or more) members selected from the group comprising of MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain capable of specifically binding an antigen of a target cell, and the engineered immune cell can exhibit reduced expression or activity of an endogenous gene encoding the same antigen of the chimeric polypeptide receptor.
- a population of the engineered immune cells can avoid targeting and killing each other, e.g., upon administration to a subject in need thereof.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to CD23.
- the engineered immune cell s endogenous gene encoding CD23 can be modified to effect reduced expression or activity of the endogenous CD23.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to CD123.
- the engineered immune cell ’s endogenous gene encoding CD123 can be modified to effect reduced expression or activity of the endogenous CD123.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to CD38.
- the engineered immune cell ’s endogenous gene encoding CD38 can be modified to effect reduced expression or activity of the endogenous CD38.
- the subject engineered immune cells comprising the chimeric polypeptide receptor against CD38 can be capable of targeting and effecting death (or degradation) of plasma cells.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to CD38.
- the engineered immune cell is an engineered NK cell that is derived from an isolated ESC or an induced stem cell (e.g., iPSC) .
- the engineered immune cell’s endogenous gene encoding CD38 can be modified to effect reduced expression or activity of the endogenous CD38.
- the engineered immune cell e.g., the engineered NK cell
- the engineered immune cell can comprise the chimeric polypeptide receptor (e.g., TFP or CAR) that comprises the antigen binding domain, and the antigen binding domain can be capable of binding specifically and preferentially to CD7.
- the engineered immune cell s endogenous gene encoding CD7 can be modified to effect reduced expression or activity of the endogenous CD7.
- any one of the engineered immune cell e.g., the engineered NK cell disclosed herein can be derived from an isolated stem cell (e.g., an ESC) or an induced stem cell (iPSC) .
- the isolated stem cell or the induced stem cell can be modified (e.g., genetically modified) to generate the engineered immune cell.
- pluripotency of stem cells can be determined, in part, by assessing pluripotency characteristics of the cells.
- Pluripotency characteristics can include, but are not limited to: (i) pluripotent stem cell morphology; (ii) the potential for unlimited self-renewal; (iii) expression of pluripotent stem cell markers including, but not limited to SSEA1 (mouse only) , SSEA3/4, SSEA5, TRA1-60/81, TRA1-85, TRA2-54, GCTM-2, TG343, TG30, CD9, CD29, CD133/prominin, CD140a, CD56, CD73, CD90, CD105, OCT4, NANOG, SOX2, CD30 and/or CD50; (iv) ability to differentiate to all three somatic lineages (ectoderm, mesoderm and endoderm) ; (v) teratoma formation consisting of the three somatic lineages; and (
- stem cells e.g., ESCs or iPSCs
- the stem cells can be genetically modified to express any one of the heterologous polypeptides (e.g., cytokines, receptors, etc. ) as disclosed herein prior to, subsequent to, or during the induced hematopoietic stem cell differentiation.
- the stem cells can be genetically modified to reduce expression or activity of any one of the endogenous genes or polypeptides (e.g., cytokines, receptors, etc. ) as disclosed herein prior to, subsequent to, or during the induced hematopoietic stem cell differentiation.
- such genetically modified CD34+hematopoietic stem cell is or is a source of any one of the engineered immune cell of the present disclosure.
- stem cells as disclosed herein can be cultured in APEL media with ROCKi (Y-27632) (e.g., at about 10 micromolar ( ⁇ M) ) , SCF (e.g., at about 40 nanograms per milliner (ng/mL) of media) , VEGF (e.g., at about 20 ng/mL of media) , and BMP-4 (e.g., at about 20 ng/mL of media) to differentiate into CD34+ hematopoietic stem cells.
- ROCKi Y-27632
- SCF e.g., at about 40 nanograms per milliner (ng/mL) of media
- VEGF e.g., at about 20 ng/mL of media
- BMP-4 e.g., at about 20 ng/mL of media
- the CD34+ hematopoietic stem cells (e.g., genetically modified with one or more features of any one of the engineered immune cell of the present disclosure) can be induced to differentiate in to a committed immune cell, such as T cells or NK cells.
- a committed immune cell such as T cells or NK cells.
- the induced differentiation process generates any one of the engineered NK cell of the present disclosure.
- genetically modified CD34+ hematopoietic stem cells are cultured in the presence of IL-3 (e.g., about 5 ng/mL) , IL-7 (e.g., about 20 ng/mL) , IL-15 (e.g., about 10 ng/mL) , SCF (e.g., about 20 ng/mL) , and Flt3L (e.g., about 10 ng/mL) to differentiate into CD45+ NK cells.
- IL-3 e.g., about 5 ng/mL
- IL-7 e.g., about 20 ng/mL
- IL-15 e.g., about 10 ng/mL
- SCF e.g., about 20 ng/mL
- Flt3L e.g., about 10 ng/mL
- the CD45+ NK cells can be expanded in culture, e.g., in a media comprising IL-2, mbIL-21 aAPC using Gas Permeable Rapid Expansion (G-Rex) platform.
- G-Rex Gas Permeable Rapid Expansion
- iPSC-derived NK cells as disclosed herein can be cultured with one or more heterologous cytokines comprising Il-2, IL-15, or IL-21. In some cases, iPSC-derived NK cells as disclosed herein can be cultured with (e.g., for cell expansion) one or more heterologous cytokines selected from the group consisting of Il-2, IL-15, and IL-21.
- iPSC-derived NK cells as disclosed herein can be cultured with two or more heterologous cytokines selected from the group consisting of Il-2, IL-15, and IL-21 (e.g., IL-2 and IL-15, IL-2 and IL-21, or IL-15 and IL-21) , either simultaneously or sequentially in any order.
- iPSC-derived NK cells as disclosed herein can be cultured with all of Il-2, IL-15, and IL-21, either simultaneous or sequentially in any order.
- the gene editing moiety as disclosed herein can comprise a CRISPR-associated polypeptide (Cas) , zinc finger nuclease (ZFN) , zinc finger associate gene regulation polypeptides, transcription activator-like effector nuclease (TALEN) , transcription activator-like effector associated gene regulation polypeptides, meganuclease, natural master transcription factors, epigenetic modifying enzymes, recombinase, flippase, transposase, RNA-binding proteins (RBP) , an Argonaute protein, any derivative thereof, any variant thereof, or any fragment thereof.
- Cas CRISPR-associated polypeptide
- ZFN zinc finger nuclease
- TALEN transcription activator-like effector nuclease
- RBP RNA-binding proteins
- Argonaute protein any derivative thereof, any variant thereof, or any fragment thereof.
- the actuator moiety comprises a Cas protein, and the system further comprises a guide RNA (gRNA) which complexes with the Cas protein.
- the actuator moiety comprises an RBP complexed with a gRNA which is able to form a complex with a Cas protein.
- the gRNA comprises a targeting segment which exhibits at least 80%sequence identity to a target polynucleotide.
- the Cas protein substantially lacks DNA cleavage activity.
- a suitable gene editing moiety comprises CRISPR-associated (Cas) proteins or Cas nucleases including type I CRISPR-associated (Cas) polypeptides, type II CRISPR-associated (Cas) polypeptides, type III CRISPR-associated (Cas) polypeptides, type IV CRISPR-associated (Cas) polypeptides, type V CRISPR-associated (Cas) polypeptides, and type VI CRISPR-associated (Cas) polypeptides; zinc finger nucleases (ZFN) ; transcription activator-like effector nucleases (TALEN) ; meganucleases; RNA-binding proteins (RBP) ; CRISPR-associated RNA binding proteins; recombinases; flippases; transposases; Argonaute (Ago) proteins (e.g., prokaryotic Argonaute (pAgo) , archaeal Argonaute (aAgo) , and
- Non-limiting examples of Cas proteins include c2c1, C2c2, c2c3, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD) , Cas6, Cas6e, Cas6f, Cas7, Cas8a, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12) , Cas10, Cas10d, Cas1O, Cas1Od, CasF, CasG, CasH, Cpf1, Csy1, Csy2, Csy3, Cse1 (CasA) , Cse2 (CasB) , Cse3 (CasE) , Cse4 (CasC) , Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, C
- the gene editing moiety as disclosed herein can be fused with an additional functional moiety (e.g., to form a fusion moiety) , and non-limiting examples of a function of the additional functional moiety can include methyltransferase activity, demethylase activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity or glycosylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristo
- gene editing e.g., knock in
- delivery of heterologous genetic material can be achieved other viral and non-viral based gene transfer methods can be used to introduce nucleic acids in host cells (e.g., stem cells, hematopoietic stem cells, etc. as disclosed herein) .
- host cells e.g., stem cells, hematopoietic stem cells, etc. as disclosed herein
- Such methods can be used to administer nucleic acids encoding polypeptide molecules of the present disclosure to cells in culture (or in a host organism) .
- Viral vector delivery systems can include DNA and RNA viruses, which can have either episomal or integrated genomes after delivery to the cell.
- Non-viral vector delivery systems can include DNA plasmids, RNA (e.g. a transcript of a vector described herein) , naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome.
- RNA or DNA viral based systems can be used to target specific cells and traffick the viral payload to the nucleus of the cell.
- Viral vectors can be used to treat cells in vitro, and the modified cells can optionally be administered (ex vivo) . Alternatively, viral vectors can be administered directly (in vivo) to the subject.
- Viral based systems can include retroviral, lentivirus, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Integration in the host genome can occur with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, which can result in long term expression of the inserted transgene.
- Methods of non-viral delivery of nucleic acids can include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid: nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA.
- Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides can be used.
- antisense oligonucleotides can be utilized to suppress or silence a target gene expression.
- Non-limiting examples of antisense oligonucleotides can include short hairpin RNA (shRNA) , microRNA (miRNA) , and small interfering RNA (siRNA) .
- the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be combined with a co-therapeutic agent to treat a subject in need thereof.
- the engineered immune cell can be administered to the subject prior to, concurrent with, or subsequent to administration of the co-therapeutic agent to the subject.
- the present disclosure provides a composition
- a composition comprising (a) any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein and (b) a co-therapeutic agent (i.e., a separate therapeutic agent) (e.g., an antibody, such as anti-CD20 antibody or anti-PD1 antibody) .
- a co-therapeutic agent i.e., a separate therapeutic agent
- an antibody such as anti-CD20 antibody or anti-PD1 antibody
- the engineered immune cell can comprise one or more of: (i) a heterologous cytokine (e.g., a heterologous IL, such as IL-15) as disclosed herein, (ii) a CD16 variant for enhanced CD16 signaling as disclosed herein, and (iii) a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, as disclose herein.
- the co-therapeutic agent comprises an anti-CD20 antibody.
- the engineered immune cell can comprise the heterologous cytokine (e.g., IL-15) as disclosed herein and one or both of: (ii) the CD16 variant for enhanced CD16 signaling and (iii) the chimeric polypeptide receptor comprising the antigen binding moiety.
- heterologous cytokine e.g., IL-15
- the engineered immune cell can comprise the CD16 variant for enhanced CD16 signaling and one or both of: (i) the heterologous cytokine (e.g., IL-15) and (iii) the chimeric polypeptide receptor comprising the antigen binding moiety.
- the heterologous cytokine e.g., IL-15
- the chimeric polypeptide receptor comprising the antigen binding moiety.
- the engineered immune cell can comprise the chimeric polypeptide receptor comprising the antigen binding moiety and one or both of: (i) the heterologous cytokine (e.g., IL-15) and (ii) the CD16 variant for enhanced CD16 signaling.
- the heterologous cytokine e.g., IL-15
- the CD16 variant for enhanced CD16 signaling e.g., CD16 signaling.
- Non-limiting examples of a co-therapeutic agent can include cytotoxic agents, chemotherapeutic agents, growth inhibitory agents, agents used in radiation therapy, anti-angiogenesis agents, apoptotic agents, anti-tubulin agents, and other agents to treat cancer, for example, anti-CD20 antibodies, anti-PD1 antibodies (e.g., Pembrolizumab) platelet derived growth factor inhibitors (e.g., GLEEVEC TM (imatinib mesylate) ) , a COX-2 inhibitor (e.g., celecoxib) , interferons, cytokines, antagonists (e.g., neutralizing antibodies) that bind to one or more of the following targets PDGFR- ⁇ , BlyS, APRIL, BCMA receptor (s) , TRAIL/Apo2, other bioactive and organic chemical agents, and the like.
- anti-CD20 antibodies e.g., Pembrolizumab
- platelet derived growth factor inhibitors e.g
- cytotoxic agent generally refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
- a cytotoxic agent can include radioactive isotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, and radioactive isotopes of Lu) , chemotherapeutic agents, e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide) , doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin.
- radioactive isotopes e.g., At211, I131, I125,
- Non-limiting examples of a chemotherapeutic agent can include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone) ; delta-9-tetrahydrocannabinol (dronabinol, ) ; beta-lapachone; lapachol; colchicines; betulinic acid; a camptothecin (including the synthetic analogue topotecan CPT-11 (irinotecan, acetylcamptothec
- ABRAXANE Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill. ) , and docetaxel ( Rorer, Antony, France) ; chloranbucil; gemcitabine 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine oxaliplatin; leucovovin; vinorelbine novantrone; edatrexate; daunomycin; aminopterin; ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO) ; retinoids such as retinoic acid; capecitabine pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as combinations of two or
- chemotherapeutic agent can also include “anti-hormonal agents” or “endocrine therapeutics” that act to regulate, reduce, block, or inhibit the effects of hormones that can promote the growth of cancer, and are often in the form of systemic, or whole-body treatment. They may be hormones themselves.
- Examples include anti-estrogens and selective estrogen receptor modulators (SERMs) , including, for example, tamoxifen (including tamoxifen) , raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene; anti-progesterones; estrogen receptor down-regulators (ERDs) ; agents that function to suppress or shut down the ovaries, for example, leutinizing hormone-releasing hormone (LHRH) agonists such as and ELIGARD) leuprolide acetate, goserelin acetate, buserelin acetate and tripterelin; other anti-androgens such as flutamide, nilutamide and bicalutamide; and aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example,
- chemotherapeutic agents includes bisphosphonates such as clodronate (for example, or ) , etidronate, NE-58095, zoledronic acid/zoledronate, alendronate, pamidronate, tiludronate, or risedronate; as well as troxacitabine (a1, 3-dioxolane nucleoside cytosine analog) ; antisense oligonucleotides, particularly those that inhibit expression of genes in signaling pathways implicated in abherant cell proliferation, such as, for example, PKC-alpha, Raf, H-Ras, and epidermal growth factor receptor (EGFR) ; vaccines such as vaccine and gene therapy vaccines, for example, vaccine, vaccine, and vaccine; topoisomerase 1 inhibitor; rmRH; lapatinib ditosylate (an ErbB-2 and EGFR dual tyrosine kinase small-molecule inhibitor also known as GW572016)
- Examples of a chemotherapeutic agent can also include antibodies such as alemtuzumab (Campath) , bevacizumab ( Genentech) ; cetuximab ( Imclone) ; panitumumab Amgen) , rituximab Genentech/Biogen Idec) , pertuzumab 2C4, Genentech) , trastuzumab Genentech) , tositumomab (Bexxar, Corixia) , and the antibody drug conjugate, gemtuzumab ozogamicin Wyeth) .
- antibodies such as alemtuzumab (Campath) , bevacizumab ( Genentech) ; cetuximab ( Imclone) ; panitumumab Amgen) , rituximab Genentech/Biogen Idec) , pertuzumab 2C4, Genentech) , trastuzumab Genen
- Additional humanized monoclonal antibodies with therapeutic potential as agents in combination with the compounds of the invention include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, feMzumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolov
- Examples of a chemotherapeutic agent can also include “tyrosine kinase inhibitors” such as an EGFR-targeting agent (e.g., small molecule, antibody, etc. ) ; small molecule HER2 tyrosine kinase inhibitor such as TAK165 available from Takeda; CP-724, 714, an oral selective inhibitor of the ErbB2 receptor tyrosine kinase (Pfizer and OSI) ; dual-HER inhibitors such as EKB-569 (available from Wyeth) which preferentially binds EGFR but inhibits both HER2 and EGFR-overexpressing cells; lapatinib (GSK572016; available from Glaxo-SmithKline) , an oral HER2 and EGFR tyrosine kinase inhibitor; PKI-166 (available from Novartis) ; pan-HER inhibitors such as canertinib (CI-1033; Pharmacia) ; Raf-1 inhibitors such as antis
- Examples of a chemotherapeutic agent can also include dexamethasone, interferons, colchicine, metoprine, cyclosporine, amphotericin, metronidazole, alemtuzumab, alitretinoin, allopurinol, amifostine, arsenic trioxide, asparaginase, BCG live, bevacuzimab, bexarotene, cladribine, clofarabine, darbepoetin alfa, denileukin, dexrazoxane, epoetin alfa, elotinib, filgrastim, histrelin acetate, ibritumomab, interferon alfa-2a, interferon alfa-2b, lenalidomide, levamisole, mesna, methoxsalen, nandrolone, nelarabine, nofetumomab, opr
- Examples of a chemotherapeutic agent can also include hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-butyrate, hydrocortisone-17-valerate, aclometasone dipropionate, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate and fluprednidene
- growth inhibitory agent generally refers to a compound or composition which inhibits growth and/or proliferation of a cell (e.g., a cell whose growth is dependent on PD-L1 expression) either in vitro or in vivo.
- the growth inhibitory agent may be one which significantly reduces the percentage of cells in S phase.
- growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase) , such as agents that induce G1 arrest and M-phase arrest.
- Classical M-phase blockers include the vincas (vincristine and vinblastine) , taxanes, and topoisomerase II inhibitors such as the anthracycline antibiotic doxorubicin ( (8S-cis) -10- [ (3-amino-2, 3, 6-trideoxy- ⁇ -L-lyxo-hexapyranosyl) oxy] -7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8- (hydroxyacetyl) -1-methoxy-5, 12-naphthacenedione) , epirubicin, daunorubicin, etoposide, and bleomycin.
- doxorubicin (8S-cis) -10- [ (3-amino-2, 3, 6-trideoxy- ⁇ -L-lyxo-hexapyranosyl) oxy] -7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8- (hydroxyacetyl) -1-methoxy-5
- Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.
- the taxanes are anticancer drugs both derived from the yew tree.
- Docetaxel Rhone-Poulenc Rorer derived from the European yew, is a semisynthetic analogue of paclitaxel Bristol-Myers Squibb) . Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells.
- the engineered immune cell (e.g., the engineered NK cell) of the present disclosure can be used (e.g., administered) to treat a subject in need thereof.
- the subject can have or can be suspected of having a condition, such as a disease (e.g., cancer, tumor, tissue degeneration, fibrosis, etc. ) .
- a cell e.g., a stem cell or a committed adult cell
- the engineered immune cell can be administered to the subject for adaptive immunotherapy.
- the subject can be treated (e.g., administered with) a population of engineered immune cells (e.g., engineered NK cells) of the present disclosure for at least or up to about 1 dose, at least or up to about 2 doses, at least or up to about 3 doses, at least or up to about 4 doses, at least or up to about 5 doses, at least or up to about 6 doses, at least or up to about 7 doses, at least or up to about 8 doses, at least or up to about 9 doses, or at least or up to about 10 doses.
- engineered immune cells e.g., engineered NK cells
- the present disclosure provides a method comprising (a) obtaining a cell from a subject; and (b) generating, from the cell, any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein.
- the cell obtained from the subject is ESC.
- the cell e.g., a fibroblast, such as an adult skin fibroblast
- the cell is modified and transformed into an iPSC.
- the present disclosure provides a method comprising administering to a subject in need thereof a population of NK cells comprising any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein.
- the method can further comprise administering to the subject a co-therapeutic agent (e.g., a chemotherapeutic agent, anti-CD20 antibody, etc. ) .
- a co-therapeutic agent e.g., a chemotherapeutic agent, anti-CD20 antibody, etc.
- the present disclosure provides a method comprising administering to a subject in need thereof any one of the composition disclosed herein.
- the composition can comprise (i) any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein and (ii) a co-therapeutic agent (e.g., a chemotherapeutic agent, anti-CD20 antibody, etc. ) .
- Any one of the methods disclosed herein can be utilized to treat a target cell, a target tissue, a target condition, or a target disease of a subject.
- a target disease can be a viral, bacterial, and/or parasitic infection; inflammatory and/or autoimmune disease; or neoplasm such as a cancer and/or tumor.
- a target cell can be a diseased cell.
- a diseased cell can have altered metabolic, gene expression, and/or morphologic features.
- a diseased cell can be a cancer cell, a diabetic cell, and an apoptotic cell.
- a diseased cell can be a cell from a diseased subject. Exemplary diseases can include blood disorders, cancers, metabolic disorders, eye disorders, organ disorders, musculoskeletal disorders, cardiac disease, and the like.
- a variety of target cells can be killed using any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein.
- a target cell can include a wide variety of cell types.
- a target cell can be in vitro.
- a target cell can be in vivo.
- a target cell can be ex vivo.
- a target cell can be an isolated cell.
- a target cell can be a cell inside of an organism.
- a target cell can be an organism.
- a target cell can be a cell in a cell culture.
- a target cell can be one of a collection of cells.
- a target cell can be a mammalian cell or derived from a mammalian cell.
- a target cell can be a rodent cell or derived from a rodent cell.
- a target cell can be a human cell or derived from a human cell.
- a target cell can be a prokaryotic cell or derived from a prokaryotic cell.
- a target cell can be a bacterial cell or can be derived from a bacterial cell.
- a target cell can be an archaeal cell or derived from an archaeal cell.
- a target cell can be a eukaryotic cell or derived from a eukaryotic cell.
- a target cell can be a pluripotent stem cell.
- a target cell can be a plant cell or derived from a plant cell.
- a target cell can be an animal cell or derived from an animal cell.
- a target cell can be an invertebrate cell or derived from an invertebrate cell.
- a target cell can be a vertebrate cell or derived from a vertebrate cell.
- a target cell can be a microbe cell or derived from a microbe cell.
- a target cell can be a fungi cell or derived from a fungi cell.
- a target cell can be from a specific organ or tissue.
- a target cell can be a stem cell or progenitor cell.
- Target cells can include stem cells (e.g., adult stem cells, embryonic stem cells, induced pluripotent stem (iPS) cells) and progenitor cells (e.g., cardiac progenitor cells, neural progenitor cells, etc. ) .
- Target cells can include mammalian stem cells and progenitor cells, including rodent stem cells, rodent progenitor cells, human stem cells, human progenitor cells, etc.
- Clonal cells can comprise the progeny of a cell.
- a target cell can comprise a target nucleic acid.
- a target cell can be in a living organism.
- a target cell can be a genetically modified cell.
- a target cell can be a host cell.
- a target cell can be a totipotent stem cell, however, in some embodiments of this disclosure, the term “cell” may be used but may not refer to a totipotent stem cell.
- a target cell can be a plant cell, but in some embodiments of this disclosure, the term “cell” may be used but may not refer to a plant cell.
- a target cell can be a pluripotent cell.
- a target cell can be a pluripotent hematopoietic cell that can differentiate into other cells in the hematopoietic cell lineage but may not be able to differentiate into any other non-hematopoietic cell.
- a target cell may be able to develop into a whole organism.
- a target cell may or may not be able to develop into a whole organism.
- a target cell may be a whole organism.
- a target cell can be a primary cell.
- cultures of primary cells can be passaged 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, 15 times or more.
- Cells can be unicellular organisms. Cells can be grown in culture.
- a target cell can be a diseased cell.
- a diseased cell can have altered metabolic, gene expression, and/or morphologic features.
- a diseased cell can be a cancer cell, a diabetic cell, and a apoptotic cell.
- a diseased cell can be a cell from a diseased subject. Exemplary diseases can include blood disorders, cancers, metabolic disorders, eye disorders, organ disorders, musculoskeletal disorders, cardiac disease, and the like.
- the target cells may be harvested from an individual by any method.
- leukocytes may be harvested by apheresis, leukocytapheresis, density gradient separation, etc.
- Cells from tissues such as skin, muscle, bone marrow, spleen, liver, pancreas, lung, intestine, stomach, etc. can be harvested by biopsy.
- An appropriate solution may be used for dispersion or suspension of the harvested cells.
- Such solution can generally be a balanced salt solution, (e.g. normal saline, phosphate-buffered saline (PBS) , Hank's balanced salt solution, etc.
- PBS phosphate-buffered saline
- Buffers can include HEPES, phosphate buffers, lactate buffers, etc.
- Cells may be used immediately, or they may be stored (e.g., by freezing) . Frozen cells can be thawed and can be capable of being reused. Cells can be frozen in a DMSO, serum, medium buffer (e.g., 10%DMSO, 50%serum, 40%buffered medium) , and/or some other such common solution used to preserve cells at freezing temperatures.
- Non-limiting examples of cells which can be target cells include, but are not limited to, lymphoid cells, such as B cell, T cell (Cytotoxic T cell, Natural Killer T cell, Regulatory T cell, T helper cell) , Natural killer cell, cytokine induced killer (CIK) cells (see e.g.
- myeloid cells such as granulocytes (Basophil granulocyte, Eosinophil granulocyte, Neutrophil granulocyte/Hypersegmented neutrophil) , Monocyte/Macrophage, Red blood cell (Reticulocyte) , Mast cell, Thrombocyte/Megakaryocyte, Dendritic cell; cells from the endocrine system, including thyroid (Thyroid epithelial cell, Parafollicular cell) , parathyroid (Parathyroid chief cell, Oxyphil cell) , adrenal (Chromaffin cell) , pineal (Pinealocyte) cells; cells of the nervous system, including glial cells (Astrocyte, Microglia) , Magnocellular neurosecretory cell, Stellate cell, Boettcher cell, and pituitary (Gonadotrope, Corticotrope, Thyrotrope, Somatotrope, Lactotroph) ; cells of the Respiratory system, including Pneumocyte (Type I pneumocyte, granulocyte,
- Apocrine sweat gland cell odoriferous secretion, sex-hormone sensitive
- Gland of Moll cell in eyelid specialized sweat gland
- Sebaceous gland cell lipid-rich sebum secretion
- Bowman's gland cell in nose washes olfactory epithelium
- Brunner's gland cell in duodenum enzymes and alkaline mucus
- Seminal vesicle cell secretes seminal fluid components, including fructose for swimming sperm
- Prostate gland cell secretes seminal fluid components
- Bulbourethral gland cell massbourethral gland cell
- Bartholin's gland cell vaginal lubricant secretion
- Gland of Littre cell Gland of Littre cell
- Uterus endometrium cell (carbohydrate secretion)
- Isolated goblet cell of respiratory and digestive tracts micus secretion
- Duct cell (of seminal vesicle, prostate gland, etc. ) , Epithelial cells lining closed internal body cavities, Ciliated cells with propulsive function, Extracellular matrix secretion cells, Contractile cells; Skeletal muscle cells, stem cell, Heart muscle cells, Blood and immune system cells, Erythrocyte (red blood cell) , Megakaryocyte (platelet precursor) , Monocyte, Connective tissue macrophage (various types) , Epidermal Langerhans cell, Osteoclast (in bone) , Dendritic cell (in lymphoid tissues) , Microglial cell (in central nervous system) , Neutrophil granulocyte, Eosinophil granulocyte, Basophil granulocyte, Mast cell, Helper T cell, Suppressor T cell, Cytotoxic T cell, Natural Killer T cell, B cell, Natural killer cell, Reticulocyte, Stem cells and committed progenitors for the blood and immune system (various types) ,
- the target cell is a cancer cell.
- cancer cells include cells of cancers including Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblastic leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute promyelocytic leukemia, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Adult T-cell leukemia, Aggressive NK-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sarcoma
- the targeted cancer cell represents a subpopulation within a cancer cell population, such as a cancer stem cell.
- the cancer is of a hematopoietic lineage, such as a lymphoma.
- the antigen can be a tumor associated antigen.
- the target cell e.g., B cells
- the target cell as disclosed herein is associated or is suspected of being associated with an autoimmune disease.
- the subject being treated with any one of the engineered immune cell (e.g., engineered NK cell) of the present disclosure can have or can be suspected of having an autoimmune disease.
- Non-limiting examples of an autoimmune disease can include acute disseminated encephalomyelitis (ADEM) , acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, allergic asthma, allergic rhinitis, alopecia areata, amyloidosis, ankylosing spondylitis, antibody-mediated transplantation rejection, anti-GBM/Anti-TBM nephritis, antiphospholipid syndrome (APS) , autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED) , autoimmune myocarditis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP) , autoimmune thyroid disease, autoimmune urticaria, axonal &neuronal neuropathies, Balo
- the autoimmune disease comprises one or more members selected from the group comprising rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus (lupus or SLE) , myasthenia gravis, multiple sclerosis, scleroderma, Addison's Disease, bullous pemphigoid, pemphigus vulgaris, Guillain-Barré syndrome, Sjogren syndrome, dermatomyositis, thrombotic thrombocytopenic purpura, hypergammaglobulinemia, monoclonal gammopathy of undetermined significance (MGUS) , Waldenstrom's macroglobulinemia (WM) , chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) , Hashimoto's Encephalopathy (HE) , Hashimoto's Thyroiditis, Graves'Disease, Wegener's Granulomatosis, and antibody-mediated transplantation rejection (e.g., for
- the target disease is T cell leukemia (TCL) , such as T-cell acute lymphoblastic leukemia (T-ALL) .
- TCL T cell leukemia
- T-ALL T-cell acute lymphoblastic leukemia
- a chimeric polypeptide receptor comprising an antigen binding domain capable of binding to CD7 as disclosed herein
- a heterologous cytokine e.g.,
- the target disease is acute myeloid leukemia (AML) .
- AML acute myeloid leukemia
- a chimeric polypeptide receptor comprising an antigen binding domain capable of binding to an antigen (e.g., CD33 and/or CD123) as disclosed herein
- a heterologous cytokine e.g., IL-15
- CD16 variant for enhanced CD16 signaling as disclosed herein can be administered to a subject
- the target disease is non-Hodgkin’s lymphoma (NHL) .
- the target disease is chronic lymphocytic leukemia (CLL) .
- CLL chronic lymphocytic leukemia
- the target disease is B-cell leukemia (BCL) .
- BCL B-cell leukemia
- any one of the engineered immune cell (e.g., the engineered NK cell) disclosed herein that comprises one or more of: (i) a chimeric polypeptide receptor comprising an antigen binding domain capable of binding to CD19 as disclosed herein, (ii) a heterologous cytokine (e.g., IL-15) as disclosed herein, and (iii) a CD16 variant for enhanced CD16 signaling as disclosed herein can be administered to a subject in need thereof to treat BCL.
- the target disease is non-small-cell lung carcinoma (NSCLC) .
- NSCLC non-small-cell lung carcinoma
- the target cells form a tumor (i.e., a solid tumor) .
- a tumor treated with the methods herein can result in stabilized tumor growth (e.g., one or more tumors do not increase more than 1%, 5%, 10%, 15%, or 20%in size, and/or do not metastasize) .
- a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks.
- a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months.
- a tumor is stabilized for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years.
- the size of a tumor or the number of tumor cells is reduced by at least about 5%, 10%, 15%, 20%, 25, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%or more.
- the tumor is completely eliminated, or reduced below a level of detection.
- a subject remains tumor free (e.g. in remission) for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks following treatment.
- a subject remains tumor free for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months following treatment.
- a subject remains tumor free for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years after treatment.
- Example 1 Engineered NK cells
- Table 1 illustrates examples of engineered NK cells with or without genetic modifications, along with possible functions, and therapeutic indications.
- therapeutic indications can include acute myeloid leukemia (AML) , multiple myeloma (MM) , Myelodysplastic syndrome (MDS) , B cell leukemia, T cell leukemia, solid tumor, and blood cancer.
- the NK cells as disclosed herein can be generated by engineering NK cells derived from a subject.
- the NK cells as disclosed herein can be derived from stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- stem cells such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- stem cells e.g., embryonic stem cells
- iPSCs induced stem cells
- one or more genetic modifications as disclosed herein can be introduced at (A) the stem cell state, (B) the hematopoietic stem cell state, and/or (C) the NK cell state.
- the NK cells as disclosed herein can be NK cell lines.
- TEE tumor microenvironment
- cells of interest can be engineered to carry (i) one or more enhanced or introduced genes (e.g., introduced transgenes) and/or (ii) one or more reduced expression level of endogenous genes (e.g., loss-of-function of genes of interest) .
- the reduced expression level of the endogenous genes can be induced by, e.g., CRISPP/Cas and one or more guide nucleic acid molecules, such as the non-limiting exemplary guide RNA sequences provided in TABLE 3.
- the cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- the cells of interest can be immune cells (e.g., NK cells) .
- immune cells e.g., NK cells
- Such immune cells can be derived from the stem cells as disclosed herein.
- immunes can be immune cell lines (e.g.. NK cell lines) .
- NK cells can be engineered to carry certain transgenes and/or loss-of-function of genes of interest, as shown in TABLE 3.
- cells of interest can be engineered to exhibit enhanced CD16 signaling (e.g., enhanced endogenous CD16 signaling, introduced transgene comprising CD16, etc. ) .
- the cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- the cells of interest can be immune cells (e.g., NK cells) .
- Such immune cells can be derived from the stem cells as disclosed herein.
- such immune cells can be immune cell lines (e.g., NK cell lines) .
- NK cells can be engineered to exhibit enhanced CD16 signaling.
- hnCD16 amino acid sequence (SEQ ID NO. 1) :
- NK-92 cells were engineered to exhibit enhanced CD16 signaling.
- the engineered NK-92 cells were modified to express CD64/CD16A fusion protein (i.e., hnCD16) (SEQ ID NO. 1) .
- the resulting hnCD16 NK-92 cells were validated by identifying enhanced expression of both CD16 (e.g., via anti-CD16-PE antibody) and CD64 (e.g., via anti-CD64-APC/AF700 antibody) using fluorescence-activated cell sorting (FACS) , as shown in FIG. 1A.
- FACS fluorescence-activated cell sorting
- Wild-type (WT) NK-92 cells were used as control.
- the hnCD16 construct sequence can comprise “FHVS” (SEQ ID NO. 2) .
- the hnCD16 construct sequence can comprise “WFHVS” (SEQ ID NO. 3) .
- the hnCD16 construct sequence can comprise “FHVSF” (SEQ ID NO. 4) .
- the hnCD16 construct sequence can comprise “WFHVSF” (SEQ ID NO. 5) .
- the hnCD16 construct sequence can comprise “VWFHVSFC” (SEQ ID NO. 6) .
- the hnCD16 construct sequence can comprise “PVWFHVSFCL” (SEQ ID NO. 7) .
- the hnCD16 construct sequence can comprise “TPVWFHVSFCLV” (SEQ ID NO. 8) .
- the hnCD16 NK-92 cells were cultured alone (unstimulated, control) or in the presence of K562 cells capable of activating NK cells (K562) or phorbol 12-myristate 13-acetate (PMA) to activate CD16 and induce cleavage thereof.
- K562 cells capable of activating NK cells
- PMA phorbol 12-myristate 13-acetate
- FIG. 1B data revealed that the hnCD16 NK-92 cells were highly resistant to the activation-induced cleavage of CD16a, as compared to peripheral blood (PB) NK cells as a control (FIG. 1B) .
- PB peripheral blood
- NK cells as a control
- treatment with PMA marginally reduced the percentage of CD16+ cells from 92%to 85%for the hnCD16 NK-92 cells, whereas the same treatment reduced the percentage of CD16+ cells from 96%to 25% (FIG. 1B) .
- hnCD16 NK-92 cells Persistency of hnCD16 in the hnCD16 NK-92 cells was also confirmed by using anait-CD64 antibody (FIG. 1C) . Also, it was observed that hnCD16 NK-92 cells did not downregulate endogenous CD16 expression upon stimulation (e.g., K652 or PMA) (FIGs. 1D and 1E) .
- the target cells (Raji cells) were treated with (i) the hnCD16 NK-92 cells and (ii) either anti-CD20 antibody or hIgG as a control.
- Engineered iPSC as disclosed herein e.g., iPSCs engineered with enhanced or introduced CD16 signaling (e.g., hnCD16, a CD16 variant) were subjected for differentiation into NK cells (e.g., iNK cells) .
- NK cells e.g., iNK cells
- the iNK cells e.g., about 5x10 5 culture containing cells
- staining e.g., staining for NK specific markers
- CD56 + cells were detected in the differentiated cells, and NKG2A + , NKp30 + , NKp44 + , and/or NKp46 + cells were detected in the CD56 + population among three exemplified clones, PU02, PU06, and PU24, which expressed enhanced CD16 signaling via hnCD16. Therefore, iPSC expressing enhanced or introduced CD17 signaling were proven to be able to differentiate into iNK cells.
- enhanced CD16 signaling e.g., overexpression of CD16, such as hnCD16
- NK cells e.g., wild-type iNK cells or iNK clones with enhanced CD16 signaling, such as PU02, PU06, and PU24 clones
- FACS FACS with PE conjugated anti-CD16 antibody to be more abundant when compared to controls wild-type (wt) NK-92 cells and ANB-ISO.
- hnCD16 were indeed overexpressed in hnCD16 NK-92 cells.
- NK cells e.g., NK92 cell line, NK cell derived from stem cells such as iPSCs
- a separate dosage of antibody for an enhancement of cytotoxicity against target cells (e.g., cancer cells)
- target cells e.g., cancer cells
- NK cells engineered to express enhanced CD16 signaling e.g., hnCD16, CD16-CD64 fusion protein, etc.
- CD16 signaling e.g., hnCD16, CD16-CD64 fusion protein, etc.
- target cells e.g., Raji cells
- a certain antibody e.g., anti-CD20 mAb
- Example 4 Enhanced function (e.g., survival and persistency) of NK Cells
- cells of interest can be engineered to exhibit (i) reduced expression of at least one endogenous gene (e.g., one or more immune regulating polypeptides) and/or (ii) enhanced or introduced expression of at least one additional gene (e.g., one or more additional immune regulating polypeptides) .
- Cells comprising (i) and/or (ii) as disclosed herein can exhibit enhanced function, such as a persistence level (or survival level) .
- the cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- the cells of interest can be immune cells (e.g., NK cells) .
- Such immune cells can be derived from the stem cells as disclosed herein.
- such immune cells can be immune cell lines (e.g., NK cell lines) .
- NK cells can be engineered to comprise at least (i) a heterologous transcription factor (e.g., STAT) and (ii) reduced expression or activity of an endogenous cytokine receptor (e.g., endogenous IL receptor, such as IL-17R) .
- a heterologous transcription factor e.g., STAT
- an endogenous cytokine receptor e.g., endogenous IL receptor, such as IL-17R
- NK cells are generated from isolated ESCs or iPSCs.
- the NK cells are engineered to express a heterologous STAT (e.g., STAT3 and/or STAT5B) .
- a gene encoding the heterologous STAT is incorporated into the NK cell’s genome via either viral transduction or via action of a gene editing moiety as disclosed herein.
- the NK cells are also engineered to exhibit reduced expression or activity of endogenous IL-17R (i.e., STAT3 + IL-17R - NK cells) .
- NK cells with either one of (i) the heterologous STAT and (ii) reduced expression or activity of IL-17R, or non-engineered NK cells are used as a control.
- the engineered STAT3 + IL-17R - NK cells can be cultured in vitro to assess viability and growth (or proliferative capacity) of the engineered STAT3 + IL-17R - NK cells in absence of an exogenous cytokine.
- the NK cells are cultured in culture medium without the addition of exogenous cytokines for 3-6 weeks.
- the engineered STAT3 + IL-17R - NK cells exhibit a significantly higher number of NK cells as compared to the control cells, indicating the enhanced survival and persistency of the engineered STAT3 + IL-17R - NK cells in vitro.
- the engineered STAT3 + IL-17R - NK cells can be administered in NCG mice having a Raji xenograft model.
- NCG mice are triple immunodeficient and lack functional/mature T, B, and NK cells, and have reduced macrophage and dendritic cell function to host the xenograft model.
- the engineered STAT3 + IL-17R - NK cells and the control cells are each administered into the respective Raji xenograft model mice via intravenous (IV) tail vein injection, at a dose of about 1 ⁇ 10 6 cells per animal.
- mice injected with the engineered STAT3 + IL-17R - NK cells exhibit higher NK cell concentrations in the peripheral blood from about 7 days to about 28 days post-infusion, demonstrating the enhanced survival and persistency of the engineered STAT3 + IL-17R - NK cells in vivo.
- Cells of interest can be engineered with (i) reduced expression of at least one endogenous gene (e.g., loss-of-function of one or more immune regulating polypeptides) and/or (ii) enhanced or introduced expression of at least one additional gene (e.g., at least one transgene encoding one or more additional immune regulating polypeptides) .
- endogenous gene e.g., loss-of-function of one or more immune regulating polypeptides
- additional gene e.g., at least one transgene encoding one or more additional immune regulating polypeptides
- NK cells e.g., cord blood NK (CBNK) cells, NK cells derived from iPSCs, etc.
- BCL3 transcription coactivator BCL3 transcription coactivator
- CBLB Cbl proto-oncogene B
- CDK8 loss-of-function of cyclin dependent kinase 8
- FCER1G loss-of-function of Fc fragment of IgE receptor Ig
- FCER1G loss-of-function of interleukin 17A
- IL17F loss-of-function of interleukin 17F
- IPP5D/SHIP1 loss-of-function of suppressor of cytokine signaling 1 (SOCS1) ; loss-of-function of suppressor of cytokine signaling 2 (SOCS2) ; loss-of-function of suppressor of cytokine signaling 3 (SOCS3) ; loss-of-function of signal transducer and activator of transcription 3 (STAT3) ; loss-of-function of BCL3 transcription coactivator (BCL3) ; loss-of-function of Cbl proto-oncogene B (CBLB) ; loss-of-function of
- the loss-of function gene editing can be fulfilled by one or more gene editing moieties as disclosed herein, such as CRIPSR/Cas9 system.
- NK cells e.g., CBNK cells
- the medium e.g., Lymphocyte Serum-Free Medium KBM 581 (Corning) , 10%Human male AB serum, 1%MEM Non-Essential Amino Acids Solution (100X, Gibco) , 1%L-Glutamine (200 mM) (Gibco) , 0.02%Vitamin C, 200U/mL IL-2) .
- cells e.g., about 1x10 7 cells
- RNP guide RNA/Cas9 protein complex
- the guide RNA and Cas9 are transfected, e.g., with the ratio of 2: 1 (guide RNA 75 picomole (pmol) , Cas9 protein 150 pmol) .
- the transfected cells are recovered (e.g., using the medium with doubled Human male AB serum (20%) ) before downstream assays.
- the editing efficiency is analyzed by fragment analysis or NGS.
- Target name gRNA sequence gRNA position Strand STAT3 TAAGACCCAGATCCAGTCCG chr17: 42322471-42322493 - TET2 CAGGACTCACACGACTATTC chr4: 105234149-105234171 - PTPN2 TAGAGGAAAGTCCTGTACAT chr18: 12802004-12802026 + PTPN6 TCGGCCCAGTCGCAAGAACC chr12: 6951687-6951709 + IL17F GTACTTGCTGCTGTCGATAT chr6: 52238923-52238945 - CD38 TATCAGCCACTAATGAAGTT chr4: 15816593-15816612 + CD70 GCCCGCAGGACGCACCCATA chr19: 6590941-6590960 +
- NK cells can be utilized as a model population of cells to examine persistence enhancing gene edits.
- a population of NK cells can be engineered comprise (i) reduced expression of at least one endogenous immune regulating polypeptide comprising one or more members selected from the group consisting of BCL3, CBLB, CDK8, FCER1G, IL17A, IL17F, SHIP1, SOCS1, SOCS2, SOCS3, STAT3, TET3, PTPN6, and CD70, and/or (ii) the enhanced or introduced expression of NKG2C.
- the persistence level of the population of engineered NK cells in such mixture can be characterized by (i) an enrichment level of the population of engineered NK cells within the mixture in a sub-optimal environment that is greater than (ii) an enrichment level of the population of engineered NK cells within the mixture in an optimal environment.
- the sub-optimal environment can comprise a lower amount (or concentration) of exogenous cytokine (e.g., exogenous IL, such as IL-2) .
- the sub-optimal environment can comprise an amount of the exogenous cytokine that is at least about 1%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more lower than that in the optimal environment.
- the sub-optimal environment can be an in vitro medium, and the optimal environment can be an in vitro medium.
- the sub-optimal environment can be an in vivo environment (e.g., blood stream of a subject) , and the optimal environment can be an in vitro medium.
- the enrichment level of the population of engineered NK cells within such mixture can be ascertained by identifying an amount (or proportion) of cells exhibiting (i) the reduced expression of at least one endogenous immune regulating polypeptide comprising one or more members selected from the group consisting of BCL3, CBLB, CDK8, FCER1G, IL17A, IL17F, SHIP1, SOCS1, SOCS2, SOCS3, STAT3, TET3, PTPN6, and CD70, and/or (ii) the enhanced or introduced expression of NKG2C.
- NK cells with reduced expression or activity level of a gene of interest may survive or persist longer in a sub-optimal environment (e.g., low cytokine) .
- a sub-optimal environment e.g., low cytokine
- NKs cells may exhibit high survival rate or persistence, regardless of whether the NK cells comprise the reduced expression or activity level of such gene of interest (e.g., FCER1G) .
- a higher enrichment e.g., INDEL% in a mixture with different types of cells in the sub-optimal (or more challenging) environment can suggest that such loss-of-function gene may induce enhanced survival or persistence to the cell.
- NK cells For example, to find the gene related to NK persistency, one or more of such population of engineered NK cells (e.g., eighteen kinds of gene-edited NK cells, such as gene-edited CBNK cells) were mixed in a mixture as disclosed herein and cultured using high cytokine (200 U/mL IL-2) or low cytokine (10 U/mL IL-2) . Editing percentage (%INDEL) of each gene was analyzed by NGS after 8 days culturing. Two mixtures were prepared using two individual electroporation of each gene, three replicates were set for each culturing condition. A flowchart showing the method design is depicted in FIG. 14A.
- %INDEL Editing percentage
- FCER1G deficient editing showed increased percentage when cultured with low cytokines, which indicated that FCER1G deficient NK cells had better persistency in low cytokine conditions, while PTPN2 had no significant difference in the same assay, as illustrated in FIG. 14B and FIG. 14C, respectively.
- an immune regulator polypeptide that is not PTPN2 e.g., FCER1G
- a cell e.g., stem cell, immune cell, such as NK cell, etc.
- one or more of such population of engineered NK cells e.g., eighteen kinds of gene-edited NK cells, such as gene-edited CBNK cells
- a mixture as disclosed herein and cultured using high cytokine (200U/mL IL-2) (more optimal environment) or injected to hIL-15-NCG mice (sub-optimal environment)
- each mixed NK cells were injected to 5 mice with an amount (e.g., an amount of 1X10 7 NK cells /mouse) .
- Over time e.g., after 8 days
- in vitro cultured NK cells or mouse tissue are harvested to extract the genome.
- Editing percentage (%INDEL) of each gene is analyzed by NGS. Two mixtures were prepared using two individual electroporation of each gene, three replicates were set for in vitro culturing, five mice were used for each mixed NK cells injection. A flowchart showing the method design is depicted in FIG. 15A.
- STAT3 deficient editing shown increased percentage in mouse tissue compared to cultured using high cytokine, which indicated that STAT3 deficient NK cells have better survival and persistency in vivo, while PTPN2 had no significant difference in the same assay.
- an immune regulator polypeptide that is not PTPN2 e.g., STAT3
- a cell e.g., stem cell, immune cell, such as NK cell, etc.
- NK cells comprising reduced expression of at least one endogenous immune regulating polypeptide that is not PTPN2
- Engineered NK cells as disclosed herein can be engineered to exhibit reduced expression of at least one endogenous immune regulating polypeptide that is not PTPN2, to enhance function (e.g., persistency in vitro or in vivo, cytotoxicity against target cells in vitro or in vivo) of the engineered NK cells compared to control NK cells lacking such reduced expression of the at least one endogenous immune regulating polypeptide that is not PTPN2.
- NK cell marker such as CD45 ( “AND” represents wildtype iPSC without gene knock out as a control; “TC” represents an iPSC clone with CISH knockout as a control; and “TD” represents various iPSC clones with SOCS2 knock out) .
- AND represents wildtype iPSC without gene knock out as a control
- TC represents an iPSC clone with CISH knockout as a control
- TD represents various iPSC clones with SOCS2 knock out
- FIG. 26B there was no difference in hCD56+ cells versus wildtype (ANB) (e.g., iPSC derived NK cells without genetic modifications) , as quantified via FACS fluoresces intensity (FIG. 26C) .
- wildtype e.g., iPSC derived NK cells without genetic modifications
- FIGs. 26D and 26E differentiated NK cells with SOCS2 knockout (SOCS2 KO) were tested under in vivo conditions comprising peripheral blood with IL-2 and IL-15 supplementation, respectively.
- FIG. 26D when cultured in peripheral blood with IL-2 supplementation, engineered NK cells with SOCS2 knockout exhibited greater persistence as compared to unmodified NK cells (QN-001) or engineered NK cells with CISH knockout.
- the number of SOCS2 KO NK cells was greater than the number of unmodified NK cells (QN-001) by at least about 300%.
- the number of SOCS2 KO NK cells was greater than the number of unmodified NK cells (QN-001) by at least about 250%.
- FIG. 26E when cultured in peripheral blood with IL-15 supplementation, engineered NK cells with SOCS2 knockout exhibited greater persistence as compared to unmodified NK cells (QN-001) or engineered NK cells with CISH knockout.
- the number of SOCS2 KO NK cells was greater than the number of unmodified NK cells (QN-001) by at least about 190%.
- the number of SOCS2 KO NK cells was greater than the number of unmodified NK cells (QN-001) by at least about 300%.
- SOCS KO e.g., SOCS2 KO
- SOCS KO can elongate the persistence of NK cells when cultured in vitro under in vivo conditions (e.g., in presence of allogeneic peripheral blood) , and thus SOCS KO can elongate persistence of NK cells when administered to a subject in need thereof.
- NK cells were engineered for SOCS2 KO using ribonucleoproteins (RNPs) (e.g., via transfection of Cas/sgRNA complex exhibiting specific affinity to the endogenous SOCS2 gene of the cell) .
- RNPs ribonucleoproteins
- Two different SOCS2 KO NK cells were generated by using two different sgRNA sequences (SOCS2-sg20 and SOCS2-sg24) .
- p-STAT5 histogram was gated at the p-STAT5 MFI of ANB (as Negative control) and the gated population ratio was depicted in the figures. As shown in FIGs.
- SOCS2 KO NK cells NK cells treated with a RNP comprising a control sgRNA (hSH2) , and unmodified NK cells (ANB) showed relative activated level of a downstream signaling protein of interleukin (e.g., p-STAT5) when cultured in presence of IL-2 or IL-15.
- a downstream signaling protein of interleukin e.g., p-STAT5
- SOCS2 knockout iPSCs clones as shown in FIG. 28A were differentiated into SOCS2 knockout NK cells.
- some of the iPSC-derived SOCS2 KO NK cells exhibited greater activated level of a downstream signaling protein of interleukin (e.g., p-STAT5) when cultured in presence of IL-2 or IL-15, as compared to the unmodified NK cells (ANB) .
- p-STAT5 a downstream signaling protein of interleukin
- the iPSC-derived SOCS2 KO NK cells from TD45 clone exhibited greater p-STAT5 signal under cytokine treatment compared to the unmodified NK cells.
- the iPSC-derived SOCS2 KO NK cells (as annotated by the respective iPSC clone numbers TD16, TD30, TD44, and TD45) exhibited greater persistence as compared to unmodified control NK cells (ANB) .
- TD16 iPSC-derived SOCS2 KO NK cells cultured in presence of low concentration of exogenous IL-2 (see [d] ) exhibited greater persistence than unmodified control NK cells (ANB) that were cultured under the same IL-2 condition (see [b] ) .
- TD16 iPSC-derived SOCS2 KO NK cells cultured in presence of low concentration of exogenous IL-15 (see [a8] or [a9] ) exhibited greater persistence than unmodified control NK cells (ANB) that were cultured under the same IL-15 condition (see [a2] or [a3] , respectively] ) .
- SOCS2 KO can enhance cytokine downstream signal and promote survival (e.g., via persistency, proliferation, etc. ) of NK cells under low exogenous cytokine condition or a condition substantially free of exogenous cytokines.
- iPSCs were engineered for knock out of an endogenous immune regulating polypeptide, such as CBL-B (or CBLB) , e.g., via transfection of Cas/sgRNA complex exhibiting specific affinity to the endogenous CBLB gene (CBLB-sg9) .
- CBLB-sg9 endogenous CBLB gene
- a sgRNA that does not target CBLB gene (SH2-sg) was used in conjunction with the Cas protein as a control.
- iPSC-derived NK cells with or without CBLB knockout exhibited comparable in vitro expansion.
- the CBLB knockout NK cells exhibited enhanced cytotoxicity against the Raji target cells, either at the effector to target (E: T) ratio of 3: 1 (graph above) or 1: 1 (graph below) .
- E: T ratio of 3: 1 the anti-Raji cell cytotoxicity of the CBLB KO NK cells was about 20%greater as compared to that of an unmodified control NK cells (see about 70%killing of Raji cells for [a3] versus about 50%killing of Raji cells for [a1] or [a2] , at 24 hour) .
- the anti-Raji cell cytotoxicity of the CBLB KO NK cells was about 40%greater as compared to that of an unmodified control NK cells (see about 50%killing of Raji cells for [b4] versus about 35%killing of Raji cells for [b1] or [b2] , at 24 hour) .
- CD107a degranulation assay via flow cytometry (as a marker for cytotoxic cells) showed that CBLB KO NK cells exhibited a greater proportion of CD107+ cytotoxic NK cells, as compared to the proportion of CD107+ cytotoxic NK cells in unmodified control NK cells.
- the trend was observed when the CBLB KO NK cells were expanded at least 3 times (left figure) or at least 6 times (right figure) after the CBLB knockout at the iPSC stage.
- IFN- ⁇ can be used as a marker to activated cytotoxic NK cells. As shown in FIG. 29D, assessment of the proportion of IFN- ⁇ positive NK cells showed that CBLB KO NK cells exhibited a greater proportion of IFN- ⁇ positive NK cells as compared to the unmodified control NK cells.
- any enhancement of cytotoxic characteristics of the NK cells as compared to NK cells lacking the CBLB KO can be attributed substantially to the cytotoxicity of the initial population of CBLB KO NK cells (e.g., not substantially due to more CBLB KO NK cells proliferating as compared to the unmodified control NK cells) .
- iPSCs were engineered for knock out of an endogenous immune regulating polypeptide, such as CDK8, e.g., via transfection of Cas/sgRNA complex exhibiting specific affinity to the endogenous CDK8gene (CDK8-sg7) .
- CDK8-sg7 A sgRNA that does not target CBLB gene (SH2-sg) was used in conjunction with the Cas protein as a control.
- FIG. 30A iPSC-derived NK cells with or without CDK8 knockout exhibited comparable in vitro expansion.
- CDK8 knockout NK cells exhibited enhanced anti-tumor cytotoxicity against target cells (e.g., K562 cells) as compared to control unmodified NK cells.
- CDK8 knockout NK cells exhibited a greater proportion of IFN- ⁇ positive NK cells as compared to control unmodified NK cells, suggesting that the CDK8 knockout NK cells were more cytotoxic against target cells than the unmodified NK cells.
- any enhancement of cytotoxic characteristics of the NK cells as compared to NK cells lacking the CDK8 KO can be attributed substantially to the cytotoxicity of the initial population of CDK8 KO NK cells (e.g., not substantially due to more CDK8 KO NK cells proliferating as compared to the unmodified control NK cells) .
- reducing expression of at least one endogenous immune regulating polypeptide in NK cells can enhance cytotoxicity of the NK cells, whether with or without affecting proliferative capacity of the NK cells.
- cells of interest can be engineered to comprise a heterologous chimeric polypeptide (e.g., a chimeric antigen receptor) comprising an antigen binding moiety against a specific antibody of a target cell (e.g., a cancer or tumor cell) , to exhibit enhanced cytotoxicity against such target cell.
- a heterologous chimeric polypeptide e.g., a chimeric antigen receptor
- the cells of interest can be immune cells (e.g., NK cells) .
- immune cells can be derived from the stem cells as disclosed herein.
- NK cells derived from stem cells one or more genetic modifications as disclosed herein can be introduced at (A) the stem cell state (e.g., iPSC state) , (B) the hematopoietic stem cell state, and/or (C) the NK cell state.
- the stem cell state e.g., iPSC state
- the hematopoietic stem cell state e.g., IL-12
- C NK cell state
- immune cells can be immune cell lines (e.g., NK cell lines) .
- NK cells e.g., NK-92 cells
- NK-92 cells were engineered to express anti-CD19 CAR, then cultured in the presence of CD19+ Raji cells to assess targeting of the Raji cells by the engineered anti-CD19 NK cells.
- Wild type (WT) NK-92 cells were used as control.
- the anti-CD19 CAR NK cells exhibited enhanced cytotoxicity against the Raji cells (as ascertained by a reduced number of alive Raji cells) as compared to the control (FIGs. 2A and 2B) .
- the anti-CD19 CAR NK cells when cultured in the presence of the Raji cells, the anti-CD19 CAR NK cells exhibited enhanced expression of endogenous CD107a (indicative of cytotoxic granule release) as compared to the control (FIGs. 2C and 2D) . Furthermore, when cultured in the presence of the Raji cells, the anti-CD19 CAR NK cells exhibited enhanced cytokine production (e.g., IFN-gamma and/or TNF-alpha production) as compared to the control (FIGs. 2E-2G) .
- cytokine production e.g., IFN-gamma and/or TNF-alpha production
- NK cells expressing a chimeric polypeptide receptor comprising an antigen binding moiety capable of specifically binding to CD33 were generated.
- Schematic of CD33 CAR structure design is shown in FIG. 16A.
- Targeted cytotoxicity of NK92 cells with CD33-CAR integration on KG1 cells, a tumor cell line with high expression of CD33, with an E/T (Effector/Target) ratio of 1: 1 was tested.
- WT-NK92 cell were used as unmodified control.
- FIG. 16B the targeted cytotoxicity of CD33-CAR on KG1 cells were greatly improved compared to control.
- NK cells expressing a chimeric polypeptide receptor comprising an antigen binding moiety capable of specifically binding to BCMA was generated.
- Schematic of BCMA CAR structure design is shown in FIG. 17A.
- E/T (Effector/Target) ratios used were 1: 1; 1: 5 and 1: 10. WT-NK92 cell were used as unmodified control.
- FIG. 19A illustrates different chimeric polypeptide receptor (e.g., CAR) constructs.
- FIG. 19A Top schematically illustrates CD19 CAR (2B4) structure design. TM short for Transmembrane domain; SCFV short for single chain variable fragment.
- FIG. 19A Middle schematically illustrates CD19 CAR (4-1-BB) structure design. TM short for Transmembrane domain; SCFV short for single chain variable fragment.
- FIG. 19A bottom schematically illustrates CD19 CAR (CD28) structure design. TM short for Transmembrane domain; SCFV short for single chain variable fragment.
- FIGs. 19B and 19C shows targeted cytotoxicity against target cells by NK cells expressing one of the chimeric polypeptide receptor design shown in FIG. 19A.
- targeted cytotoxicity of various CD19-CAR NK92 on CD19-K562 cells E/T (Effector/Target) equals 5: 1; 1: 1 and 0.5: 1) demonstrates that NK cells expressing CAR constructs with 4-1-BB signaling domain, 2B4 signaling domain, and/or CD28 signaling domain exhibited targeted cytotoxicity against CD19-presenting K562 target cells.
- WT-NK92 cell were used as unmodified control, CD19-K562 is K562 engineered with CD19 highly expressed. Referring to FIG.
- cells of interest can be engineered to exhibit enhanced cytokine signaling (e.g., enhanced IL-15 signaling by enhanced or introduced IL-15, such as heterologous secretory IL-15, heterologous membrane-bound IL-15, heterologous IL-15 cytokine-IL15 receptor fusion, etc. ) .
- the cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- the cells of interest can be immune cells (e.g., NK cells) . Such immune cells can be derived from the stem cells as disclosed herein. Alternatively, such immune cells can be immune cell lines (e.g., NK cell lines) .
- NK-92 cells were engineered with (i) hIL-15 knock in or (ii) hIL-15-hIL15R fusion polypeptide knock in.
- Two variants of the hIL-15-hIL15R fusion polypeptide were tested.
- the first variant i.e., hIL15-IL15Ra fused-1 or “fus1”
- the first variant was designed with a linker between hIL-15 and hIL15R, which linker comprising one or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, or more repeats) of “GGGGS” (SEQ ID NO. 9) , e.g., “GGGGSGGGGSGGGGSGGGGSGGGGGGSGGGGS” (SEQ ID NO. 10) .
- the second variant (i.e., hIL15-IL15Ra fused-2 or “fus2” ) was designed with a linker between hIL-15 and hIL15R, which linker comprising one or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, or more repeats) of “GGGGS” (SEQ ID NO. 9) and one or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, or more repeats) of “EGKSSGSGSESKST” (SEQ ID NO. 11) , e.g., “EGKSSGSGSESKSTEGKSSGSGSESKSTGGGGS” (SEQ ID NO. 12) .
- NK-92 cells with either of the hIL-15-hIL15R fusion polypeptide variant knocked-in were positive for hIL-15 (FIG. 3A) .
- the engineered NK-92 cells expressing either variant of the hIL-15-hIL15R fusion polypeptide for enhanced IL-15 signaling exhibited longer persistency as compared to control NK-92 cells engineered express secretory form of IL-15.
- Western blotting analysis revealed increased phosphorylation of IL-15-stimulated STAT5 in the NK-92 cells expressing either hIL15-IL15Ra fused-1 (fus1) or hIL15-IL15Ra fused-2 (fus2) , as compared to the secretory IL-15 (IL15) (FIG. 3B) .
- hIL15-IL15Ra fused-1 sequence (SEQ ID NO. 13) :
- hIL15-IL15Ra fused-2 sequence (SEQ ID NO. 14) :
- IL15 The expression of IL15 was confirmed in several iNK cells differentiated from hIL15-IL15Ra fused-1 iPSC clones, PW15, PW18, and PW23. As shown in FIG. 6, Fluorescence-activated Cell Sorting (FACS) was performed to quantify the surface expression of IL-15 in clones expressing membrane-bound IL-15 in comparison with controls, wild-type (wt) iNK cells and isotype. Thus, the clones were validated for expected overexpression level of membrane-bound IL-15.
- FACS Fluorescence-activated Cell Sorting
- KB-15 cells were eNK cells (e.g., NK cells differentiated from iPSCs and subsequently expanded) differentiated from iPSC clones expressing hIL15-IL15Ra, aCD19 CAR, and a CD16 variant for enhanced CD16 signaling.
- the in-vitro growth of 2x10 7 KB-15 cultured with or without IL-2 (100U/mL) was monitored for 30 days. The cultured cells was collected and counted every 3 to 4 days, and the medium was renewed with corresponding medium meanwhile.
- KB-15 cells were able to grow in the absence of exogenous cytokines as vigorously as the ones in the presence of exogenous cytokines.
- the engineered NK cells comprising enhanced IL-15 signaling e.g., KB-15 NK cells comprising hIL15-IL15Ra
- the engineered NK cells cultured in a medium substantially free of exogenous IL-2 exhibited enhanced persistence (e.g., on day 5, day 9, day 12, day 16, day 23, day 26, etc. ) than the engineered NK cells cultured in a medium comprising exogenous IL-2.
- membrane-bound IL-15 can have a capability to induce downstream IL signaling (e.g., STAT pathway) to a higher degree than secreted IL (e.g., IL-2, IL-15) , but the secreted IL at sufficient amount can act as a competitor for the same membrane receptor to reduce the chance of binding between the membrane-bound IL-15 and the respective receptor (e.g., IL-15R) and the signaling thereof.
- IL signaling e.g., STAT pathway
- secreted IL e.g., IL-2, IL-15
- IL15-IL15R fusion membrane-bound IL-15
- the engineered NK cells comprising enhanced IL-15 signaling is administered in vivo, where an amount of cytokines such as IL-2 in the blood stream or in a tissue of interest may be low (or sub-optimal) , the engineered NK cells can exhibit optimal persistence or survival via self-induced activation of IL-15.
- IPSC expressing membrane-bound IL-15 differentiated into iNK
- the engineered iPSC were subjected for iNK differentiation. Specifically, 5x10 5 culture containing cells was collected and used for staining with NKG2A-PE, NKp30-PE, NKp44-PE, NKp46- PE and CD56-APC antibody. As shown in FIGs. 8A-8E respectively, CD56 + cells could be detected in the total differentiated cells, and NKG2A + , NKp30 + , NKp44 + , and NKp46 + cells could be detected in the CD56 + population among three exemplified clones, PW15, PW18 and PW23, which expressed membrane-bound IL-15. Therefore, iPSC expressing membrane-bound IL-15were proven to be able to differentiate into iNK cells.
- NCG mice having a Nalm-6 xenograft model were used in an in-vivo pharmacokinetic assay.
- the mice lacked functional or mature T, B, and NK cells, and had reduced macrophage and dendritic cell function to host the xenograft model.
- eNK cells differentiated from iPSC edited with aCD19 CAR, a CD16 variant for enhanced CD16 signaling, and membrane-bound IL-15 (QN-019) were administered in the NCG mice, via intravenous (IV) tail vein injection, at a dose of about 1 ⁇ 10 7 cells per animal.
- eNK cells differentiated from WT iPSC (QN-001) were administered as a control. As shown in FIGs.
- NK cell concentrations in the peripheral blood at 8, 15 and 22 days post-infusion were detected by FACS with CD56-APC antibody.
- CD56+ QN-019 cells proliferated significantly faster than QN-001 cells after infusion into the xenograft model, which proved a preferred pharmacokinetics profile in QN-019 cells.
- iPSC expressing secretory IL-15 differentiated into iNK
- the engineered iPSC were subjected for iNK differentiation. Three clones expressing secretory IL-15, PX27, PX33, and PX39, were tested. Specifically, 1x10 5 culture containing cells was collected and used for staining with CD56-APC antibody. FIG. 10A with the percentage of CD56 + cells in the total differentiated cells illustrates that iPSC expressing secretory IL-15 could differentiate into iNK.
- FIG. 10B showing the concentration of IL-15 in iNK culture medium proves that the iNK cells were validated for secreting human IL-15 into culture medium.
- FIG. 10C shows the in-vitro growth curve of 5x10 6 eNK cells differentiated from iPSC clones expressing secretory IL-15, aCD19 CAR, and a variant for enhanced CD16 signaling (OQ-20) .
- the cultured cells were collected and counted every 4 days, and the medium in absence of exogenous cytokines was renewed with corresponding medium meanwhile. The growth of the cells within 16 days was recorded and plotted as curves. Therefore, it has been proven that eNK cells expressing secretory IL-15 facilitated in-vitro growth without exogenous cytokines.
- NK cells e.g., differentiated ex vivo from isolated stem cells, or engineered variant of isolated NK cells
- a heterologous polypeptide comprising a heterologous interleukin such as IL-15 e.g., a fusion polypeptide comprising a heterologous IL-15 and its respective receptor
- IL-15 e.g., a fusion polypeptide comprising a heterologous IL-15 and its respective receptor
- target cells e.g., tumor cells
- engineered NK cells may exhibit the persistency or cytotoxicity against the target cells in a medium that is substantially free of an exogenous interleukin protein, such as IL-15 or IL-2.
- QN-023a NK cells were engineered to express hIL15-IL15Ra.
- the QN-001 NK cells were control NK cells without the hIL15-IL15Ra.
- the in-vitro growth of the NK cells with or without exogenous cytokines (e.g., IL-2) in the media was monitored for 27 days.
- the cultured cells were collected and counted over a given period (e.g., every 3 days) , and the medium was renewed with corresponding medium meanwhile.
- the QN-023a NK cells were able to grow in the absence of exogenous cytokines as vigorously as the ones in the presence of exogenous cytokines (see [a] versus [b] in FIG.
- the QN-001 NK cells that did not express the hIL15-IL15Ra exhibited enhanced degree of proliferation (or persistence) when exogenous cytokines were added to the media (see [c] versus [d] ) .
- the QN-023a NK cells that expressed the hIL15-IL15Ra and were cultured with or without the exogenous cytokines exhibited enhanced persistence as compared to both (1) the control QN-001 NK cells cultured with the exogenous cytokines and (2) the control QN-001 NK cells cultured without the exogenous cytokines.
- the QN-023a NK cells that expressed the hIL15-IL15Ra and were cultured with or without the exogenous cytokines exhibited enhanced persistence by (1) at least between about 25%and about 30%as compared to that by the control QN-001 NK cells cultured with the exogenous cytokines and (2) at least about 300%as compared to that by the control QN-001 NK cells cultured without the exogenous cytokines.
- cells of interest can be engineered to exhibit (i) reduced expression of one or more immune regulating polypeptides (e.g., one or more endogenous immune regulating polypeptides) and/or (ii) enhanced or introduced expression of one or more additional immune regulating polypeptides (e.g., one or more heterologous immune regulating polypeptides) .
- immune regulating polypeptides e.g., one or more endogenous immune regulating polypeptides
- additional immune regulating polypeptides e.g., one or more heterologous immune regulating polypeptides
- Cells comprising (i) and/or (ii) as disclosed herein can exhibit enhanced function, such as a persistence level (or survival level) , hypo-immunity (e.g., resistance against immune rejection or cytotoxicity) , growth rate, cytotoxicity against a target cell (e.g., tumor cell) , etc.
- a persistence level or survival level
- hypo-immunity e.g., resistance against immune rejection or cytotoxicity
- growth rate cytotoxicity against a target cell (e.g., tumor cell) , etc.
- having the combination of (i) and (ii) can synergistically improve function of the cells, as compared to having either one of (i) and (ii) alone, or a combination of individual effects of (i) and (ii) , or none.
- having reduced expression of two or more immune regulating polypeptides can synergistically improve function of the cells, as compared to having an individual member of the reduced expression of the two or more immune regulating polypeptides, or a combination of individual effects of such individual members.
- having enhanced/introduced expression of two or more additional immune regulating polypeptides can synergistically improve function of the cells, as compared to having an individual member of the enhanced/introduced expression of the two or more additional immune regulating polypeptides, or a combination of individual effects of such individual members.
- the cells of interest can be stem cells, such as isolated stem cells (e.g., embryonic stem cells) or induced stem cells (e.g., iPSCs) .
- the cells of interest can be immune cells (e.g., NK cells) .
- immune cells e.g., NK cells
- Such immune cells can be derived from the stem cells as disclosed herein.
- immune cells can be immune cell lines (e.g., NK cell lines) .
- Table 2 illustrates example combinations of modified expression or activity of the plurality of immune regulator polypeptides.
- a combination of modified expression or activity of the plurality of immune regulator polypeptides from Table 2 may be introduced in cells (e.g., engineered NK cells) to, for example, reduce or avoid immune response (e.g., immune attack, such as adaptive immune rejection) from a host’s body upon administration of the cells to the host’s body.
- a combination of modified expression or activity of the plurality of immune regulator polypeptides from Table 2 may comprise (i) reduced expression or activity of one or more first immune regulator polypeptides (column 2) and (ii) enhanced expression or activity of one or more second immune regulator polypeptides (column 3) .
- a combination of modified expression or activity of the plurality of immune regulator polypeptides from Table 2 may comprise (i) knock-out of one or more endogenous immune regulator polypeptide genes (column 2) and (ii) knock-in of one or more heterologous immune regulator polypeptide genes (column 3) .
- NK cells can be engineered to carry certain transgenes and/or loss-of-function of genes of interest, such as the non-limiting exemplary guide RNA sequences are show in Table 6 below.
- RNA sequence Guide RNA position TAP1 CTTGTAGAATCCAGTCAGTG chr6: 32852449-32852471: + TAP1 GTAGAATCCAGTCAGTGAGG chr6: 32852452-32852474: + TAP1 TTACGGGCCGCCTCACTGAC chr6: 32852459-32852481: - TAPBP GAACCAACACTCGATCACCG chr6: 33313815-33313837: + TAPBP GGTGATCGAGTGTTGGTTCG chr6: 33313811-33313833: - TAPBP GATCGAGTGTTGGTTCGTGG chr6: 33313808-33313830: -
- Human iPSC cells can be engineered by knocking in gene edits such as HLA-E, CD47, PDL2, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and/or CD59. Such engineered iPSC cells can be differentiated into NK cells. Alternatively, human peripheral blood (PB) -NK cells can be engineered with AAV system. Possible functional readouts to test the engineered NK cells for hypo-immunity include mixed lymphocyte reaction (MLR) , T cell activation assay, in vitro NK-cell-induced killing assay, and complement-dependent cytotoxicity.
- MLR mixed lymphocyte reaction
- iPSC can be edited with different knock-ins and knock-outs. Subsequently, these edited iPSC can be subjected for differentiation into iNK which can be further expanded into eNK.
- iNK cells can be used for T cell proliferation assay, and eNK can be used for NK cytotoxicity test and hypoimmunity test.
- edited iPSC cells can be differentiated into iEC cells (e.g., endothelial cells derived from iPSCs) which can be used for NK susceptibility assay.
- KO genes KO method sgRNA sequence B2M RNP GAGTAGCGCGAGCACAGCTA CIITA RNP AGGCCCGGATGGCATCCTAG ICAM1 RNP CGCACTCCTGGTCCTGCTCG MICA ABE GGCAGGCTTGCATTCCCTCC MICB ABE AGGGGCCATGGGGCTGGGCC ULBP1 ABE ACTCACCGACCCATCCTGCC
- RNP method is a method of electroporating target cells with pre-mixed ribonucleoprotein (RNP) containing Cas9 and sgRNA. After delivery to the cells, the RNP edits the genome region paired to the sgRNA.
- Adenine base editor (ABE) method is a method where Cas proteins can be fused to an enzyme that can deaminate a DNA nucleoside.
- clones 05, 07, 08, 104, 111, 112 were derived by electroporating human iPSC with RNP targeting B2M.
- the Edit-1 clones were confirmed to be B2M knock-out by FACS analysis for MHC-I (see FIG. 12A) and by sanger sequencing (FIG. 12B) .
- clone 05 was sequenced to have an insertion of one nucleotide in both B2M alleles
- clone 07 was sequenced to have an insertion of one nucleotide in one B2M allele and a deletion of two nucleotides in the other allele.
- clones 03 and 06 were derived by electroporating human iPSC with RNP targeting CIITA, followed by FACS sorting for single cells.
- the edit-2 clones were confirmed to be CIITA KO by sanger sequencing.
- clone 03 was sequenced to have an insertion of one nucleotide in both CIITA alleles
- clone 06 was sequenced to have an insertion of one nucleotide in one CIITA allele and a deletion of sixteen nucleotides in the other allele.
- Edit-3 clones clones 04, 20, 25, 48, and 16, were derived by electroporating hiPSC with two RNPs, targeting B2M and CIITA, respectively.
- the Edit-3 clones were confirmed to be B2M knock-out by FACS analysis for MHC-I (see FIG. 12D) and sanger sequencing was used to confirm the knock-out of B2M and CIITA at the genomic level (see FIG. 12E) .
- Edit-4 clones clones 02 and 30, were derived by electroporating hiPSC with a construct overexpressing PD-L1, PD-L2, TGF- ⁇ , HLA-E, HLA-G, CD47, IL-10, CCL-21, CD46, CD55, CD59 and two RNPs, targeting B2M and CIITA, respectively, followed by FACS sorting for B2M - ; PDL1 + ; CD47 + single cells.
- the Edit-4 clones were confirmed to be B2M-by FACS analysis for MHC-I, and PDL1+, PD2+, CD47+, CD46+, CD55+ and CD59+ (see FIG. 12F) and sanger sequencing was used to confirm the knock-out of B2M and CIITA at the genomic level. For CIITA, only 1 allele was confirmed to be knock-out (see FIG. 12G) .
- Edit-5 clones clones 01, 02, and 26, were derived by electroporating hiPSC with a construct overexpressing of PD-L1, HLA-E, CD47, IL-10, CCL-21 and two RNPs, targeting B2M and CIITA, respectively, followed by FACS sorting for B2M-; PDL1+; CD47+ single cells.
- the Edit-5 clones were confirmed to be B2M-by FACS analysis for MHC-I, and PDL1+, CD47+ (see FIG. 12H) and sanger sequencing was used to confirm the KO of B2M and CIITA at the genomic level (see FIG. 12I) .
- Edit-6 clones clones 08, 13, 15, and 31, were derived by electroporating hiPSC with a construtct overexpressing PD-L1, HLA-E, CD47, CD46, CD55, CD59 and two RNPs, targeting B2M and CIITA, respectively, followed by FACS sorting for B2M - ; PDL1+; CD47+ single cells.
- the Edit-6 clones were confirmed to be B2M - by FACS analysis for MHC-I, and PDL1+, CD47+, CD46+, CD55+, CD59+(see FIG. 12J) and sanger sequencing was used to confirm the KO of B2M and CIITA at the genomic level (see FIG. 12K) .
- Edit-7 clones clones 32, 33, 39, and 42, were derived by electroporating hiPSC with a construct overexpressing PD-L1, HLA-E, CD47, CCL-21, CD55 and two RNPs, targeting B2M and CIITA, respectively, followed by FACS sorting for B2M - ; PDL1+; CD47+ single cells.
- the Edit-7 clones were confirmed to be B2M - by FACS analysis for MHC-I, and PDL1+, CD47+, HLA-E+, CD55+ (see FIG. 12L) and sanger sequencing was used to confirm the KO of B2M and CIITA at the genomic level (see FIG. 12M) .
- Edit-8 clones clones 15, 36, 40, and 42, were derived by electroporating hiPSC with a construct overexpressing of CD47 and two RNPs, targeting B2M and CIITA, respectively, followed by FACS sorting for B2M - ; CD47+ single cells.
- the Edit-8 clones were confirmed to be B2M-by FACS analysis for MHC-I, and CD47+ (see FIG. 12N) and sanger sequencing was used to confirm the KO of B2M and CIITA at the genomic level (see FIG. 12O) .
- clones 03, 10, 22, 27, 34, 36, 37, and 63 were derived by electroporating hiPSC with a construct overexpressing PD-L1, PD-L2, TGF- ⁇ , HLA-E, HLA-G, CD47, IL-10, CCL-21, CD46, CD55, CD59, two RNPs, targeting B2M and CIITA, and 1 Base Editor plasmid overexpressing sgRNA targeting MICA, MICB and ULBP1, followed by FACS sorting for B2M - ; PDL1+; CD47+ single cells.
- the Edit-9 clones were confirmed to be B2M - by FACS analysis for MHC-I, and CD47+, B2M+, HLA-E+, PDL1+, CD55+ , CD46+ and CD59+ (see FIG. 12P) and sanger sequencing was used to confirm the KO of B2M and CIITA at the genomic level.
- the KO of MICA/MICB/ULBP1 were confirmed using next generation sequencing.
- the symbol ⁇ represents the gene was knocked out successfully (see FIG. 12Q) .
- the enhanced resistance to antibody-mediated complement cytotoxicity may be attributed to having enhanced or introduced expression of one or more of the following immune regulator polypeptides: PD-L2, TGF-beta, CD46, CD55, CD59, and HLA-G (e.g., at least one or more of PD-L2, TGF-beta, CD46, CD55, and CD59) .
- cells comprising Edit-9 may also exhibit enhanced resistance to antibody-mediated complement cytotoxicity, as compared to cells with either Edit-5 or Edit-8.
- iPSCs with Edit-4 or Edit-9 can exhibit enhance resistance to antibody-mediated complement cytotoxicity in vitro or in vivo, as compared to that of iPSCs with either Edit-5 or Edit-9.
- differentiated cells e.g., endothelial cells, immune cells, etc.
- differentiated cells derived from iPSCs comprising Edit-4 or Edit-9 can exhibit enhance resistance to antibody-mediated complement cytotoxicity in vitro or in vivo, as compared to that of comparably differentiated cells derived from iPSCs with either Edit-5 or Edit-9.
- immune cells derived from iPSCs comprising Edit-4 or Edit-9 can exhibit enhance resistance to antibody-mediated complement cytotoxicity in vitro or in vivo, as compared to that of immune cells derived from iPSCs with either Edit-5 or Edit-9.
- NK cells derived from iPSCs comprising Edit-4 or Edit-9 can exhibit enhance resistance to antibody-mediated complement cytotoxicity in vitro or in vivo, as compared to that of NK cells derived from iPSCs with either Edit-5 or Edit-9.
- FIG. 13F shows single time killing against K562.
- E effector to target
- PI was added for staining dead cells.
- FACS was used to detect percentage of dead cell.
- K562 without co-cultured with eNK was regarded as spontaneous target cell death.
- NK-mediated specific lysis (%) (%PI positive target cells in coculture -%PI positive target cells in spontaneous cell death) / (100-%PI positive target cells in spontaneous cell death) .
- FIG. 13G shows serial killing against K562.
- K562-EGFP cells were monitored by the imaging with a frequency of every 3h.
- K562 was added daily for 6 days.
- K562-GFP only sample was set as a control.
- FIGs. 13F and 13G indicate that B2M/CIITA double Knock-Out eNK did not show any hyporesponsive phenotype against K562 cells, and most eNK with transgenes had comparable cytotoxicity to WT eNK, when tested against K562 cells. Without wishing to be bound by theory, the hyporesonsivitiy or cytotoxicity against other target cells can be different.
- corresponding eNK was co-cultured with CFSE-labeled PBMC.
- PBS was used a negative control while PHA as a positive control.
- the co-cultured cells were stained for CD3, CD4 and CD8.
- CD3 + CD8 + CFSE low were regarded as proliferating CD8 + T cells.
- PBMC from different donors were tested in FIGs. 13H-13M. The data show that B2M/CIITA double Knock-Out NK with or without transgenes did not stimulate CD8+ T cell proliferation.
- corresponding eNK was co-cultured with CFSE-labeled PBMC.
- PBS was used a negative control while PHA as a positive control.
- the co-cultured cells were stained for CD3, CD4 and CD8.
- CD3 + CD4 + CFSE low were regarded as proliferating CD4 + T cells.
- PBMC from different donors were tested in FIGs. 13N-13S. The data show that B2M/CIITA double Knock-Out NK with or without transgenes did not stimulate CD4+ T cell proliferation.
- NK cells can be engineered to express a plurality of different heterologous hypo-immunity regulator polypeptides (e.g., via gene knock-in) , thereby to exhibit enhanced resistance against immune rejection (e.g., immune rejection by heterologous blood cells, such as cord blood derived NK cells (CBNK) or peripheral blood NK Cells (PBNK) ) , as compared to that of a control population of NK cells lacking one or more of the plurality of different heterologous hypo-immunity regulator polypeptides.
- the engineered NK cells can be further engineered to exhibit reduced expression of at least one endogenous immune regulator polypeptide (e.g., via gene knock-out) , to, for example, enhance cytotoxicity against target tumor cells.
- FIG. 21 shows various combinations (e.g., Combo 1, Combo 2, Combo 3, Combo 4) of knocking-in one or more heterologous hypo-immunity regulator polypeptides and knocking-out one or more endogenous immune regulator polypeptides to generate engineered NK cells.
- knock-out of MHC-I may be achieved by knocking out MICA gene
- knock-out of MHC-II may be achieved by knocking out MICB gene.
- iPSCs were engineered and differentiated into NK cells to exhibit Combo 1 of FIG. 21, with enhanced expression of one heterologous hypo-immunity regulator polypeptide (e.g., CD47) and reduced expression of two endogenous immune regulator polypeptide (e.g., MHC-I and MHC-II) .
- CD47 heterologous hypo-immunity regulator polypeptide
- MHC-I and MHC-II two endogenous immune regulator polypeptide
- FIG. 22A the flow cytometry data confirmed (1) reduced expression level of MHC I and MHCII, (2) enhanced expression level of CD47, and (3) enhanced expression level of tEGFR safety switch gene, as compared to the wild type (WT) control NK cells.
- WT wild type
- NK susceptibility against immune rejection was assessed by assessing cytotoxicity of the NK cells described herein against target cells (e.g., Raji-GFP cells) in the presence of allogeneic immune cells such as CBNK or PBNK.
- the immune rejection assay demonstrated that introduction of a single heterologous hypo-immunity regulator polypeptide (e.g., CD47) was not sufficient to enhance resistance against immune rejection by allogeneic CBNK or PBNK (ns: not significant; *p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001) .
- a single heterologous hypo-immunity regulator polypeptide e.g., CD47
- iPSCs were engineered and differentiated into NK cells to exhibit Combo 2 of FIG. 21, with enhanced expression of a plurality of heterologous hypo-immunity regulator polypeptides (e.g., HLA-E and PDL1) c.
- a plurality of heterologous hypo-immunity regulator polypeptides e.g., HLA-E and PDL1
- the flow cytometry data confirmed (1) reduced expression level of MHC I and MHCII, (2) enhanced expression level of HLA-E and PDL1, and (3) enhanced expression level of tEGFR safety switch gene, as compared to the wild type (WT) control NK cells.
- WT wild type
- NK susceptibility against immune rejection was assessed by assessing cytotoxicity of the NK cells described herein against target cells (e.g., Raji-GFP cells) in the presence of allogeneic immune cells such as CBNK or PBNK.
- the immune rejection assay demonstrated that introduction of a plurality of heterologous hypo-immunity regulator polypeptides (e.g., HLA-E and PDL1) was sufficient to enhance resistance against immune rejection by allogeneic CBNK or PBNK (ns: not significant; *p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001) .
- the introduction of the plurality of heterologous hypo-immunity regulator polypeptides was sufficient to protect the multiple gene knockout NK cells from killing by allogeneic CBNK or PBNK.
- iPSCs were engineered and differentiated into NK cells to exhibit Combo 3 of FIG. 21, with enhanced expression of a plurality of heterologous hypo-immunity regulator polypeptides (e.g., HLA-E and PDL1) and reduced expression of two endogenous immune regulator polypeptide (e.g., MHC-I, MHC-II, and CD155) .
- HLA-E and PDL1 heterologous hypo-immunity regulator polypeptides
- MHC-I two endogenous immune regulator polypeptide
- MHC-II two endogenous immune regulator polypeptide
- CD155 two endogenous immune regulator polypeptide
- FIG. 24A the flow cytometry data confirmed (1) reduced expression level of MHC I, MHCII, and CD155, (2) enhanced expression level of HLA-E and PDL1, and (3) enhanced expression level of tEGFR safety switch gene, as compared to the wild type (WT) control NK cells.
- WT wild type
- NK susceptibility against immune rejection was assessed by assessing cytotoxicity of the NK cells described herein against target cells (e.g., Raji-GFP cells) in the presence of allogeneic immune cells such as CBNK or PBNK.
- the immune rejection assay demonstrated that introduction of a plurality of heterologous hypo-immunity regulator polypeptides (e.g., HLA-E and PDL1) was sufficient to enhance resistance against immune rejection by allogeneic CBNK or PBNK (ns: not significant; *p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001) .
- the introduction of the plurality of heterologous hypo-immunity regulator polypeptides was sufficient to protect the multiple gene knockout NK cells from killing by allogeneic CBNK or PBNK.
- iPSCs were engineered and differentiated into NK cells to exhibit Combo 4 of FIG. 21, with enhanced expression of three heterologous hypo-immunity regulator polypeptides (e.g., HLA-E, PDL1, and HLA-G) and reduced expression of three endogenous immune regulator polypeptide (e.g., MHC-I, MHC-II, and CD155) .
- HLA-E, PDL1, and HLA-G three heterologous hypo-immunity regulator polypeptides
- endogenous immune regulator polypeptide e.g., MHC-I, MHC-II, and CD155
- FIG. 25A the flow cytometry data confirmed (1) reduced expression level of MHC I, MHCII, and CD155, (2) enhanced expression level of HLA-E, PDL1, and HLA-G, and (3) enhanced expression level of tEGFR safety switch gene, as compared to the wild type (WT) control NK cells.
- WT wild type
- NK susceptibility against immune rejection was assessed by assessing cytotoxicity of the NK cells described herein against target cells (e.g., Raji-GFP cells) in the presence of allogeneic immune cells such as CBNK or PBNK.
- the immune rejection assay demonstrated that introduction of three heterologous hypo-immunity regulator polypeptides (e.g., HLA-E, PDL1, and HLA-G) was sufficient to enhance resistance against immune rejection by allogeneic CBNK or PBNK (ns: not significant; *p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001) .
- the introduction of the three heterologous hypo-immunity regulator polypeptides was sufficient to protect the multiple gene knockout NK cells from killing by allogeneic CBNK or PBNK.
- the difference in the specific cytotoxicity against the target cells between (i) the engineered NK cells comprising the plurality of heterologous hypo-immunity regulator polypeptides and (ii) control NK cells lacking the plurality of heterologous hypo-immunity regulator polypeptides may be due substantially in part to the enhanced resistance against immune cell rejection from heterologous immune cells, as the NK cells of (i) and (ii) exhibited comparable target cell cytotoxicity in absence of the heterologous immune cells (e.g., see FIs. 23B, 24B, and 25B, respectively) .
- Embodiment 1 An engineered NK cell, comprising:
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen, wherein the antigen is not CD19,
- the engineered cell lacks a heterologous IL-15R
- the engineered NK cell further comprises the CD16 variant;
- the engineered NK cell further comprises the chimeric polypeptide receptor;
- the engineered NK cell comprises (i) ;
- the engineered NK cell comprises (ii) ;
- the engineered NK cell comprises both (i) and (ii) ;
- the engineered NK cell further comprises a heterologous polynucleotide encoding the secretory IL-15; and/or
- the antigen comprises one or more members selected from the group consisting of: BCMA, CD20, CD22, CD30, CD33, CD38, CD70, Kappa, Lewis Y, NKG2D ligand, ROR1, NY-ESO-1, NY- ESO-2, MART-1, and gp100; and/or
- the antigen comprises a NKG2D ligand selected from the group consisting of MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, AND ULBP6; and/or
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 2 An engineered NK cell derived from an isolated stem cell or an induced stem cell, comprising a secretory IL-15 that is heterologous to the engineered NK cell, wherein the engineered cell lacks a heterologous IL-15R,
- the engineered NK cell further comprises a heterologous polynucleotide encoding the secretory IL-15.
- Embodiment 3 An engineered NK cell, comprising:
- engineered NK cell further comprise one or more of:
- the engineered NK cell comprises the heterologous cytokine that is not IL-15;
- the engineered NK cell comprises the reduced expression or activity of the endogenous immune regulator polypeptide, wherein the endogenous immune regulator polypeptide is not B2M;
- the engineered NK cell comprises the safety switch, optionally wherein the safety switch comprises an inducible cell death moiety; and/or
- the engineered NK cell comprises two or more of (a) - (c) ;
- the engineered NK cell comprises (a) , (b) , and (c) ; and/or
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell;
- the membrane bound IL-15 is a part of a chimeric membrane receptor comprising the IL-15 and at least a portion of IL-15R;
- the chimeric membrane receptor comprises a sequence selected from the group consisting of (i) four or more adjacent repeats of SEQ ID NO. 9, (ii) SEQ ID NO. 10, (iii) SEQ ID NO. 11, (iv) a combination of SEQ ID NO. 9 and SEQ ID NO. 11, (v) SEQ ID NO. 12, (vi) SEQ ID NO. 13, and (vii) SEQ ID NO. 14) .
- Embodiment 4 An engineered NK cell, comprising:
- CD16 variant for enhanced CD16 signaling in the engineered NK cell, the CD16 variant comprising at least a portion of CD16 and at least a portion of CD64,
- engineered NK cell exhibits reduced expression or activity of an endogenous immune regulator polypeptide
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof;
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 5 An engineered NK cell, comprising reduced activity of endogenous IL-17 signaling, wherein the engineered NK cell is derived from an isolated stem cell or an induced stem cell,
- the engineered NK cell comprises reduced expression of endogenous IL-17 or endogenous IL-17R;
- the engineered NK cell comprises reduced expression of endogenous IL-17 and endogenous IL-17R;
- the endogenous IL-17 is IL-17A;
- the endogenous IL-17 is IL-17F;
- the endogenous IL-17R comprises IL-17RA, IL-17RB, IL-17RC, IL-17RD, or IL-17RE; and/or
- the endogenous IL-17R comprises IL-17RA;
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof; and/or
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell;
- the engineered NK cell exhibits enhanced expression profile of a NK cell marker as compared to a control cell without reduced expression or activity of endogenous IL-17;
- the NK cell marker comprises human CD57 or killer immunoglobulin-like receptors (KIR) ; and/or
- the engineered NK cell exhibits enhanced survival in the presence of tumor cells as compared to a control cell without reduced activity of endogenous IL-17 signaling.
- Embodiment 6 An engineered NK cell, comprising a heterologous STAT,
- engineered NK cell is derived from an isolated stem cell or an induced stem cell
- the engineered NK cell exhibits enhanced survival in the presence of tumor cells as compared to a control cell without the heterologous STAT;
- the heterologous STAT comprises STAT1, STAT2, STAT3, STAT4, STAT3, STAT4, STAT5A, STAT5B, or STAT6; and/or
- the heterologous STAT comprises STAT3; and/or
- the heterologous STAT comprises STAT5B;
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof.
- Embodiment 7 An engineered NK cell, comprising:
- KIR Killer-cell immunoglobulin-like receptor
- engineered NK cell further comprises one or more of:
- the engineered NK cell comprises the chimeric polypeptide receptor
- the engineered NK cell comprises the heterologous cytokine
- the engineered NK cell comprises the CD16 variant
- the engineered NK cell comprises the heterologous immune regulator polypeptide; and/or
- the engineered NK cell comprises the reduced expression or activity of endogenous immune regulator polypeptide;
- the engineered NK cell comprises two or more of (a) - (e) ;
- the engineered NK cell comprises three or more of (a) - (e) ;
- the engineered NK cell comprises four or more of (a) - (e) ;
- the engineered NK cell comprises all of (a) - (e) ;
- the KIR comprises KIR2D; and/or
- the KIR2D comprises KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, or KIR2DS5; and/or
- the KIR comprises KIR3D; and/or
- the KIR3D comprises KIR3DL1, KIR3DL2, KIR3DL3, or KIR3DS1; and/or
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof;
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 8 An engineered NK cell, comprising:
- the engineered cell is derived from an isolated stem cell or an induced stem cell, optionally wherein:
- the engineered NK cell comprises reduced expression or activity of the endogenous CD94;
- the engineered NK cell comprises reduced expression or activity of the endogenous CD96
- the engineered NK cell comprises reduced expression or activity of the endogenous TGF beta receptor
- the engineered NK cell comprises reduced expression or activity of the endogenous SHIP2;
- the engineered NK cell comprises reduced expression or activity of two or more of (i) - (iv) ;
- the engineered NK cell comprises reduced expression or activity of three or more of (i) - (iv) ;
- the engineered NK cell comprises reduced expression or activity of (i) - (iv) ;
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof; and/or
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 9 An engineered NK cell, comprising:
- the engineered cell is derived from an isolated stem cell or an induced stem cell, optionally wherein:
- the engineered NK cell comprises reduced expression or activity of endogenous CD80;
- the engineered NK cell comprises reduced expression or activity of endogenous CD86;
- the engineered NK cell comprises reduced expression or activity of endogenous ICOSL;
- the engineered NK cell comprises reduced expression or activity of endogenous CD40L;
- the engineered NK cell comprises reduced expression or activity of endogenous MICA or MICB;
- the engineered NK cell comprises reduced expression or activity of endogenous NKG2D;
- the engineered NK cell comprises reduced expression or activity of two or more of (i) - (vi) ;
- the engineered NK cell comprises reduced expression or activity of three or more of (i) - (vi) ;
- the engineered NK cell comprises reduced expression or activity of four or more of (i) - (vi) ;
- the engineered NK cell comprises reduced expression or activity of five or more of (i) - (vi) ;
- the engineered NK cell comprises reduced expression or activity of (i) - (vi) ;
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof. ;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof.
- Embodiment 10 An engineered NK cell, comprising:
- engineered cell further comprises one or more of:
- the engineered NK cell comprises the chimeric polypeptide receptor
- the engineered NK cell comprises the heterologous cytokine
- the engineered NK cell comprises the CD16 variant
- the engineered NK cell comprises two or more of (a) - (c) ;
- the engineered NK cell comprises all of (a) - (c) ;
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof; and/or
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 11 An engineered NK cell, comprising reduced expression or activity of endogenous ICAM1, wherein the engineered cell is derived from an induced stem cell.
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof;
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 12 An engineered NK cell, comprising one or more of: (i) a heterologous PD-L2 or (ii) a heterologous TGF-beta,
- the engineered NK cell comprises the heterologous PD-L2;
- the engineered NK cell comprises the heterologous TGF-beta;
- the engineered NK cell comprises (i) the heterologous PD-L2 and (ii) the heterologous TGF-beta; and/or
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof; and/or
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 13 An engineered NK cell comprising one or more of:
- the engineered cell is derived from an isolated stem cell or an induced stem cell, optionally wherein:
- the engineered NK cell comprises the heterologous CCL21;
- the engineered NK cell comprises the heterologous IL-10;
- the engineered NK cell comprises the heterologous CD46;
- the engineered NK cell comprises the heterologous CD55;
- the engineered NK cell comprises the heterologous CD59;
- the engineered NK cell comprises two or more of (i) - (v) ;
- the engineered NK cell comprises three or more of (i) - (v) ;
- the engineered NK cell comprises four or more of (i) - (v) ;
- the engineered NK cell comprises all of (i) - (v) ;
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof.
- Embodiment 14 An engineered NK cell derived from an induced stem cell, comprising a heterologous cytokine that is not IL-15,
- heterologous cytokine that is not IL-15 comprises IL-21.
- Embodiment 15 An engineered NK cell derived from an induced stem cell, comprising a heterologous IL-21,
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof.
- Embodiment 16 An engineered NK cell comprising:
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of specifically binding to CD38
- engineered NK cell is derived from an isolated embryonic stem cell or an induced stem cell
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof.
- Embodiment 17 An engineered NK cell comprising:
- a chimeric polypeptide receptor comprising CD8 transmembrane domain and one or more of (i) 2B4 signaling domain and (ii) DAP10 signaling domain,
- the chimeric polypeptide receptor comprises 2B4 signaling domain
- the chimeric polypeptide receptor comprises DAP10 signaling domain
- the chimeric polypeptide receptor comprises (i) 2B4 signaling domain and (ii) DAP10 signaling domain; and/or
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof; and/or
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 18 An engineered NK cell derived from an isolated stem cell or an induced stem cell, the engineered NK cell comprising:
- a chimeric polypeptide receptor comprising one or more of (i) CD8 transmembrane domain, (ii) 2B4 signaling domain, or (iii) DAP10 signaling domain,
- the chimeric polypeptide receptor comprises CD8 transmembrane domain
- the chimeric polypeptide receptor comprises 2B4 signaling domain
- the chimeric polypeptide receptor comprises DAP10 signaling domain
- the chimeric polypeptide receptor comprises two or more of (i) - (iii) ;
- the chimeric polypeptide receptor comprises all of (i) - (iii) ;
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof.
- Embodiment 19 An engineered NK cell, comprising:
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of specifically binding to CD23
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof;
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 20 An engineered NK cell, comprising:
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of specifically binding to CD123 ,
- engineered NK cell is derived from an isolated stem cell or an induced stem cell
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof.
- Embodiment 21 An engineered NK cell, comprising:
- a chimeric polypeptide receptor comprising an antigen binding moiety capable of specifically binding to CD7
- engineered NK cell exhibits reduced expression or activity of endogenous CD7
- the engineered NK cell further comprises a heterologous IL-15 or a fragment thereof;
- the engineered NK cell further comprises a receptor comprising a heterologous IL-15R or a fragment thereof; and/or
- the engineered NK cell is derived from an isolated stem cell or an induced stem cell.
- Embodiment 22 An engineered NK cell, comprising a combination of modified expression or activity of a plurality of immune regulator polypeptides identified in Table 2,
- combination of modified expression or activity of the plurality of immune regulator polypeptides comprises (i) reduced expression or activity of one or more first immune regulator polypeptides and (ii) enhanced expression or activity of one or more second immune regulator polypeptides,
- the one or more first immune regulator polypeptides are endogenous to the engineered NK cell;
- the one or more second immune regulator polypeptides are heterologous to the engineered NK cell;
- the engineered NK cell further comprises a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen;
- the engineered NK cell further comprises a heterologous cytokine;
- the engineered NK cell further comprises reduced expression or activity of an endogenous cytokine
- the engineered NK cell further comprises a CD16 variant for enhanced CD16 signaling in the engineered NK cell;
- the engineered NK cell further comprises a safety switch;
- the engineered NK cell exhibits enhanced cytotoxicity against a target cell as compared to a control cell
- the engineered NK cell induces reduced immune response in a host cell as compared to a control cell
- the host cell is an immune cell
- the engineered NK cell is derived from an isolated stem cell
- the isolated stem cell comprises an embryonic stem cell
- the induced stem cell comprises an induced pluripotent stem cell.
- Embodiment 23 The engineered NK cell of any one of the preceding embodiments 1-22, optionally wherein:
- the engineered NK cell exhibits reduced expression or activity of endogenous CD38
- heterologous IL-15 or the fragment thereof is secreted by the engineered NK cell;
- heterologous IL-15 or the fragment thereof is membrane-bound;
- the engineered NK cell further comprises a chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen;
- the engineered NK cell further comprises an additional chimeric polypeptide receptor comprising an antigen binding moiety capable of binding to an antigen that is different;
- the antigen binding moiety of the chimeric polypeptide receptor is a multispecific binding moiety capable of specifically binding to two or more antigens that are different;
- the antigen comprises one or more members selected from the group consisting of: BCMA, CD19, CD20, CD22, CD30, CD33, CD38, CD70, Kappa, Lewis Y, NKG2D ligand, ROR1, NY-ESO-1, NY-ESO-2, MART-1, and gp100; and/or
- the antigen comprises a NKG2D ligand selected from the group consisting of MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, AND ULBP6; and/or
- the engineered NK cell further comprises a safety switch capable of effecting death of the engineered NK cell;
- the safety switch comprises one or more members selected from the group consisting of caspase (e.g., caspase 3, 7, or 9) , thymidine kinase, cytosine deaminase, modified EGFR, and B-cell CD20; and/or
- the engineered NK cell further comprises a heterologous cytokine;
- the heterologous cytokine comprises one or more members selected from the group consisting of IL6, IL7, IL9, IL10, IL11, IL12, IL15, IL18, and IL21; and/or
- the engineered NK cell further comprises a heterologous immune regulator polypeptide; and/or
- the heterologous immune regulator polypeptide comprises one or more members selected from the group consisting of HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and/or
- the engineered NK cell exhibits reduced expression or activity of an endogenous immune regulator polypeptide
- the endogenous immune regulator polypeptide comprises an immune checkpoint inhibitor or a hypo-immunity regulator
- the immune checkpoint inhibitor comprises one or more members selected from the group consisting of PD1, CTLA-4, TIM-3, KIR2D, CD94, NKG2A, NKG2D, IT, CD96, LAG3, TIGIT, TGF beta receptor, and 2B4; and/or
- the immune checkpoint inhibitor comprises SHIP2
- the hypo-immunity regulator comprises one or more members selected from the group consisting of B2M, CIITA, TAP1, TAP2, tapasin, NLRC5, RFXANK, RFX5, RFXAP, CD80, CD86, ICOSL, CD40L, ICAM1, MICA, MICB, ULBP1, HLA-E, CD47, CD113, PDL1, PDL2, A2AR, HLA-G, TGF-beta, CCL21, IL10, CD46, CD55, and CD59; and/or
- (21) comprises a CD16 variant for enhanced CD16 signaling as compared to a control cell, wherein the CD16 variant is heterologous to the engineered NK cell;
- the CD16 variant comprises a sequence selected from the group consisting of: SEQ ID NOs. 1-8;
- the engineered NK cell exhibits enhanced cytotoxicity against a target cell as compared to a control cell
- the engineered NK cell induces reduced immune response in a host cell as compared to a control cell
- the host cell is an immune cell
- the isolated stem cell comprises an embryonic stem cell
- the induced stem cell comprises an induced pluripotent stem cell.
- Embodiment 24 The engineered NK cell of any one of the preceding embodiments 1-23, optionally wherein:
- the engineered NK cell is for use in a method for inducing death of a target cell, optionally wherein the target cell is a cancer cell or a tumor cell; and/or
- the engineered NK cell is for use in a method for treating a subject in need thereof, wherein the subject has or is suspected of having a condition, optionally wherein the condition is cancer or tumor,
- engineered NK cell is either autologous or allogeneic to the subject
- the engineered NK cell is for the manufacture of medicament for inducing death of a target cell, optionally wherein the target cell is a cancer cell or a tumor cell; and/or
- the engineered NK cell is for the manufacture of medicament for treating a subject in need thereof, wherein the subject has or is suspected of having a condition, optionally wherein the condition is cancer or tumor,
- engineered NK cell is either autologous or allogeneic to the subject.
- Embodiment 25 A method comprising:
- Embodiment 26 A method comprising:
- NK cells comprising the engineered NK cell of any one of the preceding embodiments 1-24,
- the method further comprises administering to the subject a separate therapeutic agent,
- the separate therapeutic agent is a chemotherapeutic agent.
- Embodiment 27 A composition comprising:
- Embodiment 28 A composition comprising:
- an engineered immune cell comprising one or more members comprising:
- the engineered immune cell comprises the heterologous IL-15; and/or
- the heterologous IL-15 or the fragment thereof is secreted by the engineered immune cell;
- heterologous IL-15 or the fragment thereof is membrane-bound
- the engineered immune cell comprises the CD16 variant;
- the CD16 variant comprises a sequence selected from the group consisting of: SEQ ID NOs. 1-8; and/or
- the engineered immune cell comprises the chimeric polypeptide receptor;
- the engineered immune cell comprises two or more of (i) - (iii) ;
- the engineered immune cell comprises (i) - (iii) ;
- the engineered immune cell comprises an engineered NK cell
- the engineered immune cell comprises an engineered T cell
- the engineered cell exhibits reduced expression or activity of endogenous CD38;
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des systèmes et des procédés d'immunothérapies. Les cellules immunitaires peuvent être modifiées pour présenter une demi-vie améliorée par comparaison avec une cellule témoin (par exemple, une cellule immunitaire non modifiée). Les cellules immunitaires peuvent être modifiées pour présenter une prolifération améliorée par comparaison avec une cellule témoin. Les cellules immunitaires peuvent être modifiées pour cibler efficacement et particulièrement les cellules malades (p. ex., les cellules cancéreuses) qu'une cellule témoin ne peut pas ou ne sait pas cibler. Les cellules immunitaires peuvent être modifiées ex vivo, in vitro, et dans certains cas, in vivo. Les cellules immunitaires modifiées préparées ex vivo ou in vitro peuvent être administrées à un sujet pour traiter une maladie, par exemple un myélome ou des tumeurs solides. Les cellules immunitaires modifiées peuvent être autologues au sujet. En variante, les cellules immunitaires modifiées peuvent être allogéniques au sujet.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2021/128465 | 2021-11-03 | ||
CN2021128465 | 2021-11-03 | ||
CN2022124451 | 2022-10-10 | ||
CNPCT/CN2022/124451 | 2022-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023078287A1 true WO2023078287A1 (fr) | 2023-05-11 |
Family
ID=86240692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/129201 WO2023078287A1 (fr) | 2021-11-03 | 2022-11-02 | Systèmes et procédés pour des immunothérapies améliorées |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202325844A (fr) |
WO (1) | WO2023078287A1 (fr) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016094679A1 (fr) * | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Cellules, tissus et organes génétiquement modifiés pour le traitement d'une maladie |
WO2016116601A1 (fr) * | 2015-01-23 | 2016-07-28 | Oslo Universitetssykehus Hf | Lymphocyte t cytotoxique universel |
WO2018126074A1 (fr) * | 2016-12-30 | 2018-07-05 | Celularity, Inc. | Cellules tueuses naturelles génétiquement modifiées |
US20180221463A1 (en) * | 2017-01-13 | 2018-08-09 | The Chinese University Of Hong Kong | Modified NK Cells and Uses Thereof |
WO2019084288A1 (fr) * | 2017-10-25 | 2019-05-02 | Novartis Ag | Procédés de conception de cellules d'expression de récepteur antigénique chimérique |
WO2019182425A1 (fr) * | 2018-03-23 | 2019-09-26 | 주식회사 에스엘바이젠 | Lignée de cellules nk génétiquement modifiée ayant un nouveau gène codant pour le récepteur chimérique de l'antigène et son utilisation |
WO2022095902A1 (fr) * | 2020-11-03 | 2022-05-12 | Hangzhou Qihan Biotechnology Co., Ltd. | Systèmes et procédés pour des immunothérapies améliorées |
-
2022
- 2022-11-02 TW TW111141876A patent/TW202325844A/zh unknown
- 2022-11-02 WO PCT/CN2022/129201 patent/WO2023078287A1/fr unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016094679A1 (fr) * | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Cellules, tissus et organes génétiquement modifiés pour le traitement d'une maladie |
WO2016116601A1 (fr) * | 2015-01-23 | 2016-07-28 | Oslo Universitetssykehus Hf | Lymphocyte t cytotoxique universel |
WO2018126074A1 (fr) * | 2016-12-30 | 2018-07-05 | Celularity, Inc. | Cellules tueuses naturelles génétiquement modifiées |
US20180221463A1 (en) * | 2017-01-13 | 2018-08-09 | The Chinese University Of Hong Kong | Modified NK Cells and Uses Thereof |
WO2019084288A1 (fr) * | 2017-10-25 | 2019-05-02 | Novartis Ag | Procédés de conception de cellules d'expression de récepteur antigénique chimérique |
WO2019182425A1 (fr) * | 2018-03-23 | 2019-09-26 | 주식회사 에스엘바이젠 | Lignée de cellules nk génétiquement modifiée ayant un nouveau gène codant pour le récepteur chimérique de l'antigène et son utilisation |
WO2022095902A1 (fr) * | 2020-11-03 | 2022-05-12 | Hangzhou Qihan Biotechnology Co., Ltd. | Systèmes et procédés pour des immunothérapies améliorées |
Non-Patent Citations (4)
Title |
---|
E LIU, Y TONG, G DOTTI, H SHAIM, B SAVOLDO, M MUKHERJEE, J ORANGE, X WAN, X LU, A REYNOLDS, M GAGEA, P BANERJEE, R CAI, M H BDAIWI: "Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity", LEUKEMIA, NATURE PUBLISHING GROUP UK, LONDON, vol. 32, no. 2, 1 February 2018 (2018-02-01), London, pages 520 - 531, XP055664776, ISSN: 0887-6924, DOI: 10.1038/leu.2017.226 * |
GUNDUZ,M.ET AL.: "New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology.", BIOMEDICINES., vol. 9, 11 September 2021 (2021-09-11), XP093020451, DOI: 10.3390/biomedicines9091201 * |
MAROFI1 FAROOGH, MARWAN MAHMOOD SALEH , HESHU SULAIMAN RAHMAN, WANICH SUKSATAN, MOAED E. AL-GAZALLY, WALID KAMAL ABDELBASSET, LAKS: "CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.", CELL RESEARCH & THERAPY, vol. 12, 2 July 2021 (2021-07-02), pages 374, XP093062221 * |
ZHANG,J.ET AL.: "Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy.", HAEMATOLOGICA., vol. 89, no. 3, 31 March 2004 (2004-03-31), pages 338 - 347, XP002376005 * |
Also Published As
Publication number | Publication date |
---|---|
TW202325844A (zh) | 2023-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022095902A1 (fr) | Systèmes et procédés pour des immunothérapies améliorées | |
US20210228633A1 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
TWI785009B (zh) | Cd70結合分子及使用彼之方法 | |
TWI723374B (zh) | 利用腫瘤微環境之特性之嵌合受體t細胞治療 | |
US20190247431A1 (en) | Activated cd26-high immune cells and cd26-negative immune cells and uses thereof | |
TW202042824A (zh) | Tn-MUC1嵌合抗原受體(CAR)T細胞療法 | |
TW201902493A (zh) | 使用併入最佳化多功能t細胞之嵌合受體t細胞之治療 | |
TW202216175A (zh) | 嵌合抗原受體療法t細胞擴增動力學及其用途 | |
JP2023071724A (ja) | Cmvエピトープ | |
EP4240835A1 (fr) | Systèmes et procédés de régulation de l'expression ou de l'activité des gènes | |
WO2023078287A1 (fr) | Systèmes et procédés pour des immunothérapies améliorées | |
US20240093304A1 (en) | Alk fusion genes and uses thereof | |
WO2022179562A1 (fr) | Récepteurs chimériques à l'antigène dans des cellules immunitaires | |
WO2022179563A1 (fr) | Systèmes et compositions pour immunothérapies améliorées et leurs procédés | |
WO2023093763A1 (fr) | Systèmes et procédés pour les références croisées dans le cadre d'immunothérapies axées sur les cellules | |
WO2023078288A1 (fr) | Systèmes et procédés pour des immunothérapies améliorées | |
WO2023147777A1 (fr) | Systèmes et procédés pour des immunothérapies améliorées | |
WO2023147776A1 (fr) | Systèmes et procédés pour des immunothérapies améliorées | |
WO2023143475A1 (fr) | Méthodes et compositions pour immunothérapies cellulaires | |
TW202238129A (zh) | T細胞療法 | |
US20220135642A1 (en) | Cells, compositions and methods for enhancing immune function | |
Valia | Emerging Natural Killer Cell Immunotherapy for Acute Myeloid Leukemia | |
WO2021068040A1 (fr) | Ciblage d'epha3 et ses utilisations | |
OA19499A (en) | Chimeric antigen and T cell receptors and methods of use. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22889309 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |